Proteína del surfactante SP-D en el contexto pulmonar: oligomerización, actividad biológica y papel protector en la homeostasis pulmonar by Arroyo Rodríguez, Raquel
UNIVERSIDAD COMPLUTENSE DE MADRID 
FACULTAD DE CIENCIAS BIOLÓGICAS 
Departamento de Bioquímica y Biología Molecular 
 
  
 
TESIS DOCTORAL 
 
Proteína del surfactante SP-D en el contexto pulmonar: 
oligomerización, actividad biológica y papel protector en la 
homeostasis pulmonar 
 
Surfactant protein SP-D in the lung context : oligomerization, 
biological activity and protective role in lung homeostasis 
 
MEMORIA PARA OPTAR AL GRADO DE DOCTOR 
 
PRESENTADA POR 
 
Raquel Arroyo Rodríguez 
 
 
Directores 
 
Jesús Pérez Gil 
Mercedes Echaide Torreguitar 
 
 
Madrid 
Ed. electrónica 2019 
 
 
 
© Raquel Arroyo Rodríguez, 2018 


UNIVERSIDAD COMPLUTENSE DE MADRID 
FACULTAD DE CIENCIAS BIOLÓGICAS 
Departamento de Bioquímica y Biología Molecular 
PROTEÍNA DEL SURFACTANTE SP-D EN EL CONTEXTO 
PULMONAR: OLIGOMERIZACIÓN, ACTIVIDAD BIOLÓGICA Y 
PAPEL PROTECTOR EN LA HOMEOSTASIS PULMONAR 
SURFACTANT PROTEIN SP-D IN THE LUNG CONTEXT: 
OLIGOMERIZATION, BIOLOGICAL ACTIVITY AND PROTECTIVE 
ROLE IN LUNG HOMEOSTASIS 
MEMORIA PARA OPTAR AL GRADO DE DOCTOR 
PRESENTADA POR 
RAQUEL ARROYO RODRÍGUEZ 
DIRECTORES 
JESÚS PÉREZ GIL 
MERCEDES ECHAIDE TORREGUITAR 
MADRID, 2018

 3 
 
 
 
 
 
 
 
 
 
The research included in this Thesis has been conducted in the Department of 
Biochemistry and Molecular Biology of Complutense University of Madrid under 
the supervision of Prof. Jesús Pérez Gil, Ph.D. and Mercedes Echaide Torreguitar, 
Ph.D. Part of the experimental work was performed in collaboration with Jan 
Rosenbaum, Ph.D. from Airway Therapeutics LLC. (Cincinnati, OH, USA); Prof. 
Fernando Moreno Herrero, Ph.D. from “Centro Nacional de Biotecnología (CNB-
CSIC)” (Madrid, Spain); Prof. Paul Kingma, MD, Ph.D. from Cincinnati Children’s 
Hospital Medical Center (CCHMC) (Cincinnati, OH, USA); Prof. Nades Palaniyar, 
Ph.D. from SickKids Hospital (Toronto, ON, Canada); Prof. Alberto Galindo, MD 
from the Gynecology and Obstetrics Department of “Hospital 12 de Octubre” 
(Madrid, Spain); Robert Wilmanowski, Ph.D. from Glycotope GmbH (Berlin, 
Germany). Funding for short-term stays was provided by the Spanish Ministry of 
Education, Culture and Sport (EST16/00922). 
The financial support to complete this Thesis was provided by the Spanish Ministry 
of Education, Culture and Sport (FPU14/03398) and research grants from Spanish 
Ministry of Economy and Competitiveness (BIO2012-30733, BIO2015-67930-R) 
and the Regional Government of Madrid (S2013/MlT-2807). 
 
 

 5 
ACKNOWLEDGEMENTS 
AGRADECIMIENTOS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A mis directores de tesis, Jesús y Mercedes. 
A mis compañeros del grupo BIOMIL. 
A Fernando Moreno y su grupo, por acogerme con los brazos abiertos. 
A Paul Kingma y Nades Palaniyar por permitirme trabajar unos meses es sus 
laboratorios. 
A mi familia y amigos.

 7 
TABLE OF CONTENTS 
LIST OF ABBREVIATIONS 9 
SUMMARY 11 
RESUMEN 17 
INTRODUCTION 23 
Lung development 25 
Lung surfactant 25 
¨ Composition 26 
¨ Synthesis, secretion and homeostasis 27 
¨ Function 29 
Lung collectins and the innate immune defense of the lung 32 
¨ Collectin family 33 
¨ Surfactant protein SP-A 34 
¨ Surfactant protein SP-D 35 
1. Structure 36 
2. Synthesis, processing and regulation of expression 39 
3. Gene differences 40 
4. Functions 41 
5. Surfactant protein D levels as a disease marker 47 
6. SP-D beyond the lung 48 
OBJECTIVES 49 
MATERIALS AND METHODS 53 
 8 
¨ Materials 55 
¨ Methods 62 
RESULTS 79 
Chapter 1: Structural characterization of the supramolecular assembly of 
rhSP-D 
79 
Chapter 2: Isolation and functional characterization of the different 
oligomeric forms of recombinant human rhSP-D 
105 
Chapter 3: Structural and functional characterization of human pulmonary 
surfactant protein SP-D from amniotic fluid and proteinosis BAL 
123 
Chapter 4: SP-D modulates LPS-induced NETosis and protects lung 
surfactant from NETs 
139 
GENERAL DISCUSSION 161 
CONCLUSIONS 171 
REFERENCES 175 
LIST OF PUBLICATIONS 191 
 
 
 9 
LIST OF ABBREVIATIONS 
 
4-AP: 4-aminophenazone 
ABCA3: ATP-binding cassette 
transporter A3 
AF: amniotic fluid 
AFM: atomic force microscopy 
AM: amplitude modulation 
ARDS: acute respiratory distress 
syndrome 
ATII: alveolar type II cells 
BAL: bronchoalveolar lavage 
BALF: bronchoalveolar lavage fluid 
BCA: bicinchoninic acid 
CBS: captive bubble surfactometer 
CHE: cholesterol esterase 
CHO: Chinese hamster ovary 
CHOD: cholesterol oxidase  
CitH3: citrullinated histone 3 
COPD: chronic obstructive 
pulmonary disease 
CRD: carbohydrate recognition 
domain 
DPPC: 
dipalmitoylphosphatidylcholine 
Dyn: dynamic cycles 
ER: endoplasmic reticulum 
FBS: fetal bovine serum 
GA: glutaraldehyde 
GlcNAc: N-Acetyl-glucosamine 
GM-CSF: granulocyte-macrophage 
colony stimulating factor 
HRP: horseradish peroxidase 
IA: initial adsorption 
KO: knock out 
LA: large aggregates 
LAL: Limulus Amebocyte Lysate 
LB: lamellar body 
LPS: lipopolysaccharide 
LS: lung surfactant 
MAS: meconium aspiration syndrome 
MW: molecular weight  
NETs: neutrophil extracellular traps 
NOX: NADPH oxidase  
OE: organic extract 
PAGE: polyacrylamide gel 
electrophoresis 
PAP: pulmonary alveolar proteinosis 
PC: phosphatidyl choline 
PEA: post expansion adsorption 
PG: phosphatidylglycerol 
PI: phosphatidylinositol 
PL: phospholipids 
pNA: p-nitroaniline 
POD: peroxidase 
RER: rough endoplasmic reticulum 
ROS: reactive oxygen species 
RPM: revolutions per minute 
SA: small aggregates 
SDS: sodium dodecyl sulfate 
SEC: size exclusion chromatography 
SP-A: surfactant protein A 
SP-B: surfactant protein B 
SP-C: surfactant protein C 
SP-D: surfactant protein D 
TBS: tris buffered saline (150 mM 
NaCl, 50 mM Tris (pH 7)) 
TEM: transmission electron 
microscopy 
TM: tubular myelin 
WT: wild type 
 
 
 
 
 
 

SUMMARY 
 11 
  
SUMMARY 
  12 
 
  
SUMMARY 
 13 
Lungs are branched organs that in their terminal ends contain alveoli, small 
chambers where a large surface is exposed to the external environment and the gas 
exchange takes place. At this level, the first barrier to prevent the entry of pathogens 
through the respiratory pathway is a lipid-protein complex called lung surfactant 
(LS). This complex coats the air-liquid interface and it is essential to allow alveoli 
to compress and expand to carry out an effortless breathing while preventing 
alveolar collapse. This last function is referred as the biophysical function of lung 
surfactant, where phospholipids (PL), especially saturated PL, and surfactant 
hydrophobic proteins (SP-B and SP-C) are crucial. In a combined action and to 
protect the lungs from pathogens invasion, surfactant also contains two collectin 
proteins, SP-A and SP-D, which work as pattern recognition molecules that help to 
fight against invading microorganisms and to modulate the immune response 
triggered in lungs upon infection.  
Surfactant protein SP-D has been found in the alveolar airspaces and other 
locations in the human body. In addition, it has been also detected and obtained 
from amniotic fluid near term pregnancy. The 43 kDa monomer of SP-D is formed 
by a cysteine rich N-terminal domain, a long collagen region, a neck domain with 
a coiled-coil a-helical conformation, and a carbohydrate recognition domain 
(CRD), characteristic of C-type lectins. SP-D is N-glycosylated in an asparagine 
(Asn70) at the collagen domain. Three monomers associate into trimers through the 
folding of collagen regions, guided by the neck domains and stabilized by disulfide 
bonds within the N-terminal domains. Furthermore, association of trimers forms 
cruciform structures, dodecamers, and even larger oligomers with a variable 
number of trimeric arms, called “fuzzy balls” or “asterisk-like” structures. However, 
the interactions involved in protein oligomerization from trimers to large oligomers 
remain unknown to be characterized.  
SP-D participates in the host defense of lungs. It recognizes certain ligands, 
mainly carbohydrate structures present at the surface of invading microbes. 
Pathogen recognition triggers binding, aggregation, opsonization and stimulation 
of host cells to initiate clearance of these potential pathogens. In addition, it 
regulates the innate immune response in the lungs, stimulating pro- or anti-
inflammatory pathways. Moreover, it is involved in lung surfactant homeostasis, 
regulating phospholipid pool sizes and their accumulation into the alveolar space. 
Many studies have been performed to figure out which domains of SP-D are 
essential for the different protein functions. Moreover, the activity of the different 
oligomeric forms has been also studied, although not all of them have been 
individually isolated and evaluated in the different assays. Data have pointed to 
large oligomers as the most active structures.   
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Taking into account this evidence, the main objective of this Thesis has been 
to characterize SP-D oligomeric forms, the interactions that drive the 
oligomerization pathway and the possible distinct activity of those oligomers, using 
human SP-D and a full-length recombinant version of the protein. In addition, the 
protective role of SP-D on lung homeostasis and breathing compliance has been 
addressed under inflammatory conditions. The specific objectives have been: 
 
¨ Characterization and quantification of SP-D oligomeric forms and study of 
the interactions that govern the oligomerization pathway, using a 
recombinant human rhSP-D 
¨ Isolation and evaluation of the activity and function of the different 
recombinant human rhSP-D oligomers, especially to aggregate and bind to 
bacteria.  
¨ Structural and functional characterization of human SP-D from two different 
sources: amniotic fluid and BAL from proteinosis patients. 
¨ Investigation of the possible modulatory role of SP-D in LPS-induced 
NETosis and its protective role to protect lung surfactant from NETs 
inhibition.  
 
The results have shown that SP-D is assembled into trimers, hexamers, 
dodecamers and fuzzy balls, being the first time that hexamers are described as a 
defined oligomeric form of the protein. We have proposed that hexamers are 
necessary intermediate states between trimers and dodecamers or fuzzy balls. It has 
been found that non-covalent interactions govern this oligomerization process from 
trimers to higher order oligomers (hexamers, dodecamers and fuzzy balls), 
especially between N-terminal and the beginning of the collagen domains. A bright 
protrusion has been found in AFM images, which coincides with the N-
glycosylation site in the collagen domain of SP-D. Glycosylation could interfere 
with protein oligomerization. Moreover, dodecamers and fuzzy balls are the most 
abundant oligomeric forms in rhSP-D and hSP-D, respectively, being this 
quantitative distribution sensitive to external conditions, such as pH. 
The isolation of trimers, hexamers and fuzzy balls have allowed us to study and 
compare them with respect to protein functions that depend on the CRD domains. 
Results have shown that fuzzy balls are the most active oligomeric form to aggregate 
and bind to E. coli. Moreover, although the affinity of binding of trimers and 
hexamers to bacteria was similar, trimers did not aggregate bacteria, while 
hexamers did.  
SUMMARY 
 15 
The structural and functional analysis of human SP-D obtained from two 
sources, amniotic fluid and proteinosis, have revealed that hSP-D from the disease 
condition was assembled mainly as fuzzy balls, whereas in hSP-D from amniotic 
fluid, fuzzy balls were also the major structure, but very closely followed by 
dodecamers. Moreover, the oligomeric forms observed in hSP-D were the same as 
in rhSP-D, and the quantitative distribution found in hSP-D from amniotic fluid was 
similar to the one in rhSP-D. Results of functional assays of these two hSP-D 
preparations were consistent with previous results, showing that hSP-D from 
proteinosis is more active than the protein from amniotic fluid, probably due to the 
distribution of the oligomeric forms found in both cases.  
Last, we have seen that SP-D can modulate NETosis, one of the mechanism of 
neutrophils to fight against pathogens. In addition, it has been found that an excess 
of NETs may be harmful for the biophysical activity of lung surfactant and, that SP-
D protects lung surfactant from NETs inactivation.  
 
In summary, in this PhD Thesis the structure and oligomerization process of SP-
D have been studied. It has been observed that it is assembled as trimers, hexamers, 
dodecamers and fuzzy balls, being the two last ones the most abundant oligomers. 
The oligomerization process is mainly governed by non-covalent interactions and 
sensitive to environmental conditions. Fuzzy balls have been found to be the most 
active structure, at least in terms of bacteria aggregation and binding. Last, SP-D 
has shown a protective role in surfactant inactivation by NETs and a modulatory 
effect in LPS induce NETosis, a process implicated in the immune defense of the 
lungs.
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Los pulmones son órganos ramificados cuyas ramificaciones terminan en los 
alvéolos. En los sacos alveolares, una gran superficie expuesta al medio externo, es 
donde tiene lugar el intercambio de gases que constituye la base de la respiración. 
A este nivel, un complejo lípido-proteico, el surfactante pulmonar (SP), constituye 
la primera barrera para prevenir la entrada de patógenos al organismo a través de 
las vías respiratorias. El surfactante pulmonar recubre y se extiende a lo largo de la 
interfase aire-líquido en los alvéolos, permitiéndoles expandirse y contraerse 
durante la entrada y salida de aire, sin colapsar y sin un gran esfuerzo por parte de 
los músculos respiratorios. Esto es lo que se considera la función biofísica del 
surfactante pulmonar. Para llevar a cabo esta función en su composición son 
esenciales los fosfolípidos, especialmente aquellos con cadenas saturadas, y las 
proteínas hidrofóbicas (SP-B y SP-C). Por otro lado, para proteger al organismo de 
la invasión de patógenos, el surfactante pulmonar también contiene entre sus 
componentes dos proteínas de la familia de las colectinas, SP-A y SP-D, que actúan 
como moléculas de reconocimiento de patrones. Estas colectinas luchan contra la 
invasión de microorganismos y modulan la respuesta inmune desencadenada en 
los pulmones cuando hay una infección.  
La proteína del surfactante SP-D se encuentra en los espacios alveolares, así 
como en otras localizaciones del organismo. Además, ha sido detectada en líquido 
amniótico y purificada del mismo procedente de embarazos a término. El 
monómero de la SP-D (43 kDa) está formado por un dominio N-terminal, rico en 
cisteínas, seguido de un dominio colagénico largo, que continúa con un dominio 
conector con una conformación de hélice superenrollada y acaba con el dominio 
de reconocimiento de carbohidratos (“CRD”, del inglés), característico de las 
colectinas tipo C. La SP-D se encuentra N-glicosilada en una asparagina (Asn70) 
localizada en el dominio colágeno. Tres monómeros se unen dando lugar a 
trímeros a través del plegamiento y formación de una triple hélice de colágeno, con 
participación de los dominios conectores. Los trímeros son estabilizados por 
puentes disulfuro entre las cisteínas en los dominios N-terminales. La unión de 
trímeros da lugar a dodecámeros, estructuras con forma de cruz, y a oligómeros 
más grandes, con un número variable de trímeros, llamados “fuzzy balls” o 
estructuras tipo asterisco. Sin embargo, hasta la fecha se desconocen el tipo de 
interacciones implicadas en la oligomerización desde trímeros hasta los oligómeros 
grandes.   
La SP-D participa en la defensa inmune de los pulmones del hospedador. 
Reconoce ciertos ligandos, principalmente estructuras de tipo carbohidrato 
presentes en la superficie de los microorganismos invasores. El reconocimiento de 
patógenos desencadena su unión, agregación, opsonización y estimulación de 
RESUMEN 
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células del hospedador para llevar a cabo la eliminación de esos potenciales 
patógenos. Además, la SP-D regula la respuesta inmune innata en los pulmones, 
estimulando rutas pro- y anti-inflamatorias. Por otro lado, la proteína está implicada 
en la homeostasis del surfactante pulmonar, regulando el tamaño de las estructuras 
de reserva del mismo y su acumulación en la subfase alveolar. Muchos estudios se 
han llevado a cabo para encontrar qué dominios de la SP-D son esenciales para las 
diferentes funciones descritas. También se ha estudiado la actividad de las 
diferentes formas oligoméricas de la proteína, aunque no todas ellas han sido 
aisladas individualmente y evaluadas en los diferentes ensayos funcionales. Los 
datos obtenidos señalan a los oligómeros grandes (fuzzy balls) como las estructuras 
más activas de la proteína. 
Teniendo en consideración toda esta información, el principal objetivo de esta 
Tesis ha sido caracterizar las diferentes formas oligoméricas de la SP-D, así como 
el tipo de interacciones que participan en la ruta de oligomerización y la posible 
distinta actividad de estos oligómeros. Para ello se han empleado dos 
preparaciones de SP-D humanas y una forma recombinante de la SP-D humana 
(rhSP-D) que contiene la estructura completa. Además, se ha estudiado el papel 
protector de la SP-D en la homeostasis pulmonar sobre la función biofísica del 
surfactante pulmonar en condiciones de inflamación pulmonar. Los objetivos 
específicos han sido: 
¨ Caracterización y cuantificación de las formas oligoméricas de la SP-D y 
estudio de la naturaleza de las interacciones implicadas en el ensamblado 
de las mismas, usando para ello una proteína recombinante humana (rhSP-
D). 
¨ Aislamiento y evaluación de la actividad y función de los diferentes 
oligómeros de la proteína recombinante rhSP-D, especialmente en términos 
de agregación y unión a bacterias. 
¨ Caracterización estructural y funcional de dos preparaciones de SP-D 
humana de diferente origen: líquido amniótico y lavado bronco-alveolar de 
pacientes con proteinosis. 
¨ Investigación del posible papel modulador de la SP-D sobre la NETosis 
inducida por LPS y su papel protector en la inhibición del surfactante 
pulmonar por la presencia de NETs.  
 
Los resultados obtenidos han mostrado que la SP-D se ensambla en trímeros, 
hexámeros, dodecámeros y oligómeros grandes (fuzzy balls), siendo ésta la primera 
vez que los hexámeros son descritos como una forma oligomérica definida de la 
proteína. Se ha propuesto que los hexámeros son estados intermedios necesarios 
RESUMEN 
 21 
entre los trímeros y dodecámeros o fuzzy balls. Se ha visto que las interacciones 
no covalentes dirigen el proceso de oligomerización desde trímeros a formas 
superiores (hexámeros, dodecámeros y fuzzy balls), teniendo lugar entre los 
dominios N-terminal y la zona cercana a éstos de los dominios colágeno. En las 
imágenes de AFM, se ha observado un punto brillante en el dominio colágeno, que 
corresponde con el sitio de N-glicosilación de la proteína y podría tener 
implicación en el proceso de oligomerización. Además, se ha visto que los 
dodecámeros y los fuzzy balls son las estructuras más abundantes en rhSP-D y hSP-
D, respectivamente, siendo esta distribución cuantitativa sensible a las condiciones 
del medio en el cuál se encuentra la proteína, por ejemplo, el pH.   
El aislamiento de trímeros, hexámeros y fuzzy balls ha permitido estudiar y 
comparar la actividad de estas diferentes estructuras, en funciones de la proteína 
que dependen del dominio CRD. En ensayos de agregación y unión a E. coli, los 
fuzzy balls han sido los oligómeros más activos. Además, se ha visto que la afinidad 
de unión de trímeros y hexámeros a bacterias es similar, pero los trímeros no 
inducen agregación de bacterias, mientras que los hexámeros sí lo hacen.  
El análisis estructural y funcional de la SP-D humana procedente de dos fuentes 
diferentes, líquido amniótico y proteinosis, ha revelado que la hSP-D procedente 
de la condición patológica presenta principalmente fuzzy balls, mientras que en la 
hSP-D de líquido amniótico, los fuzzy balls fueron también la estructura 
mayoritaria, pero con una proporción muy parecida de dodecámeros. Los 
oligómeros observados en la hSP-D fueron los mismos que en rhSP-D, y la 
distribución cuantitativa en la hSP-D purificada de líquido amniótico fue muy 
similar a la de la proteína recombinante (rhSP-D). Los resultados de los ensayos 
funcionales de las dos SP-D humanas concordaron con resultados previos, siendo 
la hSP-D de proteinosis más activa que la proteína de líquido amniótico, 
probablemente debido a la distribución de las formas oligoméricas observadas en 
cada caso, siendo el porcentaje de fuzzy balls mucho mayor en el caso de la 
proteína de proteinosis.  
Por último, se ha visto que la SP-D puede modular la NETosis, que es uno de 
los mecanismos que poseen los neutrófilos para luchar contra patógenos invasores. 
Además, se ha visto que un exceso de NETs puede ser dañino para la actividad 
biofísica del surfactante pulmonar y, que la SP-D protege al mismo de la 
inactivación por NETs. 
 
En resumen, en la presente Tesis se ha estudiado la estructura y el proceso de 
oligomerización de la SP-D. Se ha visto que está ensamblada como trímeros, 
hexámeros, dodecámeros y fuzzy balls, siendo los dos últimos los oligómeros más 
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abundantes. El proceso de oligomerización de la proteína está mediado por 
interacciones no covalentes principalmente y es sensible a las condiciones del 
medio externo en el cuál se encuentra. Los fuzzy balls han demostrado ser la 
estructura más activa, al menos en términos de agregación y unión a bacteria. Por 
último, la SP-D ha mostrado un papel protector en la inactivación del surfactante 
producida por NETs, como consecuencia de la NETosis inducida por LPS, un 
proceso implicado en la defensa inmune del pulmón.  
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LUNG DEVELOPMENT 
The respiratory system is developed in the fetus during gestation and the firsts 
years of life until total enlargement and maturation. The respiratory tree is formed 
by the trachea and the lungs. Lungs contain a branched network formed by bronchi, 
bronchioles and alveoli, where the exchange of gases takes place during breathing. 
There are five histological stages along fetal lung development, from the first stages 
until final maturation: i) embryonic (4-7 weeks), ii) pseudoglandular (7-17 weeks), 
iii) canicular (16-25 weeks), iv) saccular stage (24-38 weeks), v) alveolar stage (just 
before birth - first few years of life) (Maeda et al., 2007, Mullassery and Smith, 
2015). During the two first stages, two lung buds are developed and branched 
accompanied with vasculogenesis. In the canicular stage, the air-blood barrier 
appears between the cells that cover the pulmonary epithelium and the blood 
vessels, the bronchial tree is expanded, and late in that period, cells in the 
epithelium start to differentiate into Type I and II cells (Herriges and Morrisey, 2014, 
Mullassery and Smith, 2015). In the saccular stage, the formation of alveolar sacs 
starts as well as the synthesis of lung surfactant (LS) (around 26 weeks) by 
differentiated Type II cells. Secretion of lung surfactant begins around week 30, 
which will be crucial at birth time to open the airway spaces and fill them with air, 
without alveolar collapse allowing the baby to start breathing (Maeda et al., 2007, 
Mullassery and Smith, 2015). Last, alveolar stage comprises high alveolarization, 
where at the end, Type I cells will cover 90-95% of the pulmonary epithelium, 
whereas type II cells will cover only 5-10% although they account for 60% of total 
cells in the alveolar epithelium (George and Hook, 1984, Fehrenbach, 2001). 
Interestingly, during lung development in the period close to term pregnancy, 
lung surfactant has been found as part of amniotic fluid (Lemke et al., 2017). This 
could be explained due to breathing movements of the fetal lungs, which contain 
lung surfactant from around week 30 and contribute to the efflux of lung fluids into 
the amniotic fluid (Underwood et al., 2005). Moreover, cells in the innermost fetal 
membranes that surround the amniotic cavity, have been shown to produce and 
secrete components similar to lung surfactant (Lemke et al., 2017). 
 
LUNG SURFACTANT 
In lungs, a lipid-protein complex called lung surfactant (LS) lines the extensive 
respiratory air-liquid interface (Pattle, 1955, Clements, 1957). This complex is 
essential as a first defense barrier to protect lungs from pathogen invasion and to 
allow lungs to compress and expand without alveolar collapse during breathing 
(Avery and Mead, 1959, Perez-Gil and Weaver, 2010, Parra and Perez-Gil, 2015).  
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¨ Composition 
Lung surfactant is composed by around 90% lipids and 10% proteins by 
mass (Johansson and Curstedt, 1997, Perez-Gil, 2008).  
Regarding lipids, phospholipids (PL) are the major component (~80%), 
including zwitterionic phosphatidylcholines (PC) (60-70%), and anionic PLs like 
phosphatidylglycerol (PG) and phosphatidylinositol (PI) that together account for 
around 8-15 % by mass (Figure 1). Neutral lipids, such as cholesterol constitute 8-
10% by mass. It is remarkable and important for LS biophysical function, the high 
proportion of saturated dipalmitoyl phosphatidylcholine (DPPC), in the order of 
40% of total LS mass in mammals (Goerke, 1998, Parra and Perez-Gil, 2015).  
 
 
Figure 1: Composition of lung surfactant. Lung surfactant is composed by 80% phospholipids, 10% 
neutral lipids and 10% proteins, including specific surfactant-associated proteins. Each chart 
represents the relative distribution, considering the total 100% of the species in that group.  
 
Four specific surfactant proteins have been described: SP-A, B, C and D. 
They can be classified in 2 groups: i) the hydrophilic collectin proteins SP-A (~6% 
by mass) and SP-D (<0.5%), and ii) the hydrophobic proteins SP-B (~1%) and SP-C 
(~1%) (Figure 1) (Weaver and Whitsett, 1991, Johansson and Curstedt, 1997). 
Collectin proteins will be described later in a separate section.  
 Surfactant proteins B and C (SP-B, C) are small cationic peptides, with a high 
hydrophobic character. SP-B contains 7 cysteines in its amino acids sequence and 
can be found as a covalent homodimer (17.4 kDa), in a parallel and superficial 
arrangement between LS lipid membranes (Figure 2) (Johansson et al., 1991, 
Vandenbussche et al., 1992, Cruz et al., 1998, Perez-Gil, 2008). Further studies 
have suggested a supramolecular organization of the protein in the form of ring-like 
structures composed by 5-6 homodimers (Olmeda et al., 2015). The absence of SP-
B is life-threatening; inactivation of the expression of the SP-B gene leads to a lethal 
DPPC
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respiratory failure at birth (Clark et al., 1995, Nogee, 2004). SP-C is the smallest 
surfactant protein (4.2 kDa), which is found as a monomer, mainly with an a-helical 
structure except for its unstructured N-terminal region, where two cysteines are 
found palmitoylated (Johansson et al., 1994). SP-C adopts a transmembrane 
orientation in LS membranes (Figure 2) (Perez-Gil, 2008, Roldan et al., 2015). 
Inactivation of the expression of the SP-C gene is not lethal, although it leads to 
severe respiratory pathologies at long-term (Glasser et al., 2001, Glasser et al., 
2003, Nogee, 2004). 
 
Figure 2: Membrane-associated surfactant proteins SP-B and SP-C and their interaction with 
phospholipids layers. Adapted from (Echaide et al., 2017), based on accepted models (Johansson et 
al., 1994, Cruz et al., 1998, Roldan et al., 2015). 
 
¨ Synthesis, secretion and homeostasis 
LS lipids and hydrophobic proteins are synthesized in the endoplasmic 
reticulum (ER) of type II cells (ATII). Then, they are transported and incorporated 
into concentric multilayered packed membranous structures, called lamellar bodies 
(LB). The transport of lipids takes place through the ATP-binding cassette transporter 
A3 (ABCA3) (Ban et al., 2007, Cheong et al., 2007) while hydrophobic proteins are 
transferred by multi-vesicular bodies. Hydrophilic proteins, SP-A and SP-D, are also 
synthetized in the ER in type II cells, but they are further modified in the Golgi 
apparatus and then, secreted to the aqueous sub-phase by a different pathway than 
hydrophobic proteins (Olmeda et al., 2017). Once surfactant complexes are 
secreted in the form of lamellar bodies, it has been shown that these highly dense 
surfactant packages unravel to form a lattice structure called tubular myelin (TM) 
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(Figure 3). SP-A, SP-B and calcium ions orchestrate this process. TM functions in 
the lung are not fully understood, although it has been proposed that it is involved 
in antimicrobial actions (McCormack and Whitsett, 2002, Perez-Gil, 2008). Finally, 
lung surfactant complexes are adsorbed into the air-liquid interface and spread 
along it to form a surface-active film (Figure 3). This process is energetically 
unfavorable because the transfer of lipids implies the transient exposure of acyl lipid 
chains to the aqueous environment, which makes it slow and inefficient. This 
problem is solved by the action of the hydrophobic proteins, which are involved in 
transferring PLs to the air-liquid interface, overcoming the energetic impediment 
and, allowing this process to happen very fast, within seconds (Walters et al., 2000, 
Lopez-Rodriguez and Perez-Gil, 2014). Besides, it has been described the existence 
of stack multilayered membranes, constituting surfactant reservoirs associated to 
the interfacial film, where again, hydrophobic proteins have a key role facilitating 
the adsorption of stored phospholipids into the interface, also with the participation 
of SP-A (Schurch et al., 1998, Parra and Perez-Gil, 2015, Lopez-Rodriguez et al., 
2016). 
 
 
Figure 3: Synthesis and secretion of surfactant complexes by ATII cells, as lamellar bodies, and 
unraveling in the alveolar aqueous phase. A, surfactant is synthesized in type II pneumocytes (ATII) 
and packed into lamellar bodies (LB) that are secreted to the alveolar aqueous sub-phase. Some of 
secreted LBs unpack to form tubular myelin (TM) and lung surfactant complexes are further adsorbed 
to the air-liquid interface. Taken from (Olmeda et al., 2017). B, surfactant complexes in the alveolar 
sub-phase, where lamellar bodies (LB) and tubular myelin (TM) can be observed; the scale bar 
represents 1 µm (right). Left bottom, inset with a magnification of tubular myelin; scale bar = 0.1 
µm. Taken from (Goerke, 1998). 
 
During breathing, after several compression-expansion cycles, surfactant 
complexes adsorbed at the interface are converted into less active lipid-protein 
A B
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complexes (Gunther et al., 1999). This “used” material is released from the interface 
as small aggregates that will be further cleared by ATII cells and alveolar 
macrophages (Olmeda et al., 2017). It has been described that 65% of the material 
is recycled by ATII cells, while 20% is cleared by macrophages (Rider et al., 1992), 
and 15% is lost by diffusion towards the upper airways via the mucociliary escalator 
(Pettenazzo et al., 1988). SP-A promotes the uptake of surfactant by ATII cells, 
where small aggregates are internalized via clathrin-coated vesicles (Bates, 2010). 
SP-C and SP-D are also involved in surfactant uptake by ATII cells, especially 
through the conversion of surfactant large aggregates (LA) to small aggregates (SA) 
(Ikegami et al., 2005, Roldan et al., 2016). It has been shown that SP-D has a lytic 
activity in large surfactant aggregates to generate small aggregates that will be 
preferentially internalized by ATII cells (Ikegami et al., 2009). Mice lacking SP-D 
accumulate increased surfactant pools that cannot be properly metabolized, where 
foamy macrophages are also found (Korfhagen et al., 1998). However, up to now 
the mechanism by which SP-D participates in the regulation of surfactant pool is 
not totally understood. Clearance and catabolism of surfactant by macrophages is 
essential to avoid intra-alveolar accumulation of lipids and proteins. In this 
pathway, the granulocyte-macrophage colony stimulating factor (GM-CSF) plays a 
key role (Ikegami et al., 2001), whose absence leads to pulmonary alveolar 
proteinosis (PAP), a disease characterized by accumulation of surfactant in the 
alveoli (Trapnell and Whitsett, 2002, Borie et al., 2011). Last, part of the lipids that 
are detached from the interface will undergo degradation by the action of 
phospholipases, mainly PLA2, which are found at the airway epithelium, alveolar 
macrophages and emigrating leukocytes, such as neutrophils (Hite et al., 2012). 
There is an important crosstalk between the pathways of surfactant synthesis 
de novo and recycling, which are closely regulated and compensated to produce 
functional surfactant complexes according to the needs and avoiding 
overaccumulation in the alveoli.  
 
¨ Function 
Lung surfactant accomplishes two main functions in the lungs. First, a 
biophysical function involved in the gas exchange process in the alveoli, which 
takes place because the air comes in and goes out as a consequence of lung 
compression and expansion cycles during breathing (Perez-Gil, 2008). Secondly, 
an immune function; the respiratory area is one of the largest surfaces exposed to 
the outer environment in the body, being LS the first barrier against the entry of 
pathogens (Han and Mallampalli, 2015).  
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Figure 4: A, schematic 
representation of the surface 
tension forces experienced by 
water molecules inside a solution 
and at the interface in the absence 
(left) or presence (right) of lung 
surfactant (LS). B, interpretation of 
Young-Laplace law applied to 
alveoli that are considered as 
spherical structures in the absence 
(left) or presence (right) of LS.  
 
 
 
 
 
 
 
 
Two different substances become in contact at the alveolar sacs: the aqueous 
fluid lining the epithelium and air. Inside the alveoli, the volume occupied by air is 
increased during inspiration, while it is reduced during expiration and this needs to 
happen without collapse (closing) of the alveolar sacs (Hills, 1999, Orgeig et al., 
2007). There is an essential concept at this point: the surface tension. Surface 
tension (g) is the energy required to increment the surface of a fluid per area or 
length unit. In the lung context, it means that the water molecules at the air-liquid 
interface experience a net attractive force towards the bulk of the fluid, while in the 
water molecules submerged deep into the solution, those forces are compensated 
by the surrounding water molecules (Figure 4A). During inspiration, alveolar units 
are completely opened and filled with a high volume of air, the area of liquid 
exposed to air inside the alveolus increases, generating high surface tension forces. 
Therefore, a high amount of energy will be required to counteract those forces, 
which lately means that the lung muscles and diaphragm will have to make a huge 
effort to open the alveoli. Besides, during expiration, there is another critical 
situation where the air volume inside the alveoli is reduced, and that needs to 
happen without alveolar collapse. In other words, a small air chamber needs to 
persist surrounded by liquid inside the alveoli, holding the high surface pressure to 
keep the alveoli opened. The forces acting during this last situation can be 
explained by the Young-Laplace law (DP= 2g /r). Pressure forces are originated by 
the surface tension of the liquid molecules lining the inner surface of a curved 
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structure. Considering the alveoli as spherical interconnected structures, lateral 
interactions between water molecules at the interface exert a net force towards the 
center of the sphere that translates in pressure, which is inversely correlated with 
the radius of the sphere. Thus, during compression (expiration), if two alveoli of 
different sizes are interconnected at a given surface tension, the smallest one 
(smaller radius) would sustain a higher pressure and it would collapse into the 
bigger one (Figure 4B, left). This would implicate a gradual collapse of alveoli in 
lungs which would end in respiratory failure (Hills, 1999, Parmigiani and Solari, 
2003, Lopez-Rodriguez and Perez-Gil, 2014). 
However, the presence of a surface-active agent at the air-liquid interface 
would prevent those situations: increased unsustainable surface tensions and 
alveolar collapse. This is what, lung surfactant, with its particular phospholipid 
composition and the presence of hydrophobic proteins, does (Perez-Gil, 2008).  
To overcome these situations and accomplish an effortless respiration, lung 
surfactant needs to fulfil three biophysical properties (Parra and Perez-Gil, 2015): 
i) Rapid adsorption to the air-liquid interface to reach the equilibrium surface 
tension. Phospholipids contained in lung surfactant are amphipathic 
molecules that can be orientated with their polar groups towards the liquid 
side and their acyl chains orientated to the air side, when they are transferred 
to an air-liquid interface. When the interface is saturated with PL, the air-
water surface tension (70mN/m) drops down to the equilibrium surface 
tension (22-25 mN/m). This process occurs very fast, within seconds, due to 
the presence of the proteins SP-B and SP-C that help to overcome the 
energetic barrier (Lopez-Rodriguez and Perez-Gil, 2014). The speed at 
which this adsorption step occurs is critical, for example, in babies opening 
their lungs and filling them with air for the first time when they are born.  
ii) Maximal surface tension reduction and film stability. During lung 
compression (Figure 5, top), the interfacial area in the alveolus decreases, 
which means that the surfactant monolayer has to be compressed and reach 
very low surface tensions, close to zero, in order to sustain this high-pressure 
status. The “squeeze out” model has been proposed to explain this situation. 
During compression, the surfactant film at the air-liquid interface is enriched 
in DPPC, due to the exclusion of unsaturated phospholipids and neutral 
lipids towards multilayered complexes at the aqueous sub-phase (Bangham 
et al., 1979, Perez-Gil and Keough, 1998). DPPC molecules can be tightly 
packed due to their saturated acyl chains, which allows surfactant to 
compress and reach the minimal surface tensions ~ 0 mN/m. Hydrophobic 
proteins participate in this transference of lipids (Schurch et al., 2010). 
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iii) Effective film re-spreading. During inspiration, the alveolar units are 
reopened again. The interfacial area increases and it needs to be replenished 
with new PLs coming from the reservoirs (Figure 5, bottom). Those reservoirs 
are multilayered surfactant membranes connected by hydrophobic proteins 
SP-B and SP-C, which again make possible the rapid transfer of lipids from 
the reservoirs to the interface to keep the equilibrium surface tension 
(Keating et al., 2012).  
 
Figure 5: Surfactant dynamics during respiratory compression-expansion cycling. During 
expiration (top) SP-B and SP-C promote refinement of the surfactant surface film (1). SP-B stabilizes 
the film (2) and promotes membrane-membrane contacts (3) leading to the formation of 
multimembrane structures. SP-C might facilitate association of excluded surfactant structures with 
the interface, anchoring by its palmitic chains (4). During inspiration (bottom), SP-B and SP-C seem 
to promote insertion (5) and re-spreading (6) of phospholipids back to the air-liquid interface. Taken 
from (Perez-Gil and Weaver, 2010). 
 
LUNG COLLECTINS AND THE INNATE IMMUNE DEFENSE 
OF THE LUNGS 
There is a second major challenge at the air-liquid border in the alveoli: the 
potential invasion by inhaled microorganisms. The huge surface exposed to the air 
by lungs – in the order of 70 m2 (Brown, 1957) – supposes a major opportunity for 
pathogens to enter in the body through this “door”. Lung surfactant acts as a first 
barrier against those insults and it is equipped with hydrophilic proteins, SP-A and 
SP-D, to fight against invading pathogens. These surfactant hydrophilic proteins 
belong to the collectin family, particularly they are C-type calcium-dependent 
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lectins, which work as pattern recognition molecules. They collaborate in the first 
line of defense of the lungs through their ability to recognize a broad spectrum of 
pathogens de novo, resulting in agglutination and enhanced clearance of 
microorganisms (Sano and Kuroki, 2005, Kingma and Whitsett, 2006, Haczku, 
2008, Ariki et al., 2012).  
 
¨ Collectin family 
Nine collectin proteins have been described up to date: mannose binding 
lectin (MBL), surfactant proteins A and D (SP-A, SP-D), collectin liver 1 (CL-L1), 
collectin placenta 1 (CL-P1), collectin kidney 1 (CL-K1), conglutinin and collectins 
of 43 kDa and 46 kDa (CL-43 and CL-46). The last three are not found in humans, 
but only in the Bovidae family (Holmskov, 2000, van de Wetering et al., 2004, 
Howard et al., 2018). They can be expressed and found in many organs, but in 
general terms, MBL, CL-L1, conglutinin, CL-43 and CL-46 are found in liver and 
circulation; SP-A and SP-D in lungs and non-pulmonary mucosas such as tears, 
amniotic epithelium, mesenteric cells, etc; CL-K1 in kidneys and CL-P1 in placenta 
and other tissues (Howard et al., 2018).  
Collectin family members have four common structural determinants (Figure 
6): an N-terminal region that is rich in cysteines, a collagen domain whose length 
varies among the family members, a neck region with a helical coiled-coil structure 
and, a carbohydrate recognition domain (CRD), the proper lectin domain. Three 
monomers associate into trimers through the folding of the collagen domains and 
with the participation of the neck region, which is finally stabilized by disulfide 
bonds within the N-terminal regions (Hakansson and Reid, 2000). Some of the 
family members can form higher order oligomers, such as dodecamers with 
cruciform-like shape in the case of SP-D or conglutinin, or for example 
octadecamers with bouquet-like shape, in the case of SP-A and MBL (Holmskov, 
2000).  
 
Figure 6: Structural domains in collectin proteins. Taking as an example the SP-D monomer, it 
contains the N-terminal domain, followed by a long collagen domain, whose length changes among 
the different collectins. The collagen domain is continued by the neck domain that presents a coiled-
coil structure, and finally a globular region at the C-terminal end, which constitutes the carbohydrate 
recognition domain (CRD).  
CRD
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Collectins are pattern recognition molecules that recognize carbohydrate 
structures or lipid moieties attached to the surface of microbes. The minimal ligand 
recognition unit appears to be the trimeric carbohydrate recognition domain. The 
presence of calcium ions in the calcium binding sites within the CRD is essential, 
because it allows this region to adopt a specific conformation that permits to 
establish interactions with the hydroxyl groups contained in the carbohydrate 
structures, which are decorating the surface of pathogens (Hakansson and Reid, 
2000, Seaton et al., 2010). Binding to pathogens may result in microbial clearance 
through aggregation, agglutination, inhibition of microbial growth, opsonization 
and activation of phagocytosis. Moreover, MBL can also induce complement 
activation. Last, collectins may also modulate inflammatory and allergic responses, 
affect apoptotic cell clearance and modulate the adaptive immune system 
(Holmskov, 2000, van de Wetering et al., 2004, Howard et al., 2018).  
 
¨ Surfactant protein A (SP-A) 
Surfactant protein A can be found as two isoforms in humans: SP-A1 and SP-
A2 (Floros et al., 2009). Its principal location is the lung, but it can be also found 
in other parts of the body, for example in the gastrointestinal and renal system 
(Vieira et al., 2017). One of the key differences between both protein isoforms is 
the amino acid in position 85, a cysteine in SP-A1 and an arginine in SP-A2, which 
affects protein oligomerization and somehow protein surfactant-related activities 
(Wang et al., 2007). Three 35 kDa monomers with the characteristic collectin 
structure associate intro trimers of 105 kDa (Figure 7, left). It has been proposed 
that each trimer consists of two SP-A1 molecules and one SP-A2 molecule (Voss et 
al., 1991, Wang et al., 2004). In native human SP-A purified from bronchoalveolar 
lavage, structures composed of up to 6 trimeric units have been observed, 
octadecamers (~650 kDa) with a bouquet-like shape (Palaniyar et al., 2001).  
SP-A recognizes and binds carbohydrates on the surface of microbes, and 
surfactant phospholipids, preferentially DPPC, by its CRD domains in the presence 
of calcium (Palaniyar et al., 2001). Carbohydrate binding preference has been 
determined by in vitro solid phase-binding assays using adsorbed mannan, and 
resulted to be: N-acetylmannosamine > L-fucose > maltose > glucose > mannose, 
with no inhibition observed by galactose, N-acetylglucosamine or N-
acetylgalactosamine (Haczku, 2008).  
Generation of recombinant versions of SP-A1 and SP-A2, as well as 
humanized mice encoding each protein, have been performed to study the 
structural and functional differences between these two variants. SP-A1 has been 
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shown to form higher order oligomers and to carry out a more important role in the 
biophysical activity of lung surfactant, whereas, SP-A2 is assembled into less 
oligomerized structures and it could be more implicated in innate immune 
functions, based on the published literature (Wang et al., 2004, Wang et al., 2007, 
Sanchez-Barbero et al., 2007, Lopez-Rodriguez et al., 2016).  
 
Figure 7: Structure and oligomeric forms of surfactant proteins SP-A and SP-D. In both cases, three 
monomers with the typical collectin structure associate into trimers. SP-A (left), the association of 6 
trimers originates octadecamers with a bouquet-like conformation. SP-D (right), the association of 4 
trimers forms a dodecamer. Adapted from (Vieira et al., 2017). 
 
SP-A host defense functions include interactions with monocytes and 
macrophages to mediate chemotaxis and phagocytosis and interactions with 
microbes to facilitate their clearance: i) bacteria, for example Staphylococcus 
aureus and Mycobacterium tuberculosis, ii) virus, like respiratory syncytial virus, 
and iii) fungi, such as Pneumocystis carinii (Kishore et al., 2006, Haczku, 2008). 
Moreover, it also participates in allergen clearance and modulation of the allergic 
response (Wang et al., 1998). 
 
¨ Surfactant protein SP-D 
In 1985, Phelps and Taeusch designated a class D of surfactant proteins that 
contained uncharacterized basic proteins of 40-45 kDa (Phelps and Taeusch, 
1985). In 1988, Persson and colleagues identified a collagenous glycoprotein of 43 
kDa, which was synthesized by rat type II pneumocytes, and it was called CP4 
(Persson et al., 1988). One year later, CP4 was purified from bronchoalveolar 
lavage of rats as part of lung surfactant and it was characterized biochemically. It 
was proposed to be designated and named as surfactant protein SP-D (Persson et 
al., 1989), according to the accepted nomenclature for surfactant-associated 
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proteins (Possmayer, 1988). Since 1989, many structural and functional studies 
have been carried out to elucidate the structure and function of SP-D.  
 
1. Structure 
SP-D encloses the four characteristic structural domains of collectin proteins: 
N-terminal domain, collagen domain, neck domain and carbohydrate recognition 
domain (CRD). The structure of the protein is described for human SP-D (Figure 8), 
which contains 355 amino acids (375 considering the signal peptide added at the 
N-terminal end). SP-D has been observed as a mixture of oligomeric forms: trimers, 
which are formed by the association of 3 monomers, dodecamers (4 trimers) and 
large oligomers (³ 6 trimers), so-called fuzzy balls (Crouch, 1998, Crouch, 2000, 
Kishore et al., 2006).  
 
 
Figure 8: Amino acid sequence and domain organization of hSP-D. The segments of the sequence 
defining the different protein domains are shaded with different colors: N-terminal (orange), collagen 
(blue), neck (yellow) and CRD (green). Amino acids Met11, Thr160 and Ser270 are in bold as possible 
genetic variants of the protein. Cysteines Cys15 and Cys20 are in red bold letter. Glycosylated (blue 
Y in the protein scheme at the bottom) residue N70 is in bold green. Hydroxylated prolines are in 
brown (Leth-Larsen et al., 1999). Lysines marked with the asterisk are always found O-glycosylated, 
the rest of lysines in bold brown can be found as partly O-glycosylated and/or hydroxylysine 
residues. 
 
A. N-terminal domain:  
The amino terminal region contains two conserved cysteines: Cys15 and 
Cys20, which are important for protein oligomerization (Crouch, 2000). These 2 
cysteines form interchain disulfide bonds to stabilize SP-D trimers. It has been 
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observed that a truncated version of SP-D, produced by the substitution of these 
cysteines by serines, may form trimers but those are not stabilized and cannot 
assemble into larger oligomers (Brown-Augsburger et al., 1996b).  
 
B. Collagen domain: 
SP-D possesses a long collagen domain formed by 59 repetitions of the triplet 
G-X-Y (in which the first amino acid is always glycine and, X and Y are different 
amino acids) (Crouch et al., 1994b, Crouch, 2000). There are several prolines and 
lysines within the collagen domain that can be hydroxylated, and hydroxylysines 
can be further O-glycosylated. In addition, SP-D collagen domain has a N-
glycosylation site in the asparagine in position 70 (Figure 8). The structure of the 
glycan attached to this Asn70 has been described as a core-fucosylated biantennary 
structure, containing N-acetylglucosamine (GlcNAc) and galactose (Leth-Larsen et 
al., 1999). Proline hydroxylation is important for the stabilization of the collagen 
helix, but the role of glycosylated hydroxylysines and the N-glycosylation in Asn70 
is not fully understood. It has been described that the N-glycan is not determinant 
for protein secretion by cells, oligomerization or interaction with several 
microorganism (Brown-Augsburger et al., 1996a, Crouch, 2000). 
 
C. Neck domain: 
This short peptide has an a-helical structure and contains four heptads with 
hydrophobic residues at position “d”, being leucine in the first three heptads and 
tyrosine in the last one (C-terminal side). The positions of these hydrophobic 
residues, as well as the consensus aromatic residues Phe225 and Tyr228, are important 
to maintain a stable a-helical coiled-coil structure in trimers (Zhang et al., 2001b).  
It has been shown that the neck domain is critical for protein trimerization, because 
truncated versions lacking the complete neck domain were only found as 
monomers. It was proposed that the role of the coiled-coil structure is to align the 
collagen chains to facilitate the subsequent “zipper-like” folding of the three chains 
until the N-terminal domain (Zhang et al., 2001b).  
 
D. Carbohydrate recognition domain (CRD): 
This domain attributes lectin activity to SP-D. It has a globular structure with 
7 b-strands and 2 a-helical segments (Figure 9A). There are four cysteines that form 
intrachain disulfide bonds Cys261-Cys353 and Cys331-Cys345. Each CRD contains 3 
calcium binding sites, where 3 calcium ions are coordinated to specific amino acids 
of the protein (Figure 9B). Calcium ion 1 is coordinated to the lateral chains of 
Glu321, Asn323, Glu329, Asn341, Asp342 and to the main carbonyl chain of Asp342. In the 
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absence of a carbohydrate ligand, coordination is completed by two water 
molecules. In the presence of a carbohydrate ligand, such as glucose or maltose, 
the positions occupied by the two water molecules are substituted by the hydroxyl 
groups in carbons 3 and 4 of the carbohydrate hexose. Moreover, 4 protein residues 
coordinate with those two hydroxyl groups: Glu321 and Asn323 with O3’ atom 
(oxygen atom of OH-group in carbon 3) and Glu329 and Asn341 with O4’ atom; all 
these four amino acids are also calcium-coordinators. Calcium ions 2 and 3 are 
coordinated also with some CRD amino acids and water molecules, and it seems 
that they do not interact with ligands, at least, with monosaccharides or 
disaccharides. It is unknown whether they collaborate in the interaction with more 
complex structures. Last, when SP-D is in its trimeric form a forth calcium binding 
site was found within the funnel in the cavity surrounded by the 3 CRD domains 
(Shrive et al., 2003).  
 
Figure 9: Structure of the carbohydrate recognition domain of SP-D. A, topological representation 
of the secondary structure elements in C-type lectin domain of SP-D. Segments with b-strand (1-7) 
and a-helical (1-2) secondary structures are numbered. Amino acids denoted with encircled 
numbers 1-5 are the ones coordinated to the carbohydrate binding calcium ion 1. The remaining 
amino acids indicated in the structure are conserved among collectin proteins. Image taken from 
(Hakansson and Reid, 2000). B, trimeric structure of a truncated version of hSP-D composed by 
neck and CRD domains, which is bound to maltose. Viewed perpendicular to the molecular 3-fold. 
Calcium ions are numbered and represented as green circles. Maltose is bound to calcium binding 
site 1. Image taken from (Shrive et al., 2003).  
 
In terms of ligand recognition and binding, it is important the amino acid in 
position 335, a phenylalanine, due to its aromatic ring, to stablish interactions with 
protein ligands (Crouch et al., 2006).   
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Trimeric units are the minimal oligomeric form observed in SP-D. Trimers 
are formed through the folding of the collagen region of three monomers into a 
triple collagen helix and the coiled-coil formation at the neck domains level. 
Trimeric structures are stabilized by interchain disulfide bonds at the N-terminal 
domain. Four trimers are joined through the N-terminal regions and form 
dodecamers with a cruciform structure (Figure 7, right). Last, large oligomers, so-
called fuzzy balls or asterisk-like structures, are composed by a variable number of 
trimeric arms from 6 to 30 or even more. The three-dimensional aspect of those 
large structures is not fully clear, as they have been observed deposited onto 
substrates by electron microscopy (EM), with an asterisk-like shape, but they could 
have spherical shape in solution, therefore so-called fuzzy balls (Crouch et al., 
1994b, Crouch, 2000, Sorensen, 2018). Despite all the structural studies, up to 
now, it is not fully understood how trimers assemble into dodecamers and larger 
oligomers, as well as the kind of interactions leading that process.  
 
2. Synthesis, processing and regulation of expression 
Surfactant protein SP-D is encoded by a single gene with 7 exons localized 
in the chromosome 10, particularly at 10q22.2-23.1 region in close proximity to 
SP-A and MBL genes (Crouch et al., 1993b).  
 
 
Figure 10: SP-D gene map, transcription and translational products and synthesis in ATII cells. 
Left, chromosome exons encoding SP-D and transcription products. Modified from (Vieira et al., 
2017). Right, SP-D synthesis in alveolar type II cells (ATII). SP-D monomers (M) are synthetized and 
partly glycosylated in the rough endoplasmic reticulum (RER) and assembled into trimers (T) and 
dodecamers (D). From RER, SP-D goes to the Golgi apparatus where the protein is further 
glycosylated and then secreted to the alveolar sub-phase.  
 
In lungs, synthesis of SP-D monomers takes place in the rough endoplasmic 
reticulum (RER) of type II pneumocytes and in bronchial epithelial cells, the non-
ciliated Club (clara) cells (Sorensen, 2018). This includes: the folding of the C-
terminal carbohydrate recognition domain, glycosylation of asparagine 70 and 
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hydroxylation of prolines and lysines within the collagen domain. Afterwards, 
trimerization is driven by neck domains and followed by the formation of the 
collagen triple helix, which is finally stabilized by disulfide bonds at the N-terminal 
domains (Figure 10). Association of trimers into dodecamers still happens in the 
RER and then molecules are transported to the Golgi apparatus where 
oligosaccharide maturation takes place prior to secretion (Brown-Augsburger et al., 
1996a). To date, nothing is known about the assembly of larger oligomers, whether 
they are also assembled in the RER or once the protein is secreted. SP-D oligomers 
are secreted to the alveolar aqueous phase where the protein carries out its function.  
SP-D is detected in lungs of 10-20 weeks’ fetuses at low concentrations and 
protein levels increase during gestation until labor (Stahlman et al., 2002, Sorensen 
et al., 2007). Several factors have been described to regulate its expression, being 
increased by retinoblastoma protein, activation of the calcineurin/NFAT pathway, 
MAP-kinase, dexamethasone, maternal steroid treatment and TNF-a (Sorensen et 
al., 2007, Sorensen, 2018). On the other hand, expression was inhibited by nitric 
oxide synthase inhibitor (L-NAME), inhibitors of phosphoinositide 3-kinases (PI3Ks) 
and inhibitors of MEK1 activation (Sorensen, 2018).  
In vitro, recombinant SP-D has been synthesized in several production 
systems, including mammalian cell lines, E. coli and Pichia pastoris. The most 
widely used system has been the mammalian cell line CHO-K1, which produces 
recombinant SP-D properly folded exhibiting the same oligomeric forms than the 
native protein, as well as its post-translational modifications: hydroxylations and 
glycosylations (Salgado et al., 2014).  
 
3. Gene differences  
Three different polymorphisms have been found in the coding sequence of 
human SP-D. Codons corresponding to amino acid residue 11 (Met or Thr), residue 
160 (Ala or Thr), and residue 270 (Ser or Thr) (Figure 8, amino acids in black bold) 
(Crouch et al., 1993b, DiAngelo et al., 1999). Further studies have demonstrated 
that those modifications can involve structural changes in protein conformation, 
different protein levels in serum and altered susceptibility to various diseases (Leth-
Larsen et al., 2005). Genotyping studies of serum hSP-D from Caucasian individuals 
have indicated a linkage between Met11, Thr160, and Ser270, and between Thr11, 
Ala160, and Thr270 (Leth-Larsen et al., 2005). 
Variations in amino acids at position 160 and 270 have not shown 
consequences in protein structure, levels and correlation with diseases. However, 
the presence of a methionine or a threonine at position 11 involves some changes 
in the protein. A study performed with a north European population showed the 
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allele frequency distribution as 59% methionine and 41% threonine (genotype 
distribution was Met/Met11 (35.4%), Met/Thr11 (47.1%), Thr/Thr11 (17.5%)). hSP-D 
expressing the Met11 allele contained a mixture of low (trimers) and high 
(dodecamers and fuzzy balls) molecular weight oligomers, whereas in the case of 
Thr11 only low molecular weight forms (trimers) were found. Besides, it was 
observed an implication in protein activity where the Thr11 showed lower activity 
binding to bacteria and Influenza A Virus (IAV), while the Met11 variant was more 
active (Leth-Larsen et al., 2005). Last, Met11 allele was associated with severe 
respiratory syncytial virus infection in infants (Lahti et al., 2002), while Thr11 could 
increase susceptibility to tuberculosis (Floros et al., 2000).  
It has been documented by Mason and colleagues that when a threonine is 
found in position 11, that threonine could be also glycosylated, giving as a result 
an SP-D monomer with a molecular weight of 50 kDa. They suggested that this 
increase in molecular weight could be caused by the extra glycosylation in Thr11 
which would not happen in the case of the Met11 variant (Mason et al., 1998). 
Differences in SP-D amino acid sequence have been found between 
different species. The Asn70 that constitutes the N-glycosylation site, and the 
collagen triplet where it is contained (NGS) are conserved among many species 
(Figure 8). Porcine SP-D showed an extra N-glycosylation site in the Asn323, located 
in the CRD (van Eijk et al., 2002). Variations in the most abundant oligomeric form 
have been shown between species, for example, dodecamers appear to be the most 
abundant oligomer in rat SP-D, fuzzy balls in pigs, while in humans there is a 
similar distribution between both (Crouch et al., 1994b, van Eijk et al., 2002, 
Sorensen et al., 2009). Despite these qualitative observations, due to the lack of a 
quantitative reproducible method, the real distribution of oligomeric forms is still 
unknown. The interactions and amino acids involved in the formation of large 
oligomers are not fully understood, as well as whether the differences in the amino 
acid sequences between species could influence them.  
 
4. Functions of SP-D  
SP-D participates in the host defense of lungs. It recognizes certain ligands 
in invading microbes and stimulates host cells to boost clearance of pathogens. 
Also, it regulates the innate immune response in the lungs stimulating pro- or anti-
inflammatory pathways (Sorensen, 2018). Moreover, it is involved in lung surfactant 
homeostasis, regulating phospholipid pool sizes and accumulation in the alveolar 
sub-phase (Ikegami et al., 2005).  
 
A. SP-D Ligands 
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Carbohydrates are the principal structures recognized by SP-D at the surface 
of pathogens. The carbohydrate recognition domains of the protein carry out this 
function, which preferentially recognize D-glucopyranosides. The carbohydrate 
binding preference of SP-D has been determined by solid binding assays using 
maltosyl-BSA to be: N-acetylmannosamine > maltose > mannose > glucose, fucose 
> galactose, lactose, glucosamine > N-acetylglucosamine (Crouch, 1998, Crouch 
et al., 2006, Haczku, 2008, Sorensen, 2018). This preference order changes 
between proteins from the collectin family and highly influences the ligand-
specificity between the family members (Holmskov, 2000). Carbohydrates are an 
important component of lipopolysaccharides (LPS), which constitutes the major SP-
D ligand in gram negative bacteria (Kuan et al., 1992, Lim et al., 1994). LPS is 
composed by the lipid A (anchor to the bacterial membrane), a core 
oligosaccharide structure, and the O-antigen (a repetitive glycan polymer which 
differs between strains) (Figure 11). LPS is referred in the literature as smooth or 
rough LPS, which depends on the nature of its O-antigen. When the O-antigen 
carbohydrate chains are reduced or eliminated, it is considered as rough LPS, 
whereas it is smooth LPS when the intact O-antigen is preserved. It has been 
published that SP-D preferentially binds to rough forms of LPS (Kuan et al., 1992, 
Yamazoe et al., 2008). 
 
 
Figure 11: Lipopolysaccharide (LPS) structure. Both molecules represent LPS. O-antigen is 
represented in red, the LPS core in blue and green and the lipid A in yellow (left) and black (right).  
 
SP-D also binds to other two lipid ligands: phosphatidylinositol (PI) and 
glucosylceramide in a calcium-dependent manner and this binding is inhibited by 
competing sugars (Crouch, 1998). PI seems to be the PL that allows SP-D to interact 
with lung surfactant membranes. It has been observed that SP-D binds to PI 
LPS
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(Ogasawara et al., 1992) and to glucosylceramide (Kuroki et al., 1992) on thin-layer 
chromatography. In addition, it has been shown that SP-D interacts with PI-
containing liposomes, and that the collagen domain could be important for these 
interactions conferring an adequate spacing between trimeric CRDs (Ogasawara 
and Voelker, 1995). 
Nucleic acids have been also described as SP-D ligands. SP-D binds to DNA 
through the collagen domain by non-covalent interactions. Although the collagen 
domain leads this interaction, it has been shown that in the presence of calcium 
this binding is stronger, so probably the CRD might contribute to it (Palaniyar et al., 
2004). 
Other SP-D-binding ligands have been published like proteins from the 
scavenger receptor cysteine rich family, such as glycoprotein-340 (GP-340) 
(Holmskov et al., 1997), or defensins like decorin (Nadesalingam et al., 2003). 
 
B. Interaction with microorganisms 
SP-D interacts with different strains of bacteria, viruses and fungi. The 
external surface of these organisms is rich in diverse polysaccharides and 
glycoconjugates that are recognized by SP-D. 
- Bacteria 
In gram negative bacteria, SP-D binds to the core oligosaccharides 
(glucose and/or heptose) of LPS molecules anchored to the outer wall of 
bacteria (Kuan et al., 1992, Lim et al., 1994, Crouch, 2000). It has been 
found that SP-D binds to Klebsiella pneumoniae, Pseudomonas aeruginosa, 
Haemophilus influenzae and Escherichia coli (Pikaar et al., 1995, Crouch, 
1998).  
In gram positive bacteria the mechanism of binding has not been 
completely elucidated. It seems that it could be mediated by SP-D binding 
to lipoteichoic acids and peptidoglycan, components of the gram-positive 
cell walls, as it has been demonstrated for Staphylococcus aureus and 
Streptococcus pneumoniae (Hartshorn et al., 1998, Crouch, 2000, Kishore 
et al., 2006). 
It has been also reported that SP-D binds to lipoarabinomannan in 
Mycobacterium tuberculosis (Ferguson et al., 1999).  
- Viruses 
It has been observed that SP-D binds to high-mannose oligosaccharides 
expressed on the hemagglutinin or neuraminidase of specific strains of 
influenza A viruses (IAVs), and it interferes sterically with hemagglutinin 
activity (Hartshorn et al., 1996b).  
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SP-D can interact with other respiratory viruses, such as the Rous 
sarcoma virus, through the G protein of the virus (Hickling et al., 1999). 
- Fungi 
In Pneumocystis carinii SP-D binds to gpA, a mannosylated glycoprotein 
associated to trophozoites, and to the b-glucans in the cell wall. It was also 
reported that SP-D binds to Cryptococcus neoformans, Aspergillus 
fumigatus, Candida albicans and Saccharomyces cerevisiae. The interaction 
with those lasts is not well understood, although it has been proposed that it 
could be mediated by the presence of b-glucans in the cell wall (Crouch, 
2000). 
 
SP-D binding to all these pathogens mediates viral agglutination, inhibition 
of the hemagglutination activity of IAV, bacterial aggregation, and inhibition of 
bacterial growth by membrane permeation (Figure 12). All of these actions 
contribute to stop microbial invasion and favor their clearance. Moreover, SP-D 
binding can promote opsonization of the microbes that will end up in their 
elimination by phagocytic cells (Crouch, 2000, Ariki et al., 2012, Vieira et al., 
2017).  
C. Interaction with host cells and modulatory effect in immune responses 
SP-D can interact with host cells and in this way, it regulates mechanisms of 
phagocytosis and cellular responses. One of the consequences of SP-D binding to 
bacteria, viruses and fungi, as well as to apoptotic cells, is their opsonization, in 
other words, they are marked to be deleted. Therefore, those organisms will be 
cleared by phagocytic cells, such as macrophages, avoiding their accumulation and 
harmful effects in the alveolar space.  
Another important role, mediated by its opsonin function, is to avoid the 
accumulation of substances with antimicrobial activities that are released by 
different cells, and help to agglutinate microbes. This is the case of neutrophils 
extracellular traps (NETs) released by neutrophils under microorganism invasion. 
NETs are a mesh of decondensed chromatin fibers decorated with antimicrobial 
granular proteins, that help to capture and ensnare bacteria (Brinkmann et al., 
2004). They have a defensive antimicrobial function, but their overaccumulation 
due to overproduction or insufficient clearance has damaging effect for lung tissues. 
In this way, SP-D binds to those NETs, signaling their phagocytosis by macrophages 
(Douda et al., 2011, Cheng and Palaniyar, 2013).  
SP-D binds and regulates the expression of some cell surface receptors to 
induce phagocytosis or to regulate the immune responses. SP-D bound to infectious 
agents may interact through its collagen domain with the calreticulin-CD91 
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complex in phagocytic cells, driving phagocytosis and enhancing the 
proinflammatory response (Figure 12). Interaction of SP-D with SIRP-a (Signal-
Inhibitory Regulatory Protein alpha) through its CRD, results in an inhibitory signal 
preventing activation of mononuclear leukocytes. However, when the CRD is 
already occupied by a ligand, SP-D is suggested to interact with the calreticulin-
CD91 complex through the collagen domain, instead of SIRP-a, and promote 
inflammatory cell activation (Vieira et al., 2017, Sorensen, 2018).  
 
 
Figure 12: SP-D function in lung homeostasis. Representation of SP-D interactions with 
microorganism and with host cells to eliminate the pathogens and modulate the immune response. 
Regulation of the PL pool of LS is also represented. Elements of the figure are not in real scale. 
References detailed in the main text. 
 
SP-D inhibits the inflammatory response induced by LPS. The CRD domains 
of SP-D bind to MD-2 in TLR4/MD-2 expressing cells, to the carbohydrate moiety 
of CD14 (a macrophage receptor for LPS) in CD14/TLR4 complex and to TLR2. SP-
D binding to these receptors causes suppression of the inflammatory pathway and, 
thereby, inhibition of LPS-induced production of cytokines and inflammatory 
mediators (Sorensen, 2018, Vieira et al., 2017).  
On the other hand, the Osteoclast-Associated Receptor (OSCAR), expressed 
in inflammatory monocytes, macrophages and dendritic cells can interact with the 
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collagen domain of SP-D and cause a pro-inflammatory response, causing the 
release of TNF-a and other cytokines (Vieira et al., 2017, Sorensen, 2018). 
SP-D regulates the production of reactive oxygen species (ROS). Interaction 
of the SP-D collagen domain with the leukocyte-associated immunoglobulin-like 
receptor 1 (LAIR-1) results in a functional reduction of ROS production by 
neutrophils (Sorensen, 2018).  
SP-D also interferes in the adaptive immune response. It suppresses T-cells 
activation and inhibits its proliferation. This finding agrees with the phenotype 
observed in SP-D null mice, where increased concentrations of activated 
lymphocytes were found, as observed by the increased proportion of CD4+ and 
CD8+ T cells that express CD25 and CD69 (Wright, 2005). 
 
D. Interaction with lung surfactant lipids 
Surfactant protein D participates in surfactant lipids homeostasis (Korfhagen 
et al., 1998). It has been found that SP-D regulates surfactant lipid pool sizes by 
participating in the conversion of surfactant large aggregates (LA) of LS into small 
aggregates (SA). In agreement with that, SP-D-/- mice present increased amounts of 
LA, and both LA and SA display abnormal structures with higher lipid density and 
size (Ikegami et al., 2005). It is known that ATII cells preferentially uptake SA forms 
of LS. As a consequence of the impaired surfactant structures and conversion to SA 
in SP-D-/- mice, LS uptake by type II pneumocytes is affected, which provokes an 
accumulation of surfactant lipids in the alveolar aqueous sub-phase (Ikegami et al., 
2005). These alterations are restored upon administration of full-length SP-D to the 
null mice. It has been found that there is a direct effect of the protein over the lipid 
aggregates, not mediated by SP-D/ATII interactions. Interestingly, SP-D levels rise 
after birth and reach a peak at day 3-5 paired with PI levels. Therefore, the 
interaction of SP-D and PI containing vesicles has been a matter of research. It has 
been found that SP-D interacts and carries out a lytic activity on PI-containing 
vesicles, which is greater with increasing PI concentrations (Ikegami et al., 2009). 
In addition, the structure of LS membranes after birth is similar to those in SP-D null 
mice, and they change to the normal structures during the first days of life. 
However, the CRD and neck domains of the protein are not sufficient to carry out 
this function. It has been shown that the presence of full-length protein is necessary, 
containing dodecamers and large oligomers, to restore efficiently this dysregulation 
(Ikegami et al., 2009). 
Despite those findings, the mechanisms by which SP-D controls surfactant 
lipid pools and influences ultrastructure are not fully understood. SP-D interacts 
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with PI through the CRD domain, but paradoxically, it is necessary to have a protein 
with the N-terminal domain and the collagen domain to perform this function. 
 Last, a protective role against PL oxidation by reactive oxygen species (ROS) 
has been also described for SP-D (Bridges et al., 2000).  It has been proposed that 
SP-D directly interferes with free radical formation or propagation, protecting lung 
surfactant lipids and hydrophobic proteins from oxidation, which is translated into 
protection of LS biophysical activity.   
 
In summary, SP-D functions are important in lung homeostasis at two levels: 
breathing and immune defense, with a stronger role in the last one. On the one 
hand, it regulates PL pools in lungs, participating in LS recycling. On the other hand, 
in the context of the immune defense, SP-D actions are focused to eliminate 
invading pathogens, in a way that the immune response will be always balanced to 
clear the microorganisms, without provoking an exacerbated inflammatory 
response that could damage lung tissues and have the opposite effect.  
It should be kept in mind that some of the SP-D functions are not very 
specific; the protein recognizes carbohydrate structures as well as other collectins 
do, such as SP-A. This is the key for a rapid first response to pathogens invasion in 
the innate immune defense. These two collectins share several duties in lungs, but 
they are distinguished by a different preference of binding to diverse pathogens and 
receptors, and a distinct potency to carry out certain functions.   
 
5. Surfactant protein D levels as a disease marker 
SP-D levels, mainly in serum and bronchoalveolar lavage (BAL), have been 
found to be useful markers in several diseases.  
In pulmonary alveolar proteinosis (PAP) and sarcoidosis, increased 
concentrations of SP-D were found in BAL and serum (Sorensen et al., 2007).  
There are several pulmonary diseases where the air-capillary barrier is 
damaged as a consequence of the course of the disease. As a consequence, SP-D 
leakages from the alveolar spaces to the blood due to the loss of integrity of the 
barrier. This is the case of respiratory distress syndrome (RDS), acute lung injury 
(ALI), cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). In all 
these cases, especially in advanced stages of the pathologies, a reduction of SP-D 
concentrations in BAL and increased levels in sera have been found compared to 
healthy people (Sorensen et al., 2007, Sorensen, 2018). In allergic asthmatic 
patients, serum and BAL SP-D levels were found to be increased (Sorensen, 2018). 
Premature newborn babies have a high risk of developing 
bronchopulmonary dysplasia (BDP). Low levels of SP-D are found in lungs of those 
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patients, together with severe inflammation and impaired breathing, which is also 
caused by the impact of mechanical ventilation in the immature lungs of these 
babies. Interestingly, treatment with exogenous SP-D inhibits the lung inflammation 
caused by the oxygen ventilation. In this case, SP-D apart of being a disease marker, 
has been shown to be a potentially effective treatment for the disease (Awasthi et 
al., 1999, Ikegami et al., 2006, Sato et al., 2010).  
 
6. SP-D beyond the lung  
SP-D has been found in many other locations and expressed by other non-
pulmonary cells in the human body. The role and functions of SP-D in those extra-
pulmonary locations is under constant revision nowadays. So far, it is believed that 
SP-D acts as a pattern recognition molecule as in lungs, collaborating in the host 
defense. A very recent review written by Grith Sorensen collected and revised all 
human organ systems and locations for SP-D that include: the integumentary, 
digestive, urinary, reproductive, nervous and circulatory systems, as well as, some 
glands (Sorensen, 2018). 
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Surfactant protein SP-D, can be found in a variety of oligomeric forms that 
include trimers, dodecamers and larger oligomers. It is known that disulfide bonds 
stabilize trimers, but the pathway and kind of interactions involved in the assembly 
of higher order oligomers is unclear, as well as the quantitative distribution of those 
in human and recombinant versions of the protein.  In addition, it is still unknown 
whether those different oligomeric forms could affect protein activity or have 
different functions.  
In the pulmonary context, SP-D has its essential role in the innate immune 
defense of the lungs, where it opsonizes pathogens that would be further cleared 
from the airways by immune cells. Furthermore, an alteration of lung surfactant 
metabolism has been reported in mice lacking SP-D (SP-D-/- knock out). However, 
how the contribution of SP-D to lung homeostasis could protect lung surfactant 
biophysical functions, especially under inflammatory insults, has not been properly 
explored. 
Altogether, the main objective of this Thesis was to characterize SP-D 
oligomeric forms, the kinds of interactions that drive the oligomerization pathway 
and the possible distinct activity of those oligomers, using human SP-D and a full-
length recombinant version of the protein. In addition, to study the protective role 
of SP-D for lung homeostasis and breathing compliance under inflammatory 
conditions.  
 
The specific objectives were: 
 
¨ Characterization of SP-D oligomeric forms and its oligomerization 
pathway. Identification and quantification of the distribution of the different 
oligomeric forms in a recombinant version of human SP-D. Study of the 
interactions that govern the oligomerization process and how they change 
under different conditions, such as pH. (Results, chapter 1). 
¨ Evaluation of the activity and function of the different oligomers. Isolation 
of rhSP-D oligomeric forms and comparison of their activity to aggregate and 
bind to bacteria. (Results, chapter 2). 
¨ Structural and functional characterization of human SP-D. Quantative 
distribution of the oligomeric forms of hSP-D purified from natural sources. 
Characterization of the glycan structure at the N-glycosylation site of the 
protein. Evaluation of the activity of two human proteins obtained from 
different sources and interpretation of the results according to their 
composition in oligomeric. (Results, chapter 3). 
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¨ SP-D in lung homeostasis: modulation of LPS-induced NETosis and 
prevention of lung surfactant NETs-inactivation. Study of the effect of SP-D 
in LPS induced NETosis, in in vitro and in vivo models. Analysis of the 
inhibitory effect of NETs in lung surfactant biophysical function and the 
activity of SP-D as a NET-protective agent (Results, chapter 4). 
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MATERIALS 
Reagents 
Chemicals and reagents were purchased from Sigma Aldrich (St. Louise, MO, 
USA) unless otherwise indicated in the text. 
 
Porcine lung surfactant (LS) 
Bronchoalveolar lavage was carried out in fresh adult porcine lungs to obtain 
lung surfactant as it has been previously described (Taeusch et al., 2005). One liter 
of cold saline solution (0.9% NaCl) was poured into the lungs through the trachea, 
lungs were massaged and the solution was withdrawn. Two or three lavages were 
performed per respiratory apparatus (trachea and two lungs). The recovered 
bronchoalveolar lavage fluid (BALF) was filtered through a muslin and centrifuged 
(1,000 X g, 5 min, 4 ºC) to remove cells and debris and it was stored at -20 ºC until 
use.  
In order to isolate lung surfactant lipid-protein complexes, BALF was thawed 
and ultra-centrifuged (100,000 X g, 1h, 4 ºC) and surfactant large aggregates were 
pelleted, which contain surface active components of LS. Supernatants were 
discarded and the pellets were resuspended in a 16% NaBr, 0.9% NaCl solution to 
perform a discontinuous density gradient centrifugation (120,000 X g, 2h, 4 ºC). 
The discontinuous gradient was formed with saline solutions that contained 
different concentrations of NaBr – from high to low density: 16% NaBr 0.9% NaCl, 
13% NaBr 0.9% NaCl and 0.9% NaCl. After centrifugation, lung surfactant 
complexes, free of other cell lipids and impurities, are found in a thick white-
yellowish compact layer placed between the middle dense and the lighter dense 
solutions. The material was carefully removed from the tubes, pooled, 
homogenized and diluted with 0.9% NaCl. It was frozen in liquid nitrogen and 
stored at -80 ºC until use.  
Isolated lung surfactant was constituted by surfactant lipids, surfactant 
hydrophobic proteins (SP-B and SP-C) and the hydrophilic protein SP-A. Also, some 
traces of proteins like immunoglobulins and hemoglobin were co-purified 
associated with surfactant complexes. Hydrophilic protein SP-D was mostly lost in 
the first ultra-centrifugation.   
 
Organic extract (OE) of lung surfactant 
Organic extraction of LS was performed to remove its hydrophilic components, 
such as collectin proteins (SP-A and SP-D), following the protocol established by 
Bligh and Dyer (Bligh and Dyer, 1959). Briefly, lung surfactant, methanol and 
chloroform were mixed in a proportion of 1:2:1 (volume), respectively. The mixture 
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was vortexed thoroughly for 30 s and incubated 30 min at 37-40 ºC with gentle 
shaking to allow the flocculation of water-soluble proteins. Then, 1 volume of 
chloroform and 1 volume of water were incorporated and a biphasic solution was 
formed after vortex. The mixture was centrifuged (600 X g, 5 min, 4 ºC) to separate 
the organic from the aqueous phase. The organic phase was kept, and 2 more 
volumes of chloroform were added and mixed with the remaining aqueous phase, 
which was centrifugated again. This step was repeated twice to maximized the 
recovering of hydrophobic material. Pooled hydrophobic fractions were kept at -
20 ºC until use. Phospholipids concentration was determined by phosphorous 
quantification described below (methods, page 64). 
 
Reconstituted porcine surfactant organic extract 
Organic extract reconstituted in an aqueous buffer was employed to evaluate 
the effect of some components in the surface-active properties of lung surfactant.  
First, 335 µL of OE at 9 µg/µL (phospholipid concentration) were first dried 
under nitrogen flow to evaporate the organic solvents and then, under vacuum in 
an UNIVAP (2h at 37 ºC) to eliminate chloroform traces. Afterwards, surfactant 
lipids and proteins were reconstituted to a final PL concentration of 60 mg/mL in a 
2 consecutive steps incubation process, where incubations were done with 
intermittent shaking (10 min shaking/10 min repose at 1400 rpm):  
1st step - 25 µL of buffer 150 mM NaCl, 5 mM Tris (pH 7.4) were added, fully 
mixed and incubated at 45 ºC for 30 min. 
2nd step - 25 µL of purified NETs (see page 58) resuspended in RPMI media 
with a DNA concentration of 0.65 µg/mL were also added, mixed and 
incubated in this case at 37 ºC for 30 min.  
To assess whether SP-D could restore NETs-inhibited surfactant function, 25 µL 
of hSP-D (page 58) in 150 mM NaCl, 20 mM Tris (pH 7.4), 5 mM EDTA at 808 
µg/mL were added instead of buffer (final SP-D concentration in the sample respect 
to PL was 0.67% (w/w)) in the first step. EDTA concentration in SP-D buffer was 
compensated to zero with 1 M CaCl2, before incorporating the protein to the 
mixture.  
Reconstituted samples were diluted to a PL concentration of 20 mg/mL with 
purified NETs in RPMI media and incubated 30 min at 37 ºC prior to use them. 
Samples reconstituted in the first and second steps with RPMI media without NETs 
and also with protein buffer without SP-D were prepared as controls.  
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Lung surfactant from PBS or LPS-instilled mice 
Balb/c wild type (WT) SP-D+/+ and Knock out (KO) SP-D-/- mice (generated by 
Dr. S. Hawgood, UCSF) were bred in the Toronto Centre for Phenogenomics (TCP), 
Canada. Mice of two ages, ~15 weeks or ~35 weeks, were used in this study. All 
procedures were performed in accordance with TCP approved protocols and 
ethical guidelines. 
¨ Mice instillation 
For airway instillation, mice were anesthetized with 2-4% isofluorane with 
O2 at 1000 mL/h until they fell sleep. Then, 5 µg of LPS (0182:B12) from E.coli in 
25 µL of sterile PBS or 25 µL of sterile PBS (negative control) were instilled 
intranasally. 24 hours after instillation, mice were sacrificed with an intraperitoneal 
injection of 0.1 mL of Euthanyl (Bimeda-MTC, Cambridge, ON, Canada).  
¨ Bronchoalveolar lavage (BAL) 
The chest of the animal was opened. An intratracheal catheter was tied into 
the proximal trachea and 1 mL of cold buffer (NaCl 150 mM, Tris 5 mM (pH 7.4)) 
was flushed into the lungs and withdrawn by a syringe three time. Three lavages of 
1 mL each were carried out per animal, obtaining around 2.5 mL of BALF from 
each mouse. BAL samples were frozen in dry ice and kept at -80 ºC until use.  
¨ Lung surfactant isolation 
BALs were thawed at 37 ºC and centrifuged for 10 min at 400 X g and the 
pellets were discarded. An aliquot of 400 µL of BAL-supernatant was saved and 
frozen for further experiments (citH3, total protein and DNA concentrations in 
BAL). 2 mL of BAL-supernatants were ultra-centrifuged (100,000 X g, 1h, 4 ºC) to 
pellet lung surfactant components. LS pellets were resuspended in 10 µL of buffer 
(150 mM NaCl, 5 mM Tris 5 mM (pH 7.4)) and PL concentration was determined 
with the phosphatidylcholine quantification kit as stated in methods (page 63). 
Before evaluating their biophysical function in the CBS, samples were diluted with 
the same buffer as before to reach a PC concentration of 10 mg/mL. BALs from mice 
were not pooled, but the LS from each single mouse was evaluated individually.  
The animal work described in this section (instillation and BAL) was carried out 
at the Toronto Centre for Phenogenomics and the laboratory of Dr. Nades Palaniyar 
at the Department of Translational Medicine in SickKids Hospital (Toronto, 
Canada).  
 
Neutrophils extracellular traps (NETs) from human neutrophils 
Neutrophils were isolated from human blood and stimulated with agonists in 
vitro to produce and release NETs. 
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¨ Human peripheral neutrophil isolation 
The study protocol was approved by the Ethics Committee of the Hospital 
for Sick Children, SickKids Hospital (Toronto, Canada). All methods were 
performed in accordance with the relevant guidelines and regulations. Peripheral 
blood from healthy male donors was collected in K2 EDTA blood tubes (Becton, 
Dickinson and Co.) after obtaining informed consent. Polymorph Prep (Axis-Shield) 
protocol was used for separating polymorphonuclear neutrophils from blood, as 
previously described elsewhere (Naffah de Souza et al., 2017, Khan et al., 2017). 
Red blood cells were lysed with a 0.2% NaCl hypotonic solution for 30 s, followed 
by restoring the isotonic condition by adding an equal volume of 1.6% NaCl, 20 
mM Hepes (pH 7.2) solution. Cellular debris were removed performing two 
consecutive washes with 0.85% NaCl, 10 mM Hepes (pH 7.2) buffer. Last, 
neutrophils were resuspended in RPMI medium (Invitrogen; Carlsbad, CA, USA) 
containing 10 mM HEPES (pH 7.2). Cells were counted and viability was checked 
by Trypan blue using a hemocytometer. Purity of neutrophils was determined by 
Cytospin preparation and imaging. Neutrophil preparations with > 95-98% pure 
alive cells were used for NETs production and NETosis experiments.  
¨ NETs preparation and purification 
NETosis was induced in neutrophils using LPS (0182:B12) from E.coli as 
agonist. LPS was added to 100,000 human neutrophils in 1 mL of Roswell Park 
Memorial Institute (RPMI) medium to reach a final concentration of 5 µg/mL. 
Samples were incubated four hours at 37 ºC, 5% CO2 with intermittent gentle 
mixing by inverting the tubes, so avoid the sedimentation of the cells. After the 
incubation, samples were centrifuged at 400 X g for 10 minutes. Supernatants were 
collected and frozen in dry ice. DNA concentration in the purified NETs was 
determined with Quant-iT PicoGreen dsDNA Kit (Invitrogen, Carlsbad, CA, USA) 
following manufacturer´s instructions. 
 
Human surfactant protein D (hSP-D) isolation 
Human SP-D was purified from two different sources, BAL of proteinosis 
patients and amniotic fluid (AF) from cesareans at term pregnancy. The purification 
protocols were different, but the isolation was based in SP-D carbohydrate binding 
properties in both cases. 
¨ hSP-D isolated from proteinosis BAL 
Human SP-D was obtained from therapeutic BALs of individuals suffering 
from pulmonary alveolar proteinosis (PAP) as previously described elsewhere 
(Strong et al., 1998). BAL was filtered through a membrane of 0.22 µm pore size 
and solutions of 1M Tris (pH 7.4) and 1M CaCl2 were added to reach a final 
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concentration of 20 mM and 10 mM, respectively, followed by adjusting pH to 7.4. 
Then, BAL was mixed with maltose-agarose beads, incubated and stirred overnight 
at 4 ºC. SP-D binds through its CRD to the carbohydrate ligands present in the beads 
in a calcium-dependent manner. After incubation, the beads were poured into an 
empty column and the column was packed and washed with 1 M NaCl to remove 
nonspecifically bound components on an AKTA FPLC system (G.E. Healthcare; L. 
Chalfont, UK). SP-D was eluted with a Tris-MnCl2 buffer: 20 mM Tris (pH 7.4), 100 
mM MnCl2.  
Fractions containing SP-D were pooled and concentrated using Amicon filter 
units (10 kDa-pore size membrane) and further purified with a Superose 6 gel 
filtration column (10x300 mm; Amersham Biosciences; L. Chalfont, UK) in 150 mM 
NaCl, 20 mM Tris (pH 7.4), 5 mM EDTA buffer. SP-D eluted as the first sharp peak 
in the void volume, followed by a broaden peak which corresponded to SP-A. 
Protein purity was examined by reducing PAGE-SDS and Coomassie staining, SP-
D monomer was observed as a ~ 43 kDa band (Figure 13).  
 
Figure 13: Schematic representation of SP-D elution profile from Superose 6 column. Inset, 
Coomassie staining of PAGE-SDS for the fractions within the SP-D peak. 
 
¨ hSP-D isolated from amniotic fluid 
Amniotic fluid was collected from women at term pregnancy (³ 37 weeks) 
in programmed cesareans at the Gynecology and Obstetrics Service of “Hospital 
12 de Octubre” (Madrid, Spain) in a collaboration with Drs. Emma Batllori and 
Alberto Galindo. Protocols were approved by the Ethics Committee of the Hospital 
and informed consent was signed by the donors.  
Centrifuge tubes, bottles, resins and columns used in the purification were 
either bought sterile and LPS-endotoxin free or sanitized with 0.2 M NaOH. 
Amniotic fluid samples were filtered through a muslin and centrifuged (1000 
X g, 5 min, 4 ºC) to remove cell debris, followed by ultra-centrifugation (100,000 X 
g, 1h, 4 ºC) to remove lipids and surfactant proteins associated to lipids (SP-B, SP-
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C and the major fraction of SP-A). Supernatants were frozen and stored at -80 ºC 
until employed.  
Prior to affinity chromatography, supernatants were pooled and 1M Tris (pH 
7.4) and 0.5 M EDTA were added to reach a concentration of 20 mM and 5 mM, 
respectively. The fluid was then stirred for 1h at 4 ºC and filtered, first, through a 
strainer of 100 µm-pore and then, in filter bottles with a 0.45 µm-pore size 
membrane. Then, 1 M CaCl2 was incorporated to get a final concentration of 10 
mM and the pH was checked and adjusted to 7.4. The sample was loaded into a 
column with SuperdexÒ-75 beads equilibrated with buffer 100 mM NaCl, 20 mM 
(Tris pH 7.4), 10 mM CaCl2. SP-D binds to the beads through its CRD domains in a 
calcium-dependent manner, as explained before. The column was washed with a 
high salt solution 1 M NaCl, 20 mM Tris (pH 7.4), 10 mM CaCl2 to remove any 
non-specifically bound proteins, such as albumin (Strong et al., 1998). Last, SP-D 
was eluted with a Tris-MnCl2 buffer: 20 mM Tris (pH 7.4), 100 mM MnCl2 in 1 mL 
fractions. PAGE-SDS under reducing conditions developed by silver staining, was 
carried out with 10 µL of each sample to check for fractions that contain SP-D and 
protein purity. Fractions that contained higher concentration of SP-D were dialyzed 
overnight against 200 mM NaCl, 20 mM Tris (pH 7.4), 1 mM EDTA. Afterwards, 
they were aliquoted, frozen in liquid nitrogen and stored at -80 ºC until use. 
 
Production and purification of recombinant human SP-D (rhSP-D) 
Full length rhSP-D (Met11, Thr160, Ser260) was synthesized by Chinese hamster 
ovary (CHO) cells and purified in two-steps chromatography columns. 
¨ Cell culture 
Stably transfected CHO cells expressing SP-D were stored and ready to start 
the cell culture growth produced in Cincinnati Children’s Hospital as previously 
described (Ikegami et al., 2006). Briefly, a dihydrofolate reductase-deficient (DHFR) 
CHO cell line was transfected with a cDNA encoding full length SP-D. Transfected 
cells were selected with increasing concentrations of methotrexate and high 
expressing clones were selected, cloned and stored in liquid nitrogen. 
For protein production, SP-D expressing CHO cells were grown in Iscove’s 
Modified Dulbecco’s Medium (IMDM) (Lonza; Basel, Switzerland) supplemented 
with 10% heat-inactivated fetal bovine serum (FBS), glutamine and antibiotics 
(penicillin and streptomycin) (all from Gibco, Thermo Fischer Sci.; Waltham, MA, 
USA). Cell passages were carried out when confluence was 80%, by trypsin 
treatments, until cells were grown in 2L-roller bottles. For bioproduction, cell media 
was switched to serum free Ex-cellÒ chemically defined CHO media. Cells secrete 
rhSP-D to the media that was harvested to start SP-D isolation. 
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¨ rhSP-D purification 
Chromatography equipment, bottles, resins and tubes used in this 
purification where LPS-decontaminated with 0.2 M NaOH or bought sterile and 
LPS-free. Moreover, water for injections (US Pharmacopeia) was employed to 
prepare the buffers.   
Cell harvested media was supplemented with EDTA (3mM) and stirred 40 
min at 4 ºC, before centrifugation (10,000 X g, 40 min, 4 ºC). Supernatants were 
filtered through 0.22 µm-pore membranes and diluted 1:1 with 25 mM Tris (pH 
7.4). An anion exchange chromatography was carried out with ceramic Q hyperD 
resine (Pall Corp, NY, USA) that was equilibrated with 60 mM NaCl, 20 mM Tris 
(pH 7.4), 0.01% Tween-80 in a column. The media was loaded into the column 
followed by extensive washing with 60 mM NaCl, 20 mM Tris (pH 7.4) to remove 
impurities. Elution of the protein was carried out with 800 mM NaCl, 20 mM Tris 
(pH 7.4). Fractions that contained the protein were identified by dark color and 
PAGE-SDS developed by silver staining. Moreover, protein concentration in the 
fractions was determined by BSA assay (methods section). Protein concentration 
obtained by this method was significantly high, although purity was low. 
¨ rhSP-D from Airway Therapeutics LLC. (Cincinnati, OH, USA) 
The structural characterization of rhSP-D described in Chapter 1 was carried 
out with a rhSP-D preparation provided by Airway Therapeutics LLC. (Cincinnati, 
OH, USA) that was produced by Drs. A. Jain and W.H. Brondyk in Sanofi (Boston, 
MA, USA). The production and purification methods were described in (Arroyo et 
al., 2018), being the foundation of the method the same as described above. 
  
 
SP-D proteins used in this Thesis  
SP-D Source Purified in Experiments 
(Chapter) 
 
hSP-D 
 
BAL proteinosis Palaniyar’s lab 4 
BAL proteinosis Kingma’s lab 1 and 3 
AF Perez-Gil’s lab 3 
rhSP-D 
CHO cells Kingma’s lab 2 
CHO cells Airway Therapeutics – Sanofi 1 
Table 1: List of the different surfactant proteins D (SP-D) preparations used in the present Thesis. 
hSP-D from Kingma’s lab was a gift and rhSP-D from Airway Therapeutics was obtained thanks to a 
collaboration project. Other were produced and purified as part of the experiments of this Thesis. 
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Isolation of the different oligomeric forms of rhSP-D by size exclusion 
chromatography (SEC) 
 Separation of rhSP-D oligomers was addressed by gel filtration 
chromatography using a Sepharose CL-6B equilibrated in 200 mM NaCl, 20 mM 
Tris (pH 7.4), 10 mM EDTA. The rhSP-D preparation used in these experiments was 
the one purified with the ceramic Q hyperD resine. 1 mL of rhSP-D at 4-5 mg/mL 
was applied into the column (1.5 x 90 cm). The elution fractions were collected 
and analyzed by ELISA and AFM (methods section) to identify the isolated SP-D 
oligomers. Fractions of trimers, hexamers and fuzzy balls were identified and used 
for further experiments. 
 A shorter column (1.5 x 40 cm) with the same resin, equilibrated and run 
with the same buffers was used for assessing protein redistribution assays. 
 
METHODS 
Protein quantification 
¨ BCA Assay 
Purified SP-D was quantified with Pierce™ BCA Protein Assay Kit 
(ThermoFisher Sci.; Waltham, MA, USA). In this assay, protein quantification is 
based on Biuret reaction where Cu2+ is reduced to Cu1+ in the presence of proteins 
under alkaline conditions. Then, bicinchoninic acid (BCA) chelates Cu1+ and forms 
a colored complex which absorbs at 562 nm (l = 562 nm) (Smith et al., 1985). The 
stoichiometry of the reaction is shown in figure 14.  
 
Figure 14: Chemical reactions that take place in the BCA assay. 
Quantification was performed following manufacture’s protocol for 
microplate procedure.  
¨ ELISA 
Fractions eluted from the SEC column were assessed by ELISA, with the aim 
to identify the fractions that contained isolated rhSP-D oligomers. It was also 
applied to quantify protein concentration in those fractions that contained the 
oligomers. 
Protein + Cu2+ Cu1+
[OH-] (alkaline pH)
Cu1+ + 2 BCA
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Microtiter plate wells were coated with 100 µL of a mouse antiSP-D 
monoclonal antibody (2D12A88-Seven Hills Bioreagents; Cincinnati, OH, USA) 
diluted 1:5000 in 100 mM NaHCO3-Na2CO3 (pH 9.6) buffer, overnight at 4 ºC. 
Plates were washed 5 times between incubations and all washes and dilutions from 
this point were carried out with dilution buffer (0.05% TBS-tween, 5 mM CaCl2). 
Wells were blocked with 1% BSA in dilution buffer for 1 hour at RT. After washing, 
50 µL of protein samples and appropriate dilutions of standards were added in 
duplicates and incubated for 1 hour. Plates were washed and 50 µL of rabbit anti-
mouse SP-D antiserum (dilution 1:7500) were incorporated and incubated for 1 
hour. After washing, 100 µL of a goat anti-rabbit IgG HRP-conjugated antibody 
(1:10000) were added and incubated for 1 hour. Wells were washed and 100 µL of 
TMB (3,3',5,5'-tetramethybenzidine) (BioFXÒ Surmodics; E. Prairie, MN, USA) 
were added for 2 minutes and the reaction was stopped with 100 µL of 2N H2SO4. 
Plates were read at 450 nm (l = 450 nm) (Kingma et al., 2006). 
The fractions that contained higher levels of rhSP-D in the first ELISA were 
further quantified by a second ELISA-kit (Biovendor; Brno, CZ) that was more 
sensitive.  
 
Phospholipis quantification 
¨ Phosphatidylcholine (PC) quantification 
PC represents ~80% of phospholipid concentration in lung surfactant 
(Veldhuizen et al., 1998). For this reason, PC concentration in LS from mice was 
determined as a reference of phospholipids concentration in those samples, using 
a commercial kit (Spinreact; Girona, ES). Briefly, PC was hydrolyzed by 
phospholipase D to choline and phosphatidic acid. Choline was oxidized to 
betaine and hydrogen peroxide (H2O2) by choline oxidase. Finally, a colorimetric 
reaction took place between H2O2, phenol and 4-aminophenazone to produce a 
colored substance (quinonimine). The absorbance of the sample was measured in 
a spectrophotometer at 505 nm (l = 505 nm) and it was proportional to the PC 
concentration. 
 
Figure 15: Chemical reactions involved in quantification of PC concentration by the commercial Kit 
used.  
PC+ H2O Choline + Phosphatidic acid
Phospholipase D
Choline + 2 O2 + H2O Betaine + 2 H2O2
Choline oxidase
2 H2O2 + Phenol + 4-AP Quinonimine + 4 H2O
POD
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Lung surfactant samples from mice were diluted 1:10 and manufacturer’s 
protocol was performed.  
¨ Phosphorus assay 
Total phospholipid concentration in organic extract from LS was determined 
by phosphorus quantification (Rouser et al., 1966). Samples were dried in glass 
tubes in a sand bath, 0.45 mL of 70% perchloric acid were added and incubated 
(260 ºC, 30 min) to allow phosphorus mineralization. While incubation, tubes were 
capped with glass ampoules to avoid acid evaporation. Then, 3.5 mL of miliQ water 
and 0.5 mL of 2.5% ammonium molybdate (w/v) were added and vigorously mixed, 
followed by addition of 0.5 mL of 10% ascorbic acid (w/v) and incubation at 100 
ºC, 7 min. The reaction of phosphorus with ammonium molybdate generates 
phosphomolybdic acid, which is reduced by ascorbic acid to phosphomolybdate 
that possesses a blueish color. Samples were placed in ice to stop the color reaction 
and measured in a spectrophotometer at 820 nm (l = 820 nm). Samples with a 
known PL concentration were also assessed to build a standard curve, from where 
the concentrations of the unknown samples were interpolated. The values were 
transformed to PL concentrations considering 734 Da as the average molecular 
mass of surfactant lipids.   
 
Cholesterol quantification 
Cholesterol quantification was addressed with a commercial kit (Spinreact; 
Girona, ES), where a colored compound (quinonimine) was generated after 
oxidation of cholesterol with several coupled reactions. Therefore, intensity of the 
color was proportional to the cholesterol concentration in the sample. Briefly, 
cholesterol esters in samples were broken down to free cholesterol and fatty acids 
with cholesterol esterase (CHE) enzyme. Cholesterol was oxidized by cholesterol 
oxidase (CHOD) to 4-cholestenona and hydrogen peroxide (H2O2), which was 
transformed to quinonimine by the peroxidase (POD) enzyme in presence of 
phenol and 4-aminophenazone (4-AP). The absorbance of the sample was 
measured in a spectrophotometer at 505 nm (l = 505 nm). 
 
Figure 16: Chemical reactions involved in cholesterol concentration quantification assessed by the 
commercial kit, described in the text. 
 
Cholesterol esters + H2O Cholesterol + fatty acids
CHE
Cholesterol + O2 4-cholestenona + H2O2
CHOD
2 H2O2 + Phenol + 4-AP Quinonimine + 4 H2O
POD
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Cholesterol concentration in LS samples from mice (diluted 1:5) was 
determined following manufacturer’s kit protocol and all values obtained were 
reported relative to the PC concentration in those samples.  
 
Limulus Amebocyte Lysate (LAL) Assay 
Endotoxin concentrations in purified SP-D were determined with LAL Assay 
(Lonza; Basel, Switzerland). In this method, the endotoxin catalyzes the 
transformation of a proenzyme found in LAL to its active form in a concentration 
dependent manner (Young et al., 1972). Then, the activated enzyme catalyzes the 
release of a color substance (p-nitroaniline) from the substrate that will be measured 
photometrically at 405–410 nm, once the reaction is stopped. Absorbance and 
endotoxin concentration are linear in the 0.1–1.0 EU/mL range. 
Manufacturer’s protocol was followed to determine the endotoxin levels in 
purified SP-D. 
 
Atomic Force Microscopy (AFM) 
The atomic force microscopy belongs to the family of Scanning Probe 
Microcopies. It was first described by Binnig and colleagues (Binnig et al., 1986) 
and its operation principle is based on the tip-sample interactions . Up to now, it 
has been widely applied to characterize the structure of different materials, among 
them, many biological systems (Carvalho and Santos, 2012, de Pablo and Carrion-
Vazquez, 2014).  
¨ Components of the microscope 
The cantilever that scans the surface of the sample has a triangular or 
pyramidal shape commonly, and in its free-end holds what it is referred as the tip. 
The chemical composition of the cantilever defines its hardness. They are made of 
silicon (Si) or silicon nitride (Si3N4), being the ones composed by Si the hardest, 
more appropriate for experiments in air. This cantilever is excited by a small piezo 
in the cantilever holder device and it oscillates at the resonance frequency. The 
mechanical movement of the cantilever is defined by the Hooke’s law: 𝑭""⃗ = 𝒌𝒙"⃗     (eq. 1) 
Where, 𝑘 represents the spring constant of the cantilever and it is relevant in the 
sensitivity of the measurement (de Pablo and Carrion-Vazquez, 2014).  
The laser, which has a wavelength of l = 633 nm, is focused on the tip of 
the cantilever and it is reflected to a four quadrants photodiode. The laser must be 
also aligned with the center of the photodiode, so in non-contact regime the zero 
of lateral and vertical forces correspond to the center of the photodiode. 
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A magnetic disc that holds the sample is placed onto a piezoelectric tube, 
which allows the movement of the sample in the direction X, Y and Z with 
nanometric precision.  
The electronics receives information from the photodiode, it sends it to the 
computer and back to the piezo to respond to the topographic changes in the 
sample. Last, the computer, with a proper signal digital processor. 
 
 
 
Figure 17: Schematic representation of AFM main components described in the text. 
 
¨ Contact and dynamic AFM operational modes 
In contact mode, the tip is permanently in touch with the sample while 
scanning (Binnig et al., 1986). It produces higher resolution images, but it is not 
advisable for biological samples because the higher forces applied over the tip can 
damage and break biological structures.  
In dynamic mode, the cantilever has a sinusoidal oscillation while scans the 
sample and the tip occasionally contacts the sample (de Pablo and Carrion-
Vazquez, 2014). This mode is characterized by the oscillation amplitude and the 
oscillation frequency of the cantilever, and the phase difference between the input 
and the output signal after the feedback of the cantilever. Two dynamic modes have 
been described according to the variable that is controlled by the system: 
Amplitude-Modulation (AM-AFM) or tapping and Frequency-Modulation (FM-
AFM) modes. In tapping mode, the oscillation amplitude is the variable controlled 
by the system and kept constant along the measurements. In these experiments, 
when the tip faces a structure with different height during the scanning of samples, 
the oscillation amplitude changes; this information is received by the feedback 
MATERIALS AND METHODS 
 67 
system, that compensates the change increasing or decreasing the voltage that the 
piezo applies. Therefore, the sample is moved up or down in Y-direction to adjust 
the sample-tip distance and restore the oscillation amplitude. Thus, a topographic 
image of a sample is obtained with the information reported by the movements of 
the piezo to keep the oscillation amplitude constant. 
Only AM-AFM is described here, not FM-AFM, because it was the mode 
used in the present Thesis.  
¨ Sample preparation 
Atomically flatten substrates are needed for AFM experiments. Mica 
moscovita is a phyllosilicate mineral that can be exfoliated in a reproducible way, 
producing atomically flatten surfaces. It was the material used in the present thesis. 
In this Thesis, 20 µL a of protein solution at 0.85 ng/μL was incubated for 4-
5 min onto freshly cleaved mica. The surface was thoroughly rinsed with 6-7 mL of 
deionized water to remove buffer components. Finally, the sample was dried under 
nitrogen air flow. Samples at acidic and basic pH were prepared in the same way, 
but pH was previously changed by dilution up to the final protein concentration 
(0.85 ng/µL), with citrate buffer (200 mM NaCl, 20 mM citrate, 1 mM EDTA) when 
shifting to acid pH or Tris buffer 200 mM NaCl, 20 mM Tris (pH 8.5), 1 mM EDTA 
for basic pH. Protein was incubated at 4 °C during a minimum of 30 min before 
use. 
AFM experiments were performed in Dr. Fernando Herrero Moreno’s laboratory 
at the Centro Nacional de Biotecnología (CNB-CSIC), in Madrid, Spain. The 
samples were scanned under an AFM from Nanotec (Nanotec Electrónica, Madrid, 
Spain) using PointProbePlus tips, type PPP-NCH (Nanosensors, Neuchâtel, 
Switzerland). Amplitude modulation mode (AM-AFM, tapping) was used for 
imaging in air, at room temperature and low humidity. The system was isolated 
from mechanical vibrations and thermal variations. The software employed to 
control the system, imaging processing (general plane subtraction, line flattening) 
and height profiles was the WsxM freeware (Horcas et al., 2007). 
 
Cryo-TEM 
Cryo-TEM implies traditional transmission electron microscopy (TEM) with a 
cryo-sample holder and a specific protocol for preparation of the samples. It is a 
high-resolution technique which allows the observation of unaltered molecular 
structures, because fixation and staining agents are not needed.  
Samples for cryo-TEM are prepared in two steps: i) the solution with the 
molecules is loaded into a holey carbon grid and the excess of solution is removed 
by blotting, ii) the grid is rapidly frozen by plunging it into a cryogen substance. As 
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a result, samples are covered by a thin layer of vitrified water and are kept at 
cryogenic temperatures all the process, even in the microscope holder (Czarnocki-
Cieciura and Nowotny, 2016, Stark and Chari, 2016). 
Then, the structures are observed in a TEM where an electron beam is generated 
and focused on the sample through condenser electromagnetic lens. Some 
electrons are scattered and others go through the sample, which depends on the 
density of the sample. Unscattered electrons hit a fluorescent screen at the bottom 
of the microscope, giving the final image displayed in different grey colors 
according to the density of the components. 
Different dilutions of rhSP-D in the range 0.02-0-04 µg/µL were applied to 
holey carbon copper grids (R2/2; Quantifoil, DE) and vitrified using a Cryoplunge 
(Gatan; CA, USA). The grids were imaged in a JEM-1230 transmission electron 
microscope (JEOL; Tokyo, JP) operated at 100 kV and recorded at a final 
magnification of 5.68 Å/pixel using an F416 CMOS camera from TVIPS (Gauting, 
DE).  
 
Confocal microscopy 
Chamber slides with 12 wells (Ibidi; Munich, DE) were seeded with 100 µL of 
RPMI media containing 50000 neutrophils. The same method described above was 
used for preparing the agonists or agonist with SP-D prior to add them to the cells. 
In this case, two final calcium concentrations were tested: 0.5 mM and 2mM. After 
stimulation, cells were placed at 37 ºC, 5% CO2 incubator for 2 hours. Then, cells 
were fixed with 4% (w/v) PFA overnight at 4 ºC. After fixation, samples were washed 
three times with PBS and then permeabilized with 0.05% (w/v) Triton X-100 for 10 
minutes. Cells were washed three times with PBS again and primary antibodies 
were added to the samples followed by incubation at 4 ºC overnight. The antibodies 
used were anti-myeloperoxidase mouse antibody (ab25989, Abcam; EN, UK) at 
1:500, used for staining MPO (with secondary antibody conjugated with a green 
fluorescence Alexa fluor 488 dye; 1:5000 dilution; ThermoFisher Sci.; Waltham, 
MA, USA), while rabbit anti-citrullinated histone 3 antibody (ab5103; Abcam, EN, 
UK) at 1:500 dilution was used for detecting the presence of citrullinated histone 
H3 (CitH3, with secondary antibody conjugated with a far-red fluorescence dye 
Alexa fluor 647; 1:5000 dilution; ThermoFisher Sci.; Waltham, MA, USA). DNA 
was stained with DAPI (1:100 dilution). After incubation with the secondary 
antibody, slides were washed and mounted by glass cover slips (ThermoFisher Sci.; 
Waltham, MA, USA) with anti-fade fluorescent mounting medium (Dako; CA, 
USA). The images were taken using an Olympus IX81 inverted fluorescence 
microscope with a Hamamatsu C9100-13 back-thinned EM-CCD camera and 
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Yokogawa CSU × 1 spinning disk confocal scan head with Spectral Aurora Borealis 
upgrade, four separate diode-pumped solid-state laser lines (Spectral Applied 
Research, 405, 491, 561, and 642 nm). Samples were imaged at 40×/0.95 
magnification and images were processed by Volocity software (version 6.3, Cell 
Imaging Perkin-Elmer). 
 
Gel electrophoresis and Western Blot 
¨ Native PAGE (polyacrylamide gel electrophoresis) 
Native electrophoresis was carried out in the absence of chemical 
denaturing agents and heating shock. Protein samples were prepared with loading 
buffer (5X) containing 5% Blue G-250 and 1 M 6-aminocaproic acid. 
Electrophoresis was performed in 4-15% polyacrylamide precast gels (BioRad; CA, 
USA)  at 4 ºC at 110V for 30 minutes, followed by 2 hours at 180 V (Schagger, 
2001). 
¨ SDS-PAGE 
For non-reducing conditions, loading buffer (5X) containing 10% SDS, 312.5 
mM Tris (pH 6.8), 50% glycerol, 0.15% bromophenol blue, prepared in miliQ 
water was added to the sample. For reducing conditions, 20% b-mercaptoethanol 
was added to the previously described non-reducing loading buffer. Samples were 
heated at 99 ºC for 10 minutes prior to load them into the gels.  
Gels that contained a different percentage of polyacrylamide were used 
according to the different proteins tested. SP-D was run in 4-15%, 4-20%, 8% 
acrylamide gels; SP-A, SP-B and SP-C were run in 4-20% or 16% acrylamide gels; 
for citH3 12% acrylamide gels were used.  
Electrophoresis were run at 110 V for 10 min and then the voltage was 
increased to 150-180 V until completion. 
¨ Cross-linking 
Protein cross-linking was performed with glutaraldehyde (GA) (Merck-
Millipore, MA, USA) at a final concentration of 0.5% or 1% (v/v) for 2, 15 or 30 
minutes, according to a protocol modified from (Leitner et al., 2010). Reaction was 
stopped by adding non-reducing loading buffer and heating at 99 ºC for 10 minutes.  
¨ Silver staining 
Gels were fixed for 30 min in fixing solution (40% ethanol, 10% acetic acid) 
and then placed for 30 min in sensitising solution (30% ethanol, 0.5% 
glutaraldehyde, 12.6 mM sodium thiosulphate, 0.8 M sodium acetate). Afterwards, 
three 5-min washes with miliQ water were performed to remove the excess of the 
previous solutions. Gels were immersed in a silver solution (0.6 mM silver nitrate, 
0.04% formaldehyde) for 20 min and after a quick wash with miliQ water, protein 
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bands were developed with developing solution (0.2 M sodium carbonate, 0.02% 
formaldehyde). Color development reaction was stopped with stop solution (50 mM 
EDTA (pH 8.0)) for 10 min. 
¨ Coomassie staining 
Gels were fixed and stained with a solution of 1mg/ml Coomassie Brilliant 
Blue R-250, 50% MeOH, 10% acetic acid for 20 min. Protein bands were 
visualized upon destaining with a 10% acetic acid, 45% MeOH solution. 
 
Antibodies and dilutions used 
Primary 
antibody 
Dilution Reference Supplier 
Secondary 
Antibody 
Dilution Supplier 
SP-A 1:10000 - 
Dr. Joanna 
Floros 
Rabbit 1:10000 Dako 
SP-B 1:5000 
WRAB-
48604 
Seven Hills 
Bioreagents 
Rabbit 1:5000 Dako 
SP-C 1:5000 
WRAB-
76694 
Seven Hills 
Bioreagents 
Rabbit 1:5000 Dako 
SP-D 
1:2500 
WMAB-
1A10A9 
Seven Hills 
Bioreagents 
Mouse 1:5000 
Cell 
Signaling 
1:5000 
WMAB-
2D12A88 
Seven Hills 
Bioreagents 
Mouse 1:5000 
Cell 
Signaling 
citH3 1:500 Ab5103 Abcam Rabbit 1:5000 Dako 
Table 2: Primary antibodies and their associated secondary antibody, both with their working 
dilutions and suppliers are listed in this table.  
 
¨ Western Blot (WB) 
Proteins were transferred from the gel to nitrocellulose (Amersham 
Biosciences; L. Chalfont, UK) or PVDF (BioRad; Hercules, CA, USA) membranes. 
In the case of SP-A, B and C, PVDF membranes were preferred while for SP-D and 
citH3 nitrocellulose membranes were used. Two transfer systems were employed: 
i) a humid chamber, in the case of surfactant proteins (A, B, C, D), where the transfer 
was carried out at 350 mA, 1h, 4 ºC; ii) a semidry Trans-Blot® Turbo™ Transfer 
System (BioRad, Hercules, CA, USA), for citH3 and some WBs of SP-D, where the 
transfer was conducted at 1.3 A, 7 min, room temperature.  
Membranes were blocked with 5% milk in 0.1% PBS-Tween (PBS-T) for 2 
hours at room temperature. The primary antibody was diluted to optimal 
concentration (Table 2) in the previous buffer and incubated at 4 ºC overnight. Four 
washes of 10 min with PBS-T were carried out to eliminate the unbound antibody, 
and the secondary antibody was incubated for 1 h at room temperature. After 
repeating the washes, protein bands were developed using chemiluminescent 
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detection, the membrane was incubated 1 min in Immobilion Western 
Chemiluminescent HRP substrate solution (Merck-Millipore, Burlington, CA, USA) 
and the images were recorded in ImageQuant LAS500 (GE Healthcare; L. Chalfont, 
UK). 
 
Dot Blot 
LPS (0182:B12) dilutions at 2.5, 5, 10, 20, 60 and 80 µg/mL were dotted (2 µL) 
onto a nitrocellulose membrane (Amersham Biosciences; L. Chalfont, UK). 370 ng 
of SP-D and SP-D buffer were also applied as positive and negative controls. After 
drying at room temperature, membranes were blocked with 5% BSA in TBST-Ca 
buffer (150 mM NaCl, 50 mM Tris (pH 7.4), 0.02% Tween, 5 mM CaCl2) at 4 ºC 
overnight. Three washes with TBST-Ca buffer were done and the different 
membranes were incubated with 5 µg/mL or 15 µg/mL of SP-D in TBST-Ca or 5 
µg/mL of SP-D in TBST-EDTA 20 mM for 5 hours at room temperature. A control 
with TBST-Ca without SP-D was also performed. After incubation, membranes were 
washed four times with TBST-Ca and incubated with SP-D antibody (Cocalico 
Biologicals, PA, USA) at 1 µg/mL at 4 ºC overnight, followed by four washes with 
TBST-Ca. Membranes were then incubated for 1 hour with the secondary antibody, 
donkey anti-rabbit IgG-HRP (ThermoFisher Sci.; Waltham, MA, USA) dilution 
1:10000 and antibody was washed away as described above. SP-D complexes were 
detected by ECL (Millipore). 
 
Sytox Green kinetics assay 
Sytox green (Life Technologies; Carlsbad, CA, USA), a cell-impermeable 
nucleic acid binding dye, was used for monitoring NETosis over time. Microplates 
of 96-wells were seeded with 100 µL suspension containing 50000 neutrophils and 
5 µM Sytox green. Agonists (positive control), or agonists with SP-D (at 10, 20, 40 
µg/mL), or RPMI with protein buffer (negative control) were prepared in 10 µL of 
media and incubated for 30 minutes at 37 ºC, 5% (v/v) CO2. Calcium concentration 
in SP-D was adjusted prior to use to 5 mM CaCl2. After the appropriate incubation 
time, the mixture (10 µL) was added to the cells and the fluorescence intensity of 
the dye was tracked at 30-minute time intervals up to 240 minutes after cell 
activation, using a POLARstar OMEGA fluorescence plate reader. Between plate 
readings the plate was kept at 37 ºC, 5% (v/v) CO2. Final calcium concentration in 
the experiment was 0.5 mM. The final concentrations of the different agonists in 
these experiments were 25 nM PMA, 2.5 µM Ionomycin and 5 µg/mL LPS. For dose-
response LPS curves, different LPS concentration were tested. The green 
fluorescence at time 0 min was subtracted from the fluorescence at each time point 
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and was then divided by the fluorescence values of cell lysed with 0.5% (v/v) Triton 
X-100 (100% DNA – total DNA present in the cell). 
 
Deglycosylation experiments 
Two µg of SP-D were treated with 500 U of PNGase F enzyme. (New England 
Biolabs Inc., Ipswich, MA, USA) according to the manufacturer’s protocol. In some 
cases, it was further treated with 0.025 U of neuraminidase (sialidase) from 
Arthrobacter ureafaciens from Sigma (St. Louise, MO, USA), also following the 
manufacturer’s protocol.  
Results were analysed by AFM and PAGE-SDS developed with silver staining.  
 
N-glycan profiling 
 Hydrophilic interaction ultra-performance chromatography with 
fluorescence detection coupled electrospray injection quadrupole time-of-flight 
tandem mass spectrometry (HILIC-UPLC-FLD-ESI-Q-TOF MS/MS) was performed 
to carry out the characterization of the glycan attached to Asn70 of SP-D. First, the 
purified protein was denatured and N-Glycans were released during incubation 
with N-glycanase F. Then, free N-glycans were labeled with a fluorophore 
(RapiFluor, Waters; MA, USA) at the reducing end, followed by a purification step 
employing a HILIC solid phase extraction. An I-class system with fluorescence 
detection (Waters) was used for HILIC-UPLC. The mixture of purified fluorescently 
tagged N-glycans was separated on an an Acquity UPLC BEH Glycan column 
(150x2.1mm, 1.7u, Waters) at 60°C with a flowrate of 0.5mL/min. 100% 
acetonitrile (A) and 100mM ammoniumformiate, pH4.5, were used as the eluent 
system and the gradient of 22%B to 44%B in 82min was applied. The fluorescence 
wavelength settings were: λex 265nm and λem 425nm.  
A coupled Bruker Impact HD ESI-Q-TOF-MS(MS) was used for N-glycan 
identification in positive ion mode. N-glycans were identified according to 
molecular masses in combination with fragment analyses. Quantification of N-
glycan structures was performed from fluorescence peak areas. N-glycan 
parameters were calculated from the relative molar amounts of the identified N-
glycans. 
N-glycan profiling was carried out in collaboration with Glycotope GmbH 
(Berlin, DE). 
 
pH experiments and thermal denaturation of rhSP-D  
For protein stability experiments against thermal denaturation, rhSP-D was 
diluted to the final required concentration with citrate buffer at pH 4.2 (200 mM 
MATERIALS AND METHODS 
 73 
NaCl, 20 mM citrate, 1 mM EDTA) and incubated in ice for 30 minutes. Then, 
samples were heated at desired temperature (35, 40, 45, 50, 55, or 60 ºC) for 15 
minutes and crosslinked as described above. Electrophoresis was performed under 
non-reducing conditions and AFM samples were prepared and scanned as 
described above.  
 
Carbohydrate binding preference assay 
SP-D binding preference to maltose, N-acetylglucosamine (GlcNAc), glucose 
or galactose, was assessed by competitive binding of the protein to mannan agarose 
beads, in the presence of the different competitors at several concentrations. SP-D 
binding to mannan agarose beads depends on the affinity of the protein for the 
competitor agent. The method was slightly modified from a microplate assay 
previously described elsewhere (Palaniyar et al., 2004, Kingma et al., 2006) 
Mannan agarose beads were washed and resuspended in TBS three times, and 
the number of beads in the final suspension was counted with a hemocytometer.  
Reaction mixes were prepared by adding in every tube: 5,000 beads, different 
concentrations of the carbohydrate competitor (0.01-200 mM), 2 µL of 250 mM 
CaCl2 and the necessary volume of TBS to reach 100 µL as final volume in each 
tube. Last, 300 ng of SP-D were added and the samples were incubated in a 
thermomixer at 4 ºC for 2 hours with constant shacking at 600 rpm. It was important 
to compensate EDTA concentration with CaCl2 in protein buffer before adding the 
protein to the reaction mix. A positive control without mannan beads and a negative 
control in the presence of 20 mM EDTA were also conducted.  
After incubation time, unbound SP-D was separated from SP-D bound to the 
beads by centrifugation (13,000 X g, 1 min, 4 ºC). Fifty µL of the supernatant, 
containing the unbound protein, were collected and concentrated in an UNIVAP 
at 37-40 ºC to reduce the final volume to 6-8 µL. In order to quantify the unbound 
protein, PAGE-SDS of the samples under reducing conditions was carried out in 4-
15% acrylamide gels. Protein bands were developed by silver staining and 
densitometry analysis was performed with ImageJ software. The percentage of 
unbound SP-D for each condition was obtained from densitometry of the bands, 
and all values were reported relative to the intensity of the band when 20 mM EDTA 
was added to the reaction mixture (100% unbound SP-D). The percentage of bound 
SP-D was calculated by difference (equation 2) and represented against its 
competitor concentration.  
 %𝑩𝒐𝒖𝒏𝒅𝑺𝑷0𝑫 	= 𝟏𝟎𝟎 −%𝑼𝒏𝒃𝒐𝒖𝒏𝒅𝑺𝑷0𝑫	  (eq. 2) 
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SP-D E. coli binding assay 
An ELISA-like binding assay was developed to determine the binding affinity of 
SP-D to the gram-negative bacteria E. coli.  
Microtiter plates were coated with a suspension of E. coli DH5a at 5x108 
cells/mL in 50 mM NaHCO3-Na2CO3 (pH 9.6) buffer. Then, 200 µL of the bacterial 
suspension were pipetted into the wells and the plate was incubated at 4 ºC, 
overnight. Plates were washed 5 times between incubations and all washes and 
dilutions from this point were carried out with dilution buffer (0.05% TBS-tween, 5 
mM CaCl2). Wells were blocked with 2% BSA in dilution buffer for 2 hours at RT. 
After washing, samples of serial diluted (1:2) SP-D (from 1µg/µL to 2.3 ng/µL) were 
added to the wells in duplicates to obtain a standard curve. Protein was incubated 
for 1 hour, washed and 50 µL of mouse anti-SP-D antibody (dilution 1:5000) (Seven 
Hills Bioreagents, Cincinnati, OH, USA) were incorporated and incubated for 1 
hour. After washing, 100 µL of a horse anti-mouse IgG horseradish peroxidase 
(HRP)-conjugated antibody (1:7500) (Cell Signaling, Danvers, MA, USA) were 
added. One hour later, plates were washed and 100 µL of TMB/E (3,3',5,5'-
tetramethybenzidine) (Merck-Millipore; MA, USA) were added for 3 minutes and 
the reaction was stopped with 100 µL of 2N H2SO4. Plates were read for absorption 
at 450 nm. 
A modified version was also developed with different antibodies. Rabbit anti-
SP-D primary antibody (1:100) (Santa Cruz; Dallas, TX, USA) and anti-rabbit Ig 
HRP-conjugated antibody (1:1000) (Dako; S. Clara, CA, USA) were used. The 
epitope for this anti-SP-D is located in the N-terminal domain of the protein, instead 
of the CRD domain. In this case, incubation with TMB substrate was maintained for 
15 minutes before stopping the color reaction.  
 
Bacterial aggregation assay 
SP-D aggregation activity was determined by measuring light transmission 
through a suspension of E. coli DH5a after addition of the protein. The method was 
slightly modified from (Kingma et al., 2006). 
Bacterial cultures were grown at 37 ºC overnight. Then, cells were centrifuged 
(1,000 X g, 5 min, 4 ºC) and the supernatant was discarded. One wash was 
performed by resuspending the cells in 5 mL of 150 mM NaCl, 20 mM Hepes (pH 
7.4) and repeating the centrifugation step. Finally, bacteria were diluted with the 
previous buffer until an optical density at 700 nm (OD700nm) of ~ 1.1. Calcium 
concentration was adjusted to 5 mM in the final reaction by adding the required 
volume of 1 M CaCl2 solution (Hartshorn et al., 1998). 
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Samples were prepared in spectrophotometer cuvettes with 650 µL that 
contained: 
- 470 µL of bacterial suspension 
- 180 µL that contained: i) SP-D to reach the final concentration assessed 
(concentrations ranged from 10 µg/mL to 0.1 µg/mL) and ii) 200 mM NaCl, 20 
mM Hepes (pH 7.4) buffer. 
The absorbances of samples were read every 2.5 min at OD700nm during 2-3 
hours. The decreased in optical density through the time indicates the extent of 
bacterial aggregation. In order to compare the activity of SP-D from different 
sources or different oligomeric forms, the percentage (%) of aggregated bacteria at 
different SP-D concentrations was calculated from the absorbance decay in samples 
at specific time points. All values were relative to the absorbance at t = 0 of the 
bacterial suspension without SP-D, considered as 100% absorbance = 0% 
aggregation. 
 
Captive Bubble Surfactometer (CBS) 
Captive Bubble Surfactometer (CBS)  is a non-commercial device that was 
originally designed by Dr. Samuel Schürch (Schurch et al., 1989). It allows to 
evaluate the surface activity of materials adsorbed to the air-liquid interface of an 
air-bubble that is confined in a chamber under controlled conditions. The surface 
tension (g) can be calculated from the shape (volume, diameter and height) of the 
bubble, which is monitored and recorded during the experiment, and the CBS 
software will transform those measurements in surface tension values (Schoel et al., 
1994). The major advantage of the equipment is that it somehow mimics, in vitro, 
the physiological situation of a single alveolus in the lung during breathing. This 
characteristic makes it particularly useful to evaluate the performance of lung 
surfactant samples under different physiological or pathological conditions.  
The air bubble is created in a cylindric glass chamber filled with buffer. The 
chamber has a small (2 mm) hole at the bottom, to allow the entry of a thin capillary 
and air to create the bubble (0.035-0.040 cm3). The composition of the buffer that 
fills the chamber is 150 mM NaCl, 5 mM Tris (pH 7.4), containing 10% sucrose 
(w/v) to increase the density and avoid mixing and dilution of the introduced lung 
surfactant samples within the buffer. The opposite side of the chamber is sealed 
with a 1% agarose (w/v) cap that separates the bubble from a piston, which will be 
moved up and down by the system to compress and expand the space in which the 
bubble is confined. The glass chamber is inserted in a bigger chamber, with two 
transparent walls, where a water bath is created to control the temperature by a 
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feedback system and an external source of heat. Prior to the injection of the sample, 
the buffer inside the chamber is subjected to degasification by pressure and heat.  
Experiments in the CBS are characterized by three steps: 
¨ Initial adsorption (IA) 
Once the bubble has been created and centered, injection of the sample is 
executed introducing in the chamber a transparent capillary connected to a syringe. 
Typically, 150 nL of the sample are applied near the surface of the bubble and the 
surface tension is monitored during the adsorption of the material, for 5 min.  
In this step, it is observed the ability of lung surfactant to reach the interface 
and form a film capable of reducing air-water surface tension (~70 mN/m) to 
equilibrium surface tension (typically for lung surfactant ~22-23 mN/m), in a few 
seconds.  
 
 
Figure 18: Changes in the bubble shape due to 
decrease of surface tension (g) upon injection of 
the material during initial adsorption (IA). Within 
the first seconds after application of the sample, the 
surface tension goes down to values close to 22-
25 mN/m, which is reflected in the shape of the 
bubble that becomes flatter.  
 
 
 
 
 
 
 
¨ Post expansion adsorption (PEA) 
After IA, the chamber is sealed and the bubble is rapidly expanded to 0.15 
cm3 by the movement of the piston controlled by the software. Surface tension of 
the bubble is monitored during further 5 min, where reorganization, transfer and 
spreading of surfactant into the expanded interface can be analyzed.  
 
 
Figure 19: Changes in the bubble shape due to 
decrease of surface tension (g) upon rapid 
expansion of the bubble during post expansion 
adsorption (PEA). Within the first seconds after 
expansion of the bubble, the surface tension 
goes down to values close to 22-25 mN/m 
which is reflected in the shape of the bubble 
that becomes flatter. 
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¨ Q-static compression-expansion cycling 
Four slow step-wise compression and expansion cycles are applied to the 
bubble. Cycles are performed with 1 second delay between compression steps, 
each reducing 20% its previous volume. Maximum volume is set during post-
expansion and minimum volume is set manually during each cycle. During this 
slow compression-expansion cycles, the film undergoes relaxation and 
reorganization processes. First Q-static cycle often shows a plateau with a decrease 
in area and little change in surface tension during compression, a process known 
as “squeeze-out”, which consists in a partial depuration of the less active material 
out from the interface. During expansion steps, similar isotherms to that from 
compression are observed, but during the first Q-stat cycle the reorganization of the 
material at the interface originates isotherms with different tilt during compression 
and expansion, with some hysteresis. The area enclosed by the compression and 
expansion isotherms illustrates the ability of the material to reorganize during the 
compression and expansion cycles, which represents the hysteresis of the cycle, 
meaning the energy spent by the compression-expansion process. The subsequent 
cycles exhibit progressively reduced hysteresis, indicating that the refinement of the 
material at the interface is irreversible. 
 
Figure 20: Changes in the bubble 
shape associated with surface tension 
(g) during Q-static compression-
expansion cycles. Compression-
expansion isotherms for Q-static 
cycles 1, 2, 3 and 4 show the changes 
in surface tension upon reducing and 
increasing the area of the bubble. The 
image illustrates how the shape of the 
bubble changes during the first Q-
static compression.  
 
¨ Compression-expansion dynamic cycling 
The bubble is finally subjected to fast compression-expansion cycles, which 
mimics breathing at physiological rates, typically at 20 cycles/min for humans and 
for mice the maximum speed that the device reaches 30 cycles/min, although 
mouse breathing rate is much higher. The surface tension of the bubble is monitored 
during cycling by the software and represented in the compression-expansion 
isotherms that plot the changes in surface tension, as a function of the relative area 
of the bubble. The area enclosed by the compression and expansion isotherms 
represents the hysteresis of the cycle, and thus, the energy spent by the 
compression-expansion process. Good lung surfactants exhibit reduced or no 
Relative area
! (mN
/m
)
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hysteresis and reduced compression is needed for they to reach the characteristic 
minimum surface tensions (~2mN/m). 
 
 
Figure 21: Changes in the bubble shape 
associated with surface tension (g) during 
dynamic compression-expansion cycles. 
Compression-expansion isotherms for 
cycles 1, 10 and 20 show the changes in 
surface tension upon reducing and 
increasing the area of the bubble. The 
image illustrates how the shape of the 
bubble changes during the first dynamic 
compression.  
 
 
Statistics analysis 
All statistical analyses were performed on GraphPad Prism 7. Two-way 
ANOVA with Bonferroni post-test, One-way ANOVA with Tukey’s post-test and t-
test were done as appropriate. Significant differences were considered with a p-
value of <0.05(*),  £0.01(**), £0.001(***), £0.0001(****). 
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The recombinant human rhSP-D used in this chapter was provided by 
Airway Therapeutics LLC. and the experiments were done in 
collaboration with the company, supervised by Dra. Jan Rosenbaum. 
The AFM experiments included in the present chapter were done in 
collaboration with Dr. Fernando Moreno-Herrero at the “Centro 
Nacional de Biotecnología” (CNB-CSIC). Cryo-TEM samples were 
obtained and imaged in the Electron Microscopy Facility (EMF) of the 
Biological Research Center (CIB-CSIC, Madrid). The results were 
published in the following article: 
Arroyo, R., Martin-González, A., Echaide, M., Jain, A., Brondyk, W.H., 
Rosenbaum, J., Moreno-Herrero, F., Perez-Gil, J. “Supramolecular 
Assembly of Human Pulmonary Surfactant Protein SP-D”. 
Journal of Molecular Biology, 430 (2018), 1495-1509,  
DOI: 10.1016/j.jmb.2018.03.027 
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Introduction 
SP-D was first described as CP4 protein by Persson and colleagues in 1988 
(Persson et al., 1988). They characterized a 43 kDa product from type II 
pneumocytes, composed of collagenous and non-collagenous domains and the 
presence of asparagine-N-linked carbohydrates (Persson et al., 1988, Persson et al., 
1989). Numerous structural and functional studies have been carried out since then 
to further characterize SP-D from several organisms. Moreover, different 
recombinant versions of SP-D have been produced, with Chinese hamster ovary 
(CHO) cells being the most widely-used system to produce the human recombinant 
protein (rhSP-D) (Hartshorn et al., 1996a, Ikegami et al., 2006).  
 
 
Figure 1.1: Amino acid sequence and domain organization of hSP-D. The segments of the sequence 
defining the different protein domains are shaded with different colors: N-terminal (orange), collagen 
(blue), neck (yellow) and CRD (green). Cysteines C15 and C20 are in red bold letter. Glycosylated 
(blue Y at the protein scheme) residue N70 is in bold green. Hydroxylated prolines are in brown 
(Leth-Larsen et al., 1999). Amino acid triplets in purple represent triples prone to form ionic 
interactions between triple helices in the collagen region. Lysines marked with the asterisk are 
always found O-glycosylated, the rest of lysines within these triples can be found as partly O-
glycosylated and/or hydroxylysine residues. The underlined amino acid sequence constitutes the so-
called “charged patch”, with the expected charge of the amino acids at pH 7 indicated below. 
 
The SP-D monomer contains 355 amino acids (43 kDa) arranged in four 
structural domains (Figure 1.1), including: i) an N-terminus domain, where two 
conserved cysteines (C15 and C20) are important for protein oligomerization 
(Zhang et al., 2001a), ii) a collagen domain, characterized by a series of Gly-X-Y 
triplet sequence repeats, iii) an a-helical coiled-coil neck region and, iv) a globular 
domain, the carbohydrate recognition domain (CRD). The CRD contains four 
additional cysteine residues implicated in intramolecular disulfide bonds (Brown-
N-terminal domain                            Collagen domain 
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Augsburger et al., 1996a), and four calcium-binding sites important for its calcium-
dependent immune activity (Crouch et al., 1994b, Crouch, 1998, Shrive et al., 
2003). The sequence of SP-D also contains an asparagine in position 70 (N70), 
which is glycosylated, and a number of lysines that are partially O-glycosylated 
(Leth-Larsen et al., 1999). Most prolines within the collagen domain are at least 
partially hydroxylated when located in third residue position (G-X-P) of the 
characteristic G-X-Y collagen domain triplets.  
Three monomers form trimers through the folding of the collagenous region 
into triple helices and the assembly of a coiled-coil bundle of a-helices in the neck 
region. Two disulfide bonds between cysteines 15 and 20 stabilize this trimeric 
structure (Crouch, 1998). It has been described that trimers either associate into 
higher order oligomers such as dodecamers, which are structures formed by four 
trimers, or the so-called “asterisk-like” or “fuzzy balls”, larger oligomers composed 
by 6 or more trimers, existing in a wide and variable range of sizes. It is currently 
unknown whether the different oligomeric forms of SP-D might provide selective 
contributions to the various aspects of SP-D physiology. It is also unknown how 
such oligomerization-function relationships could be modulated by physiologically 
relevant factors. This gap in knowledge is in part due to the difficulties of 
characterizing the conformational diversity of SP-D under different environmental 
constraints in a manner that provides both qualitative and quantitative outputs. 
New tools are also needed to identify and discriminate the protein domains or 
regions and the nature of the interactions involved in the formation and stabilization 
of the different protein oligomers. 
In this chapter, we present a detailed analysis of the structure of a recombinant 
human SP-D produced in CHO cells, with the goal of providing both a qualitative 
and quantitative assessment of the conformational diversity and the determinants 
defining the oligomerization pathway of the protein. Using high-resolution atomic 
force microscopy (AFM) and electrophoresis methodologies, we have described the 
different SP-D oligomeric forms, defined and quantitatively characterized some of 
their relevant features. The distribution of oligomeric forms of rhSP-D has been for 
the first time quantified as a function of pH. Our results indicate that rhSP-D is 
assembled in four oligomeric states: trimers, hexamers, dodecamers and larger 
oligomers (fuzzy balls), with dodecamers being the most abundant structure in all 
experimental conditions tested. We have developed a cross-linking protocol to 
detect the presence of SP-D dodecameric forms by PAGE-SDS, in which dodecamer 
is only visualized after chemical crosslinking and in the presence of denaturing 
agents, indicating the importance of ionic and hydrophobic interactions in 
dodecamer formation and stabilization. 
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Results 
Qualitative and quantitative analysis of rhSP-D oligomeric forms by AFM 
Atomic force microscopy of rhSP-D samples deposited onto mica surfaces at 
pH 7.4 revealed that rhSP-D is assembled in a variety of different oligomeric 
structures including trimers, hexamers, dodecamers, and larger aggregates, usually 
described as asterisk-like or fuzzy balls, composed by a variable number of trimers 
(Figure 1.2A). Details of the four different oligomeric species observed are shown 
in figures 1.2B and 1.2C. Different clones of rhSP-D were studied. Some differences 
in the oligomeric forms distribution were found between them, that could be caused 
by the purification process and buffers. For this reason, it was important to obtain 
human SP-D as a control (Chapter 3), to figure out which one was the most similar 
to native protein. One representative clone of those assessed was chosen for this 
study. The dodecamer was the most abundant structure in this and other rhSP-D 
clones studied.  
 
 
Figure 1.2: AFM images of rhSP-D at pH 7.4. A-C: AFM images of rhSP-D, where illustrative 
examples of different oligomeric forms can be observed, including trimers (T), hexamers (H), 
dodecamers (D), and fuzzy balls (FB). A, 1-µm scan, the scale bar represents 200 nm. B and C, 300 
nm scan; the scale bar represents 60 nm.  
 
To perform a quantitative analysis, a collection of high-quality images of 1 µm-
scan area was taken among different sample preparations and regions, a set of 
which can be observed in Figure 1.3. Molecules were counted and classified into 
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groups according to their oligomeric state. Table 1.1 and Figure 1.4 summarize the 
results obtained for a total of 660 molecules identified.  
 
 
Figure 1.3: Set of AFM images of rhSP-D at pH 7.4. AFM images of rhSP-D, where the different 
oligomeric forms previously mentioned can be observed along all the preparation. Top left image, 
2-µm scan, while the rest are 1-µm scan. The scale bar represents 200 nm.  
 
A relative distribution of the different protein oligomers was calculated 
considering three different parameters: i) % molecules, from the number of 
individual molecules within each oligomerization state, ii) % weight, from the 
amount of total protein mass across each of the 4 groups considering the molecular 
weight of each oligomer, defined as 43,000 Da/monomer unit times the number of 
monomer units per oligomer; and iii) % trimers, from the amount of trimers 
contained per oligomeric form group. According to these results, 41% of molecules 
and 51% of mass of rhSP-D is assembled as dodecamers, with dodecamers being 
the major single oligomeric species constituent of this recombinant protein. The 
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heterogeneous higher order oligomers (‘fuzzy balls’) are the second most abundant 
species (29%) in mass, and trimers and hexamers constitute minor components, 
with 11% and 9%, respectively, of protein mass.  
 
Table 1.1: Quantitative distribution of different oligomeric forms of SP-D as determined from 
individual molecules observed under AFM at pH 7.4 
 
Weight (MDa), % molecules and % weight are defined as described in Results. Weight (g) is defined 
as weight in daltons/Avogadro's number. 
 
                        
Figure 1.4: Quantitative distribution of oligomers. The distribution of oligomers has been 
represented as the percentage of molecules (A) and the percent by mass (B) of the different 
populations. 
 
Structural characterization of rhSP-D oligomeric forms 
To further characterize the distinct oligomeric forms, we measured the position 
and size of relevant structural features from AFM height profiles of individual 
trimers, hexamers, dodecamers, and other higher-order structures (Figure 1.5). 
 
¨ Trimers: rhSP-D trimer images in figure 1.5A show the carbohydrate recognition 
domain with unprecedented resolution, enough to differentiate its three 
individual globular domains. Previous results published in the literature showed 
only a solid bright white spot at the end (Crouch et al., 1994a, Leth-Larsen et al., 
2005, Hartshorn et al., 2008). A bright protuberance was observed at 47 ± 5 nm 
from the C-terminal end, which likely corresponds to the N-glycosylation site of 
the molecule, located at residue N70 in the collagen domain (Leth-Larsen et al., 
1999).  
 
Oligomeric
Form Nº Molecules % Molecules Weight (MDa) Weight (g) % Weight Nº Trimers % Trimers
Total 660 100 278.2 4.62E-16 100 2169 100
Trimer 244 37 31.5 5.23E-17 11 244 11
Hexamer 100 15 25.8 4.28E-17 9 200 9
Open 76  11    19.6 3,26E-17 7 152,00 7
Closed 24 4   6.2 1,03E-17 2 48,00 2
Dodecamer 273 41 140.9 2.34E-16 51 1092 50
Fuzzy Balls 45 7 80.1 1.33E-16 29 633 29
37%
15%
41%
7%
% Molecules
B11%
9%
51%
29%
% Weight
A
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Figure 1.5: Structural analysis of the oligomeric forms of rhSP-D. The first column contains a 
schematic drawing of each type of oligomer that has been analyzed and includes representative 
characteristic parameters calculated from the AFM images. The position of the glycosylation site is 
indicated by a “Y”. All parameters were calculated after measuring and averaging 50 individual 
molecules, and the average and its standard deviation are shown. The second column illustrates 
representative AFM images from each type of SP-D oligomer; the scale bar represents 30 nm. Yellow 
arrows mark the bright spot at the N-glycosylation site (N70). The blue arrow points to the segment 
overlapping two clearly distinct hexamers within a dodecamer. The third column illustrates the 
height profiles taken from each oligomer along the green line drawn in the images of the fourth 
column. The numbers above the profile indicate 1: N-terminal domain, 2: N-glycosylation site; 3: 
CRD.  
To prove that the rhSP-D used in these experiments was N-glycosylated, de-
glycosylation experiments were carried out with PNGase F, which removes the 
sugar core attached to an asparagine residue through an N-acetyl-glucosamine 
group (see Figure 1.6). A consistent shift to a lower electrophoretic mobility was 
found between intact rhSP-D and PNGaseF-cleaved rhSP-D (Figure 1.6A) 
accompanied by a disappearance of the majority of the bright protuberances in 
AFM images of the protein (Figure 1.6B), confirming that the recombinant human 
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rhSP-D is N-glycosylated. The AFM height profile of the trimer (Figure 1.5A) 
additionally confirmed the three relevant features (numbered 1-3), 
corresponding to the N-terminal end, the N-glycosylation site and the CRD, 
respectively. In addition, we often observed several conspicuous, regularly 
spaced, and bright segments along the collagen domain, which could 
correspond to the collagen triple helical twists. However, resolution limitations 
precluded the unequivocal assignment. 
 
 
Figure 1.6: De-glycosylation of rhSP-D. A, silver staining non-reducing SDS-PAGE analysis of rhSP-
D treated (+) or not (-) with PNGase F; T (trimer), D (dimer), M (monomer), P (PNGase F). Panel B 
shows AFM images of trimers, hexamers and dodecamers before (-) and after (+) PNGase F treatment. 
The yellow arrow indicates the N-glycosylation site seen as a bright protrusion in the glycosylated 
protein. The scale bar represents 25 nm. C, Height profiles of trimers (top) and dodecamers (bottom) 
before (left) and after (right) PNGase F treatment. Horizontal dotted lines have been traced at the 
height of the N-glycosylation site height. 
 
¨ Hexamers: rhSP-D hexamers are structures consisting of two trimers linked by 
the N-terminal domain (Figure 1.5B). Two populations of hexamers with different 
shapes were found: hexamers with a closed conformation (V-like) and hexamers 
with an open (rod-like) configuration, with the latter being the most abundant as 
quantitated in Table 1.1. The presence of hexamers opens the possibility that 
these oligomers could be a structural intermediate between trimers and 
dodecameric forms, especially considering the way the N-terminal regions of 
dodecamers are seen under AFM. The maximal observed distance between two 
opposed CRD domains in the hexamers contained into the dodecamer molecule 
was 136 ± 8 nm (Figure 1.5C), slightly longer than published data for rat SP-D 
(114 ± 3 nm) (Crouch et al., 1994b). The symmetrical height profile of the 
dodecamer exhibited the highest point in the middle of the molecule, which 
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matches with the N-terminal domain of both hexamers constituting the 
interaction point (Figure 1.5C, height profile). 
¨ Dodecamers: The rhSP-D dodecamer appears to be formed by close association 
of two hexamers, although the part of the molecules that would be responsible 
for this interaction is not fully clear. The central junction exhibited a radius of 12 
± 2 nm and an apparent height of 1.0 ± 0.4 nm as determined from the AFM 
profile (Figure 1.5C). In the dodecamers, it is quite frequent to observe a close 
apposition of the zone between N-glycosylation sites from the two possible 
different hexamers at one or even at both sides of the N-terminal domain (see 
Figure 1.7C and F). It is not known whether this interaction could have an 
influence in protein oligomerization because in other cases is not observed 
(Figure 1.7A, E). An open question is whether “V-like” and “rod-like” hexamers 
might promote formation of different types of higher order oligomeric structures.   
 
 
Figure 1.7: AFM images of rhSP-D. A-F: magnifications of some dodecamers. The blue arrow points 
to the segment overlapping two clearly distinct hexamers within a dodecamer. G-H: magnification 
of fuzzy balls. A-H, the scale bar represents 20 nm. 
 
¨ Higher order oligomers: They include heterogeneous higher order asterisk- or 
fuzzy ball-like oligomers composed of a variable number of trimeric arms, 
usually in a range between 6 and more than 20, as it is observed in figure 1.3 
and 1.5D. They adopted a circular disposition once adsorbed onto the mica-
substrate with a diameter similar to that of dodecamers. It is apparent that the 
center of fuzzy balls is not a solid unique junction, but a cluster of several small 
nearby centers, which could correspond to the N-terminal domain of trimers pre-
associated in dodecamers or hexamers (Figure 1.7G). The width and the height 
of the central structure increased with the number of trimers contained in the 
fuzzy ball, while the total diameter of the full complex remained constant (Figure 
A B C
D E F
G
H
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1.8). Most fuzzy balls presented well-separated pairs of trimers around the 
central interacting region, suggesting that these structures are built from 
hexamers in their closed (V-like) conformation.   
 
Figure 1.8: Structural characterization of rhSP-D fuzzy balls. Some parameters of fuzzy balls were 
measured and plotted against the number of trimers per molecule. A, total diameter of the whole 
molecule, taken as the average of two diameters measured for each molecule. B, the center 
diameter, taken as the average of two measurements of the central stem of each molecule, as 
indicated by the black arrow. C, the height of the center (N-terminal domain) of each fuzzy ball, 
measured as indicated. 
 
Characterization of rhSP-D by Cryo-TEM  
Despite the fact that AFM is a powerful technique, which allowed us to observe 
in detail many of the structural determinants of the protein and quantify the 
distribution of the oligomeric forms, molecules observed were restricted to a 2 
dimensional (2D) planar conformation defined by its interaction with the mica 
surface. This was a limitation to figure out the conformation of rhSP-D oligomers in 
solution, particularly the conformation of fuzzy balls. Cryo-TEM was used then in 
an attempt to sort out this question. Figure 1.9 shows molecules selected from the 
images obtained. Despite the difficulty to identify them, some clusters where trimers 
are branching out from a central point can be observed, which we attributed to 
fuzzy balls (Figure 1.9, top panel left and zooms). In addition, some dodecamers 
were identified (Figure 1.9, bottom panel). The conformation of SP-D oligomers and 
their arrangement in the sample supposed an obstacle to identify dodecamers and 
small oligomers. When they were arranged perpendicular to the plane only their 
CRDs could have been identified and, when parallel to the plane it was challenging 
to recognize their thin collagen arms.  
These results did not allow us to discern unequivocally the 3D conformation of 
fuzzy balls. Although they looked like circles in most of the images, which 
corresponds to spheres in solution, the limited resolution impeded us from 
distinguishing the molecules and their terminal ends properly and figuring out the 
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real conformation. Moreover, in the case of dodecamer and lower order species, 
we cannot ignore that probably we were only identifying a few examples of them. 
Further optimization of the experimental conditions to improve resolution is 
required to complete the characterization of the configuration of SP-D in solution. 
 
Figure 1.9: Cryo-TEM micrographs of rhSP-D. Top panel, left, image obtained in Cryo-TEM, arrows 
indicate some identified fuzzy balls, scale bar 100 nm; right, selected particles from the images were 
zoomed, the scale bar represents 25 nm. Bottom, selected dodecamers from the images were 
zoomed, the first and second row contain the same images, but in the second row the molecules 
have been traced with a yellow dotted line to help to assist identification; the scale bar represents 
25 nm. 
 
Electrophoretic analysis of rhSP-D  
In order to gain insight about the type of interactions leading to formation of 
different rhSP-D oligomers and to confirm the presence of the structures observed 
by AFM in the samples examined in bulk, a biochemical analysis using PAGE with 
gradient polyacrylamide gels was conducted. The rupture of interchain disulfide 
bonds with bME totally transformed all oligomeric species into monomeric form, 
FUZZY BALLS
DODECAMERS
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as deduced by its electrophoretic behavior (Figure 1.10A). Under non-reducing 
conditions and in the presence of SDS, the sample was found to consist mainly in 
trimers (Figure 1.10A). Blue native electrophoresis was carried out to analyze the 
protein native state. We expected to see protein bands principally at the theoretical 
mobilities corresponding to the molecular weights of hexamer, dodecamer and at 
least smaller sized fuzzy balls in the gels, but the experiments revealed that under 
such conditions most of the protein was not able to enter into the gel, remaining in 
the well (Figure 1.10B, first lane in the gel). It was necessary to add SDS to the 
sample to allow the protein to enter the gel, but rhSP-D was then only observed 
primarily in the form of trimers (Figure 1.10B left and 1.10C).  
 
 
Figure 1.10: Biochemical analysis of rhSP-D by electrophoresis. The quaternary structure of rhSP-
D has been analyzed by PAGE-SDS (A and C) and native electrophoresis (B). The different conditions 
and reagents used for treating each sample are indicated above the gels and membranes. A, the gel 
on the left has been developed by silver staining and the WB-membrane on the right side has been 
developed with anti-SP-D antibody as indicated in Methods. B, the membrane on the left is an anti-
SP-D WB, while the gel on the right has been revealed by silver staining. C, western blot anti-SP-D. 
SDS* means that SDS was added to the sample before crosslinking with GA. The molecular weight 
of the protein standards is indicated to the left of the gels and membranes. 
 
In order to detect higher order oligomeric conformations, we subjected the 
rhSP-D native structure to crosslinking by glutaraldehyde (GA), a bifunctional 
reagent that binds and interconnects neighboring reactive groups within the protein 
and between protein chains. After 2 minutes of GA crosslinking reaction, PAGE 
performed under non-reducing conditions revealed protein bands with mobilities 
corresponding to hexameric and dodecameric structures; whereas after 30 min of 
crosslinking reaction, substantially lower amounts of hexamer were apparent 
(Figure 1.10A, see WB). Fuzzy balls oligomers were not seen in these gels and 
membranes after cross-linking, probably because their big size does not allow them 
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to penetrate into the gels. Cross-linked samples were also subjected to a modified 
native electrophoresis, where the typical native loading buffer was substituted by 
non-reducing loading buffer (which contains SDS), in order to push the protein 
through the pores (Figure 1.10B right, third lane). On the contrary, no protein bands 
were observed in the gel when the experiment was carried out with cross-linked 
samples and native loading buffer. 
 
Effect of pH on the conformation and oligomerization of rhSP-D 
To further characterize the oligomerization pathway of SP-D and the type of 
interactions involved, the effect of acidic and basic pH on rhSP-D structure was 
studied. Protein was diluted to the desired concentration for AFM experiments with 
buffers at different pHs (8.5, 5.5, 4.2 and 3.0). AFM imaging of these samples was 
carried out followed by a quantitative analysis of the distribution of oligomeric 
forms (Figure 1.11).  
 
Figure 1.11: Effect of pH on the conformation and oligomeric distribution of rhSP-D. A, 
representative AFM images taken from rhSP-D samples at the different pHs indicated; the scale bar 
represents 200 nm. B, percentage by mass of the different oligomeric forms of rhSP-D at the different 
pHs (after assigning and counting 218 molecules at pH 3.1, 154 at pH 4.2, 175 at pH 5.5, 660 at 
pH 7.4 and 310 at pH 8.5). C, the effect of pre-incubation at different pH conditions on the 
electrophoretic behavior of the protein was evaluated after the samples were subsequently 
crosslinked with GA 0.5% for 15 minutes. Different symbols indicate the different types of oligomers: 
fuzzy balls (open triangle), dodecamer (triangle), hexamer (star) and trimer (circle). D, magnified 
representative images of the dodecamer conformation observed under different pH conditions. 
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The results revealed that the proportion of protein assembled as dodecamers 
was higher in a more acidic environment, concomitant to a reduction in the 
percentage of fuzzy balls. We found that at pH 5.5 and 4.2 there is a reduction of 
10-15% by weight in the proportion of fuzzy balls compared to that at pH 7.4, 
together with an increase in dodecamers, but not in trimers (Figure 1.11B). This 
supports the hypothesis that dodecamers are joined by weak interactions to create 
fuzzy balls, instead of being formed directly by covalent interactions between 
trimers, with all of them linked together by the N-terminal end, a possibility 
previously suggested (Crouch et al., 1994b, Brown-Augsburger et al., 1996a). At 
pH 3.0, the increase in dodecamer content was similar (10%), but a higher decrease 
in fuzzy ball-like oligomers (25%) was observed. This was accompanied in this case 
by a 9% increase in both trimers and hexamers, suggesting that at extremely low 
pH, fuzzy balls could start to dissociate into dodecamers and further into hexamers 
and/or trimers. At basic pH (8.5), a reduction in the proportion of trimers and 
hexamers was observed, accompanied by an increase in dodecamer content and 
in large oligomers (34%). The content in higher order fuzzy ball-like oligomers 
seems to continuously increase from pH 3 to pH 8.5, indicating that the more 
alkaline pH promotes formation of larger oligomers beyond the dodecamer. 
Changes in the distribution of oligomers due to acidic pH were confirmed by 
electrophoresis, where rhSP-D samples at different pHs were subsequently 
crosslinked with GA (Figure 1.11C). The most prominent dodecamer band was 
observed at pH 4.2.  
Interestingly, a conspicuous change in the conformation of dodecamers was 
clearly observed in the AFM images as a consequence of acidic pH (Figure 1.11D). 
At the most acidic pHs (4.2 and 3.0) most of dodecamer molecules appeared in a 
sort of closed configuration, with the four trimers and the 4 trimeric CRD domains 
clustered in a nearby space. These cryptic structures appeared in all possible 
orientations and only at these pHs, discarding any artifact from the washing and 
drying sample preparation procedures. At pH 5.5, an intermediate state between 
those at pH 7.4 and 4.2 was observed, with some dodecamers attaining a closed 
conformation and others in a standard X-like open conformation (Figure 1.11A). In 
order to better quantitate the characterization of this structural conversion, the four 
angles present within each dodecamer were measured, and data were pooled for 
each pH condition, and represented as histograms (Figure 1.12A, top).  
At pH 7.4, the histogram was composed of two main angle populations, one 
corresponding to acute angles of 30º-50º and the other to obtuse angles of 140º-
150º, indicating that the dodecamers exhibit an X-like shape. Interestingly, the two 
acute angles were not identical in each X-like dodecamer. The ratio a1/a2 
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calculated for 273 dodecamers, where a1 is the smallest acute angle in the molecule 
and a2 the biggest acute angle, peaked at 0.7 (Figure 1.13). This suggests that 
dodecamers are likely composed of two hexamers in open (rod-like) conformation 
as the assembly by two hexamers in closed conformation would have provided a 
value closer to 1.0. 
 
Figure 1.12: Effect of pH on the conformation of rhSP-D oligomers as evaluated by measurement 
of the angles defined by the position of their trimeric arms. A, the four angles formed by the relative 
position of the individual trimeric arms within each dodecamer (A, top) were measured and pooled, 
and their relative frequencies represented with a histogram at each of the different pHs . Inside each 
of the graphs, a representative picture of a dodecamer with the typical configuration at the 
corresponding pH has been included, indicating the angles measured. “n” is the total number of 
angles measured for each condition. A similar analysis was performed for the angle enclosed by the 
two trimers within each hexamer (A, bottom). B, to analyze the pH-induced changes in the 
conformation of the fuzzy balls, the frequency distribution of the total molecule diameter and the 
center diameter (N-terminal domain) is illustrated at pH 7.4 (top panels) and 4.2 (bottom panels). 
The histograms have been fitted to a Gaussian distribution. A representative AFM image of a fuzzy 
ball at each pH condition is showed on the right.  
 
At pHs 4.2 and 3.0, the histograms of angles only show one main peak around 
acute angles of 20º-40º and a large dispersion of different values of obtuse angles. 
These data reflect how most dodecamers are in a closed conformation. At pH 5.5, 
an intermediate state is observed, where the peak of acute angles is present and the 
incidence of obtuse angles with values between 100º to 180º is still significant, but 
the peaks are not as prominent as observed at pH 7.4. This indicates that some 
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dodecamers are changing to a closed conformation while others are still in a X-like 
conformation.  
 
Figure 1.13: Ratio of acute angles a1/a2 in rhSP-D dodecamers. Frequency distribution of the ratio 
between the two acute angles in each of 273 dodecameric rhSP-D molecules, determined at pH 
7.4.  
 
The angle formed by each hexamer (as a result of the relative position between 
its two trimers) was also measured and data was compiled in histograms (Figure 
1.12A, bottom) showing the same trend as that observed in dodecamers. 
Changes in conformation between pH 7.4 and 4.2 were also studied in fuzzy 
balls. In this case, the parameters evaluated were the total molecule diameter and 
the center diameter. The results revealed that fuzzy balls at pH 4.2 are characterized 
by a shorter total molecule diameter and larger center diameter than at pH 7.4. 
These results are in agreement with dodecamer conformational changes and imply 
that fuzzy balls are formed from hexamers and/or dodecamers in a closed 
conformation at acidic pH (Figure 1.12B). 
 
Effect of calcium on the conformation and oligomerization of rhSP-D 
SP-D encloses four calcium binding sites in the CRD, which are important for 
its innate immune activity (Crouch, 1998, Shrive et al., 2003). To determine 
whether the presence of calcium could influence rhSP-D structure, its conformation 
and the distribution of oligomeric forms, AFM experiments were carried out at pH 
7.4 in the presence of CaCl2 5 mM, instead of EDTA 1mM. The addition of calcium 
did not show conspicuous differences when compared to the EDTA condition. The 
distribution of oligomeric forms was similar in both cases, as well as the histogram 
of the angles enclosed within dodecamers (Figure 1.14). Although calcium affects 
the disposition and conformation of some protein segments within the CRD domain 
to allow the interaction of some amino acids with their ligands (Shrive et al., 2003),  
it does not seem to have substantial impact on the supramolecular structure and 
conformation of SP-D.  
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Figure 1.14: Structure and distribution of oligomeric forms of rhSP-D in the presence of 5 mM 
calcium. A, representative AFM image of rhSP-D in 5 mM calcium. The scale bar represents 200 
nm. B, distribution of oligomeric forms of rhSP-D at pH 7.4 in 200 mM NaCl, 20 mM Tris, 1 mM 
EDTA, (black bars) (n=660) or 200 mM NaCl, 20 mM Tris, 5 mM CaCl2 (grey bars) (n=520). C, 
relative frequency of distribution of the four angles enclosed within dodecamers in the presence of 
5 mM calcium (n=980). 
 
Thermal stability of rhSP-D at neutral and acidic pH 
The thermal stability of the structure of rhSP-D, especially of dodecamers, was 
examined by gel electrophoresis and AFM at pH 7.4 and 4.2, and the results are 
shown in figure 1.15. The structure of rhSP-D is more resistant to thermal 
denaturation in an acidic environment than at neutral pH.  When heated to 40-45 
ºC at pH 4.2 it is still possible to observe bands in the gels corresponding to 
hexamers and dodecamers; while at pH 7.4, the bands of these oligomeric forms 
are not clearly defined at the same temperatures. It appears that the conformational 
changes occurring in the protein at pH 4.2 make it more resistant to thermal 
denaturation. AFM imaging of rhSP-D at pH 7.4 and 45 ºC show how the SP-D is 
disassembled and many collagen triple helical domains are unstructured (i.e. 
marked by a dotted circle in figure 1.15). In contrast, at the same temperature at pH 
4.2, hexamers are the most abundant species observed in AFM images, followed 
by trimers, all of them composed of properly assembled collagen triple helices (see 
figure 1.15, solid-line circles). AFM images therefore confirm that rhSP-D thermal 
stability is highly dependent on collagen thermal stability. 
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Figure 1.15: Thermal denaturation of rhSP-D. Top, a PAGE-SDS gel followed by western blot of 
rhSP-D after exposure to different temperatures at pH 7.4 or 4.2 prior to crosslinking as described 
in the methods section. The pH and temperature of treatment of each sample are indicated at the 
top of the WB membrane, the assigned oligomeric states of each band is on the right, and the 
molecular weight of standards on the left. Bottom, representative AFM images of rhSP-D after 
incubation at 45º at pH 4.2 (left) or 7.4 (right). Structures enclosed in white solid circles are examples 
of intact trimers with a preserved native structure, while structures enclosed in dotted circles are 
examples of disassembled trimers due to thermal stress. The scale bar represents 200 nm. 
 
Discussion 
Trimers, dodecamers and higher order oligomers have been described as the 
different oligomeric forms of SP-D (Crouch et al., 1994b, Crouch et al., 1994a, 
Hartshorn et al., 1996a, Brown-Augsburger et al., 1996a, Leth-Larsen et al., 2005). 
However, the actual distribution and function of these different forms still remain 
as open questions. The particular shape of dodecamers and higher order oligomers 
known as ‘asterisk-like’ or ‘fuzzy balls’ makes difficult to separate and quantify the 
different fractions using conventional chromatographic procedures (Crouch et al., 
1994b, Ogasawara and Voelker, 1995, Leth-Larsen et al., 2005). Electrophoresis 
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experiments have failed to catch SP-D structures larger than trimers. Even in 
electron microscopy, SP-D cannot be observed under-close-to-native conditions 
due to the fixing and shadowing treatment required for sample observation that 
always occurs under vacuum (Crouch et al., 1994b, Hartshorn et al., 1996a). Plain 
electron microscopy images, typically obtained in the absence of specimen tilting 
and tomography make also impossible to determine whether some or all of the 
largest aggregates are closer to flat (“asterisk”-like) or spheric (“fuzzy ball”-like) 
three-dimensional assemblies when they are free in solution. For all these reasons, 
a quantitative analysis of the oligomeric distribution of SP-D under different 
conditions remains a challenge. In the current chapter, we have used AFM as a tool 
to analyze, both qualitatively and quantitatively, the structures of rhSP-D produced 
in CHO cells under close to native conditions. Previous AFM observations had 
provided a rather qualitative description of SP-D structure (Leth-Larsen et al., 2005, 
Hartshorn et al., 2008). We have found that rhSP-D is a mixture of trimers, 
hexamers, dodecamers and higher order oligomeric species. The variety and 
morphology of the structures observed are similar to those previously reported by 
transmission electron microscopy (Hartshorn et al., 1996a), except that the 
dodecamer is confirmed as the most abundant species in the rhSP-D studied here. 
Dodecamers had been already described as the most abundant oligomeric structure 
of rat SP-D and its recombinant version (rrSP-D) as examined by electron 
microscopy (Crouch et al., 1994a, Crouch et al., 1994b).  
However, it is relevant that the conspicuous presence of a population of 
hexamers in the previous studies (Hartshorn et al., 1996a, Leth-Larsen et al., 2005, 
Hartshorn et al., 2008) was either ignored (Leth-Larsen et al., 2005, Hartshorn et 
al., 2008), or considered as a possible artifact of the assembly of SP-D (Hartshorn 
et al., 1996a). We propose here that the hexamer is likely an intermediate in 
dodecamer and fuzzy ball assembly. In the model proposed in figure 1.16, three 
monomers associate into trimers, which are stabilized by disulfide bonds; trimers 
then form hexamers and these are subsequently paired into dodecamers. These two 
last structures are found associated into higher order oligomers of variable mass, 
termed ‘fuzzy balls’ based on their dandelion-like appearance on the surface of the 
mica in the AFM images illustrated herein. We propose that the oligomerization 
process that take trimers to fuzzy balls is governed by different non-covalent 
interactions at the different oligomerization levels.  
The high-quality AFM images obtained in the current study have allowed the 
observation of unprecedented structural details, including individual CRD domains 
in trimers, defined N-glycosylation sites, presumed collagen triple helical twists and 
the junction points around the N-terminal region in dodecamers and fuzzy balls. 
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The repeated observation of hexamers in different sample preparations and the fact 
that dodecamers observed on the surface of the mica seem to be composed of two 
hexamers (see Figure 1.7), raise the question of what kind of interactions could be 
involved in the assembly of hexamers to form dodecamers. Moreover, the 
identification of segmented fuzzy ball centers, possibly corresponding to individual 
dodecamers and/or hexamers, suggests that the assembly of the higher order 
oligomeric structures is a reversible and dynamic process that might contribute to 
the modulation of SP-D function in response to local conditions within the cell or 
tissue under different physio-pathological contexts. 
 
 
 
Figure 1.16: Proposed model for rhSP-D oligomerization pathway. Three monomers of rhSP-D first 
associate through the folding of the collagenous sequence segment into triple helices and the 
assembly of a coiled-coil bundle of a-helices in the neck region. These trimers are stabilized by two 
disulfide bonds in the cysteine-rich N-terminal domain (Brown-Augsburger et al., 1996a). Two 
trimers would then form hexamers with the participation of non-covalent interactions, such as ionic 
interactions, between the two N-terminal domains. The next step would be the association of two 
hexamers into dodecamers by ionic and hydrophobic interactions, which could present sugars from 
opposed hexamers for interaction, at one or both sides of the N-terminal domain. Fuzzy balls would 
be formed by association of dodecamers and/or hexamers through weaker non-covalent 
interactions, most likely involving hydrophobic interactions. At extreme acidic pH, the configuration 
of the hexamers, dodecamers and fuzzy balls changes from open to closed, which could influence 
the whole assembly pathway because it is accompanied by an increase in the proportion of 
dodecamers and lower order species and a decrease in the amount of fuzzy balls.  
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Using truncated versions of SP-D, Zhang and colleagues showed that the neck 
domain is indispensable for trimer formation (Zhang et al., 2001b). Based on the 
study of mutant vs. wild type proteins, it was proposed that residues C15 and C20 
at the amino terminal domain of SP-D are crucial to establish interchain covalent 
interactions, which then allow the assembly of trimers into higher order oligomers 
(Crouch et al., 1994b, Brown-Augsburger et al., 1996a, Brown-Augsburger et al., 
1996b). On the other hand, the role of the collagen domain in protein assembly is 
still not fully clear. Ogasawara and Volker showed that the absence of the collagen 
domain prevents a recombinant rat protein from forming higher order oligomers 
(Ogasawara and Voelker, 1995); in contrast, Kingma and colleagues reported 
association of 4 trimers in a collagen-deleted SP-D mutant expressed in mice, 
attributing to the N-terminal domain the leading role in the assembly of higher order 
oligomers (Kingma et al., 2006).  The cross-linking protocol developed in the 
current work is a useful tool that could complement future studies to clarify this 
question. 
Our results provide additional evidence on the oligomerization of SP-D. 
Trimers are the minimal structural unit observed in AFM images (Figure 1.2 and 
1.3). The length of the collagen domain as measured under AFM, 48 ± 5 nm, agrees 
well with its expected theoretical length, 51 nm, considering a distance of 8.6 Å 
per G-X-Y collagen domain triplet (Beck and Brodsky, 1998, Okuyama, 2008). The 
position of the N-glycosylation site relative to the beginning of the collagen domain 
was determined at 9.2 ± 2.5 nm, a bit shorter than the theoretical value of 12.9 nm 
that could be expected only considering the position of the glycosylation site in the 
sequence and standard geometric considerations of the collagen triple helix. This 
indicates that specific interactions and condensing effects may modulate the 
structure of the collagen domain region at a local scale. 
The possible existence of SP-D hexamers was mentioned in only two previously 
published studies. Crouch and colleagues suggested the possible existence of 
paired SP-D trimers associated in overlapping antiparallel arrangements (Crouch et 
al., 1994b) and Leth-Larsen et al. found a peptide of 15-16 kDa after collagenase 
digestion which dissociated into six polypeptide chains after reduction (Leth-Larsen 
et al., 1999). AFM images of rhSP-D (Figures 1.2 and 1.5) show the conspicuous 
presence of hexamers composed of two trimers joined through their N-terminal 
domains. Several lines of evidence obtained from these images indicate that 
hexamers are a necessary intermediate state in the oligomerization process: i) the 
absence of Y-shaped structures formed by three trimers, ii) the conspicuous 
association of two hexamers in some dodecameric assemblies, which do not exhibit 
a unique solid central hub at the N-terminal region (see blue arrow in Figure 1.5C, 
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and panels B and D of Figure 1.7), and iii) the parallelism between angle values 
formed by the trimeric arms in hexamers and dodecamers (Figure 1.12A).  
In addition, we propose that dodecamers would be formed by two hexamers 
(Figure 1.16) and stabilized by a combination of non-covalent interactions between 
two hexamers at the N-terminal domain and the beginning of the collagen stem. In 
figure 1.1 the segment in rhSP-D sequence at the beginning of the collagen domain 
is marked as a charged patch, which contains a high density of basic and acidic 
residues and is highly conserved among different species. It is reasonable to 
consider that these residues could form ionic inter-chain links between triple 
helices from different hexamers. It has been published that in human collagen I the 
frequently found Lys-Gly-Asp/Glu triplets are highly stabilized by salt bridges 
(Persikov et al., 2005a, Persikov et al., 2005b), through formation of favorable ion 
pairs (Freudenberg et al., 2007). The amino acid sequence of rhSP-D contains eight 
of these triplets (Figure 1.1, purple residues), three of them close to the N-terminal 
region. Those triplets might establish inter-triple helix ionic bonds, due to its close 
proximity around the N-terminal region, contributing to dodecamer formation and 
stabilization. This idea is supported by AFM images (Figure 1.2 and blue arrow in 
figure 1.5C, figure 1.7) where the two hexamers in some dodecamers are observed 
with those regions (from N-terminal to the N-glycosylation site) interacting or 
closely apposed. Electrostatic interactions between carbohydrates linked to N70 
could also play a complementary role in oligomerization.  
The higher order oligomers observed in SP-D samples, typically described as 
‘fuzzy-ball’ assemblies, could be the result of the association of dodecamers and/or 
hexamers. These assemblies have been traditionally interpreted as the result of the 
coalescence of multiple trimeric arms with a nearly spherical geometry. However, 
our images illustrate how, once deposited onto mica, they adopt a conformation 
with the N-terminal region protruding out from the mica (Figure 1.8C). This supports 
the existence of specific interactions between the collagen segments close to the 
N-terminal domains of different hexamers and/or dodecamers. Consequently, these 
higher order SP-D oligomers should probably not be seen as truly spherical 
arrangements –as the ‘fuzzy ball’ term may suggest- but as widespread 
arrangements of hexamers and dodecamers in a bouquet joined through the N-
terminal ends. Unfortunately, the low resolution of rhSP-D molecules in cryo-TEM, 
which shows protein structure without being deposited onto any substrate, did not 
contribute to elucidate fuzzy balls conformation in the three dimensions. The 
stability of the fuzzy balls could be weak compared to that of dodecamers, being 
more sensitive to environmental conditions such as pH (see figure 1.11), a probable 
consequence of the key role of ionic interactions in the supratrimeric protein 
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oligomerization of SP-D. Interestingly, there is also a parallelism in the behavior of 
surfactant collectins SP-A and SP-D upon exposure to acidic pH. A conformational 
change, from open-arms to a tight closed-structure with the collagen domains 
grouped in a “stem-like” region and a shorter diameter of the CRD domains, has 
been reported for SP-A as a function of changes in pH or in the ionic environment 
(Efrati et al., 1987, Ridsdale et al., 1999, Palaniyar et al., 2001).  
We have observed by gel electrophoresis and AFM experiments that acidic pH 
promotes changes in SP-D conformation that include an increase in the thermal 
stability of the protein. Previously published data showed a dependence of collagen 
thermal stability on pH (Bianchi et al., 1967, Freudenberg et al., 2007), suggesting 
that the higher stability of SP-D at pH 4.2 could be associated with a higher stability 
of its collagen domain segments. In fact, thermal denaturation of the protein as 
observed under AFM (see figure 1.15) seems to include a conspicuous denaturation 
of putative collagen domain triple helices, which appear unstructured at 45 ºC at 
pH 7.4. 
A precise characterization of the distribution of SP-D oligomeric forms is the 
first step to address why SP-D exists as a variety of oligomeric forms, something that 
has been provided for recombinant human rhSP-D in this chapter. However, 
considering that trimers, hexamers, dodecamers and fuzzy balls have all been 
observed here and in previous structural studies with protein from different sources 
(Crouch et al., 1994b, Hartshorn et al., 1996a, van Eijk et al., 2002, Leth-Larsen et 
al., 2005, Hartshorn et al., 2008), it seems reasonable to propose that SP-D exists 
in a dynamic equilibrium between these different oligomeric forms, sensitive to the 
surrounding environment, with the hexamers playing a key role in the assembly 
process. It has been described that higher order multimers are more effective to 
promote influenza virus aggregation in vitro (Hartshorn et al., 1996a). Along the 
same line, structures larger than trimers, probably dodecamers and fuzzy balls, are 
required for binding to bacteria (Leth-Larsen et al., 2005) and for lung surfactant 
homeostasis (Zhang et al., 2001a). Further findings will be provided in the next 
chapter regarding activity of the different oligomeric forms, as well as a structural 
analysis of native human SP-D from two different sources (Chapter 3), to confirm 
that the structures observed in this chapter in rhSP-D are present in native protein 
and are not artifacts of the recombinant protein production process.   
It is unknown whether the conformational changes observed here under acidic 
conditions may have any functional implication. It has been published that the pH 
in the lung fluid may become acidic under disease or inflammation (Ng et al., 
2004), down to around 6.5. The effect of pH on SP-A function and structure has 
been studied (Ruano et al., 1998, Ruano et al., 1999), but not much is known about 
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its effect on SP-D. The closed conformation and higher proportion of dodecamers 
could be particularly important for the fate of the protein along secretory or 
endocytic pathways, where it may reach organelles with acidic pH (close to 5.5) 
(Demaurex, 2002). Dodecamers in closed conformation are somehow similar to 
fuzzy balls, described as the most active species against certain pathogens, 
suggesting that this conformational change could lead to a more active molecule 
with the CRD domains grouped in an orientation to simultaneously bind a higher 
number of ligands or receptor subunits clustered at the same surface.  
 
In summary, in this chapter we have presented the characterization of the 
different oligomeric forms of a recombinant human SP-D and determined its 
quantitative distribution. We propose a model for SP-D assembly that includes 
hexamers as an essential intermediate in the pathway to dodecamer assembly. The 
importance of environmental conditions such as pH on SP-D oligomerization and 
its three-dimensional configuration has been also demonstrated. Moreover, it was 
shown that the presence of calcium, which is crucial for some activities of SP-D, 
does not influence protein oligomerization and conformation at the supramolecular 
level. 
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Part of the experiments included in this chapter were performed during 
a short-term stay in the laboratory of Dr. Paul Kingma at Cincinnati 
Children’s Hospital Medical Center (Cincinnati, OH, USA) assisted and 
supervised by Paul Kingma, Ph.D., MD. AFM images were obtained in 
the laboratory of Dr. Fernando Moreno Herrero in “Centro Nacional de 
Biotecnología” (CNB-CSIC) (Madrid, Spain).  
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Introduction 
Up to date, it has been described that surfactant protein SP-D is assembled in 
trimers, dodecamers and large oligomers (fuzzy balls) (Crouch et al., 1994b, 
Crouch, 2000). The results described in chapter 1 of this Thesis have added 
hexamers as an additional oligomeric form of the protein.   
Previous studies have attempted to isolate SP-D oligomers. In one of them, the 
isolation was performed using hSP-D purified from amniotic fluid, but the 
resolution was limited to distinguish between low oligomeric forms, trimers and 
possibly hexamers, and high molecular weight oligomers: dodecamers and fuzzy 
balls (Leth-Larsen et al., 2005, Sorensen et al., 2009). In another study, Hartshorn 
and colleagues isolated recombinant human rhSP-D dodecamers and fuzzy balls, 
but no clear quantitative evidences were showed to demonstrate that this separation 
was actually achieved (Hartshorn et al., 1996a).  
Influenza A virus (IAV) and some bacterial species, such as Escherichia coli, 
have been defined as SP-D ligands in vivo (Crouch, 1998, Crouch, 2000). SP-D 
recognizes carbohydrate structures at microbial surfaces and binds to them, which 
causes aggregation and opsonization of the infectious particles (Sano and Kuroki, 
2005, Vieira et al., 2017). Therefore, both, bacteria and virus have been used for 
evaluating protein activity. The functional activity of isolated oligomeric forms of 
SP-D has been assessed mainly by binding assays to purified ligands, like LPS or 
carbohydrates, IAV and bacteria. Also, virus aggregation assays have been 
performed. In general terms, the main conclusion obtained seem to be that large 
oligomers have a higher affinity for binding to the bacteria strains tested and to IAV 
(Leth-Larsen et al., 2005), with the large fuzzy balls exhibiting higher potency to 
aggregate IAV compared to dodecamers (Hartshorn et al., 1996a).  
The objective in this thesis chapter was to isolate the different oligomeric forms 
of recombinant human rhSP-D in order to evaluate and compare their functional 
activity. Also, we pursued to achieve a higher degree of fractionation than just 
separating low and high molecular weight oligomeric forms, obtaining if possible 
isolated trimers, hexamers, dodecamers and fuzzy balls in sufficient amount to 
carry out functional assays. An additional objective was to define whether the 
hexamers found in chapter 1 were functional structures or just an intermediate in 
protein oligomerization. The results of these experiments demonstrated that it is 
possible to obtain fractions highly enriched in trimers, hexamers and fuzzy balls. 
However, dodecamers were found dispersed within the fractions between fuzzy 
balls and hexamers, contaminated with those two species. Fuzzy balls were the 
most active oligomeric form with respect to bacterial binding and aggregation 
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assays. Also, hexamers triggered bacteria aggregation, although with less pontency 
than fuzzy balls.   
 
Results 
Production and purification of recombinant human SP-D  
Recombinant human SP-D (rhSP-D), variant Met11 Thr160 Ser270, was produced 
in mammalian CHO cells, as described in methods.  
Purification of rhSP-D is usually performed by two consecutive 
chromatographic steps. First, an anion exchange column, which allows us to 
concentrate the sample and remove glucose from cell media. Second, a 
carbohydrate affinity column, which removes non-specific proteins and specifically 
binds SP-D, eluting pure SP-D at the end (Ikegami et al., 2006).  
 
Figure 2.1: Electrophoretic analysis of rhSP-D purified produced by CHO cells. A, protein purified 
through an anionic exchange chromatography, evaluated by PAGE-SDS developed with Coomassie 
blue (left) and by WB (right) with anti-SP-D in the presence or absence of reducing conditions. B, 
protein purified by two consecutive chromatographic steps. First, an anionic exchange 
chromatography and second, an affinity chromatography in a Superdex matrix. The final purified 
protein was analyzed by PAGE-SDS developed with silver staining, in the presence or absence of 
reducing conditions.  
 
A complete purification procedure was performed with a first batch of rhSP-D, 
meaning that the two columns were run and pure SP-D was obtained (Figure 2.1B). 
However, the protein yield obtained with this procedure was too low for the 
purpose of the study, a total amount of 600-700 µg diluted in 4-5 fractions. Hence, 
a modified approach was followed using only the first column (anionic exchange) 
and then, applying the partly purified protein in a gel filtration column (sizing 
column), with the goal to fractionate the different rhSP-D oligomeric forms and 
separate them from other proteins in a single step. The protein yield obtained from 
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the ion exchange ceramic column was high, recovering as much as several 1mL-
fractions with a concentration of protein of around 3-5 mg/mL, although not all this 
protein was SP-D. The electrophoretic analysis of fractions eluted from this ceramic 
column revealed the presence of rhSP-D trimers, that were reduced to monomers 
in the presence of b-mercaptoethanol (Figure 2.1A). When these samples were 
observed under AFM, rhSP-D was found to be assembled into the different species 
described in chapter 1: trimers, hexamers, dodecamers and fuzzy balls (Figure 2.2). 
As expected, samples presented also a high amount of impurities, probably 
unspecific proteins, observed as small bright balls in AFM images (see round bright 
spots in Figure 2.2, left). 
 
 
Figure 2.2: rhSP-D obtained after 1-step ion exchange chromatography. rhSP-D produced by CHO 
cells and purified through an anionic exchange chromatography (ceramic column) was imaged by 
AFM. Left, scan area of 2 µm, where white solid circles mark the presence of fuzzy balls, white 
dotted circles indicate dodecamers, black solid circles enclose hexamers and black dotted circles, 
trimers. The scale bar represents 200 nm. Right, magnifications of AFM images showing illustrative 
examples of different oligomeric forms: trimers (T), hexamers (H), dodecamers (D) and fuzzy balls 
(FB). The scale bar represents 50 nm. 
 
On the whole, we were able to produce rhSP-D by CHO cells and purify it with 
a ceramic anion exchange column, obtaining high protein (SP-D) yields that 
contained some amounts of co-eluting unspecific proteins. Moreover, rhSP-D 
purified in this way presented all the oligomeric forms previously described.  
 
Isolation of recombinant human rhSP-D oligomeric forms  
Size exclusion chromatography (SEC) was carried out to separate trimers, 
hexamers, dodecamers and fuzzy balls. Sepharose CL-6B was poured and 
equilibrated into a long column (90 cm) to ensure an efficient separation between 
the different oligomers. Chromatography was performed as stated in methods, 
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applying onto the sizing column around 4 mg of protein obtained from the ceramic 
column. Eluted fractions were assessed by SP-D ELISA to quantitate the protein 
concentration and to obtain a column elution profile (Figure 2.3A). In spite of the 
fact that the column profiles did not show very defined peaks, the pattern observed 
was repetitive after comparing more protein samples resolved by SEC. The profiles 
always exhibited a main peak around 60 mL elution volume, with a characteristic 
shoulder at 65-67 mL and small peaks at subsequent elution volumes (Figure 2.3A). 
 
Figure 2.3: Size exclusion chromatography (SEC) of rhSP-D. A, elution profile of rhSP-D in a 
Sepharose CL-6B column, obtained with SP-D ELISA. B-C, electrophoresis analysis after cross-
linking of selected fractions eluted from the column at increasing elution volumes (the elution 
volume of each fraction is indicated above the gels). B, polyacrylamide gradient (4-15%) gel 
developed by silver staining. C, western-blot developed with anti-SP-D (1A10A9). The position in 
the gels of the different protein oligomeric forms are indicated on the right.  
 
A calibration of the sizing column was performed with standard globular 
proteins of different size, and the expected elution volumes for different rhSP-D 
oligomers were calculated according to their theoretical molecular mass. However, 
the flexible and fibrous structure of SP-D oligomers, far from the structure of 
globular proteins, likely implies very distinct hydrodynamic properties, making 
these standard references useless. Only the determination of the column void 
volume was useful to estimate the elution volume of the large fuzzy balls. Therefore, 
other methods were necessary to identify rhSP-D oligomer peaks.  
Selected samples, corresponding to some of the vague, but repetitive, peaks 
along the profile were examined by electrophoresis and AFM. PAGE-SDS and WB 
of rhSP-D crosslinked with glutaraldehyde (GA) were performed using 
polyacrylamide gradient (4-15%) gels. According to these results (Figure 2.3B), 
dodecamers were spread over the eluted fractions (see silver stained gel and WB). 
The band with the mobility of hexamers became more evident at volume 75.9 and 
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77.3, and the band of trimers started at volume 85 (more obvious in the silver 
stained gel than in the WB, Figure 2.3B-C). The presence of fuzzy balls in gels was 
not expected, as they do not penetrate into gels due to its size and molecular mass. 
Silver staining and WB are very sensitive techniques that detect species even if they 
are at very low concentration. These techniques provide an estimation of where 
each of the oligomers elute in the chromatography, but they do not discern whether 
the fractions contained a majority of each form. Hence, protein samples were 
analyzed by AFM. Selected images of fractions that correspond to the indicated 
elution volumes are shown in Figure 2.4. It was found that fraction eluted at 60.5 
mL (V60.5) contained only fuzzy balls, sample eluting at V77.3 mL enclosed mainly 
hexamers, and that at V89.2 mL, trimers. It is remarkable that those eluted fractions 
were significantly enriched in one type of oligomer.  
 
Figure 2.4: AFM images of samples from selected eluted fractions from SEC. Representative AFM 
images of rhSP-D corresponding to elution volumes V60.5 (fuzzy balls), V77.3 (hexamers), V 89.2 
(trimers) and V101 (unspecific proteins). The scale bar represents 200 nm in the largest images and 
50 nm in the insets.  
V60.5 V77.3
V89.2 V101
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Quantification of the distribution of oligomeric forms, as percentage of protein 
mass, was performed with images taken from samples of these selected elution 
volumes. Fuzzy balls constituted 95% of the protein in V60.5, hexamers accounted 
for 74% in V77.3 and trimers constituted 80% in V89.2 (see Figure 2.6A).  
Unfortunately, isolated dodecamers were not found. Eluted fractions from 60.5 mL 
to 75 mL of the chromatographic profile were carefully examined, especially those 
around volume 66 mL, matching with the shoulder observed in the elution profile 
at the right-side of the main peak (Figure 2.3A). Some of these fractions exhibited a 
mixture of dodecamers and hexamers, but none of them had a significant amount 
of dodecamers to be considered pure. AFM images of samples at V66 are shown in 
Figure 2.5. The quantification of the distribution of oligomeric forms in that fraction 
revealed a distribution of 20% trimers, 28% hexamers, 38% dodecamers and 14% 
fuzzy balls. Dodecamers were the most abundant oligomer, but they constituted 
only around 40% of the total protein mass.  
 
Figure 2.5: AFM images and quantification of the distribution of the oligomeric forms in fraction 
V66. A, representative AFM images of rhSP-D corresponding to elution volume V66. The scale bar 
represents 200 nm. B, quantitative analysis of the distribution of oligomeric forms in fraction V66 
by percentage of protein mass (% weight). 
 
The presence of dodecamer bands in the electrophoretic analysis at the latest 
elution volumes, when they were not observed in those fractions under AFM, was 
contradictory. Therefore, the electrophoretic analysis was only used as a guide to 
estimate where the different oligomeric forms were and, which fractions should be 
examined under AFM. From our experience, AFM results are more relevant than 
electrophoresis; besides, AFM images allowed us to classify and count the different 
molecules in order to obtain the percentage of distribution. We could not discard 
that the cross-linking agent – glutaraldehyde - could promote some 
oligomerization. Regarding trimer bands in the WB, they can be observed but are 
not really well defined when compared to those revealed by silver staining. An 
explanation was found later, as the antibody used for this WB, anti-SP-D 1A10A9 
(see table 2 in methods section), sometimes does not recognize the trimer 
V66
0
20
40
60
80
100
Elution Volume (mL)
%
 W
ei
gh
t Trimers
Hexamers
Dodecamers
Fuzzy Balls
A B
RESULTS. Chapter 2 
 113 
efficiently, but it does it with the dodecamer (Airway Therapeutics LLC., personal 
communication). 
The concentration of recombinant rhSP-D in fractions enriched in trimers, 
hexamers and fuzzy balls was quantified with a commercial ELISA kit that was more 
sensitive and precise in order to do further experiments. Routinely, SP-D 
concentration is quantified by BCA. In our case, we wanted to specifically quantify 
SP-D, avoiding the possible interference of the small amounts of contaminants still 
observed in the AFM images at the later fractions. Besides, the elution of the sizing 
column provides low protein concentrations. For this reason, we used in this 
chapter the ELISA kit as quantification method instead of the BCA assay. 
The second goal pursued with the sizing column, to increase protein purity 
removing those unspecific proteins observed as bright spots in figure 2.3B, was 
achieved successfully. The band pattern observed in figure 2.2A (gel, two first 
lanes), with bands at lower molecular weights than rhSP-D monomer, was not seen 
in the fractions eluted from the sizing column (Figure 2.3B). Selected fractions 
eluted around volume 100 mL were analyzed by AFM (Figure 2.4, V101) and 
contained the bright spots with a ball-shape that were identified as contaminants in 
Figure 2.2, before running the sizing column. 
In summary, rhSP-D trimers, hexamers and fuzzy balls were efficiently isolated 
with enough purity grade (Figure 2.6). Fractions enriched in dodecamers were not 
found, although they were observed spread along the elution fractions between 
volumes ~ 63-74 mL by cross-linking and electrophoresis. 
 
Figure 2.6: Identification of the eluted fractions that were significantly enriched in the different 
oligomeric forms of rhSP-D. A, quantitative analysis of the distribution of oligomeric forms in the 
indicated fractions by percentage of protein mass (% weight). B, position of the fractions containing 
isolated fuzzy balls, hexamers and trimers in the elution profile of a Sepharose CL-6B column (sizing 
column).  
 
Redistribution of SP-D Oligomeric forms  
rhSP-D exhibits a mixture of different oligomeric forms, as studied in chapter 1 
and found also in the experiments of this chapter. Since hexamers, dodecamers and 
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fuzzy balls are assembled through non-covalent interactions, it might be possible 
that when oligomers are isolated and stored, they could progressively redistribute 
to end in a close to “native” distribution of oligomeric forms. The potential 
redistribution of isolated fuzzy balls was assessed after 3 hours, 24 h and 5 days of 
storage at 4 ºC. The quantity of hexamers and trimers isolated was low compared 
to fuzzy balls, so they were rather preserved for functional studies.  
 
Figure 2.7: Size exclusion chromatography of a preparation of purified rhSP-D fuzzy balls after 
different incubation times at 4 ºC. Column elution profiles were obtained by SP-D ELISA of fractions 
resulting from the size exclusion chromatography in Sepharose CL-6B of rhSP-D fuzzy balls, after 
different incubation times: 3 hours (blue), 24 h (red) and 5 days (green) at 4 ºC. 
 
To assess potential oligomeric forms redistribution, the same resin (Sepharose 
CL-6B) was poured into a shorter column (~ 40 cm) and ~ 150 µg of rhSP-D isolated 
fuzzy balls were applied onto the column. Column elution profiles were built with 
SP-D ELISA, as described before. Experiments at the different times were repeated 
twice and the average of two replicates was represented to show the elution 
profiles. The profiles of the protein after all incubation times (3h, 24h and 5 days) 
showed a main peak at the void volume ( ~ 29-30 mL), which corresponded to the 
elution of fuzzy balls (Figure 2.7), without displaying any significant shift in the 
elution profile. Therefore, we concluded that there was no significant redistribution. 
It could be still possible that longer incubation times at 4 ºC or shorter times at room 
temperature might induce some redistribution. 
 
Binding of the different oligomeric forms to Escherichia coli 
To address whether different isolated recombinant human rhSP-D oligomers 
(trimers, hexamers and fuzzy balls) could exhibit different affinity of binding to 
bacteria, one of the protein ligands in vivo, binding assays to Escherichia coli strain 
DH5a were performed in an ELISA-like assay. 
Different concentrations of rhSP-D oligomers were incubated into microtiter 
plate wells coated with bacteria. Protein binding was measured by SP-D ELISA. It 
was found that fuzzy balls had higher binding affinity to bacteria, compared to 
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hexamers and trimers (Figure 2.8A). There were no apparent differences between 
hexamers and trimers. However, when absorbance values were relativized 
considering as 100% the maximum absorbance obtained at 2000 ng/mL of rhSP-D 
fuzzy balls, significant differences were found between hexamers and trimers at the 
highest SP-D concentration tested (Figure 2.8B). The experiments were performed 
with two anti-SP-D antibodies that differed in their protein epitope. In one case the 
epitope was located in the CRD of SP-D, while in the second case, it was at the N-
terminal domain. SP-D binds to bacteria through the CRDs. If the epitope of the 
antibody is located in the CRD of the protein, it could be blocked when SP-D is 
bound to bacteria, leading to a potential underestimation of the protein bound. The 
differences observed between the oligomeric forms of rhSP-D with respect to their 
ability to bind to E. coli were repetitive with both antibodies, although the one that 
binds to the CRD showed better reactivity. Therefore, there were no issues with the 
protein recognition by these two antibodies. Results showed here were obtained 
with the antibody that recognizes the epitope at the CRD of the protein.  
 
 
Figure 2.8: Binding of trimers, hexamers and fuzzy balls of rhSP-D to E. coli. Plates were coated 
with bacteria and incubated with 2-fold dilutions starting at 2000 ng/mL of each rhSP-D isolated 
oligomeric form. Bound SP-D was detected with antibodies in an ELISA-like assay. A, representation 
of the absorbance of bound SP-D at the different SP-D concentrations tested (n = 2), Two-way 
ANOVA with Tukey’s post-test was performed, differences between fuzzy balls and hexamers and 
trimers were significant from 125 ng/mL of SP-D ****p<0.0001. The difference between hexamers 
and trimers at 2000 ng/mL was significant **, p=0.0096. B, relative absorbance considering 100% 
the value obtained for fuzzy balls at an SP-D concentration of 2000 ng/mL. Two-way ANOVA with 
Tukey’s post-test was performed *, p<0.05; ****, p<0.0001. 
 
Bacterial aggregation induced by the different oligomeric forms of recombinant 
human rhSP-D 
In lungs, one of the functions accomplished by SP-D is the agglutination of 
invading pathogens, such as bacteria, which facilitates their clearance via 
mucociliary escalator. Therefore, bacterial aggregation assays of E. coli were carried 
out to evaluate in vitro the activity of isolated rhSP-D oligomers.  
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Figure 2.9: Bacterial aggregation by the different oligomeric forms of rhSP-D. Bacterial suspensions 
of E. coli DH5a were incubated with or without (control) different concentrations of rhSP-D isolated 
oligomeric forms. A, absorbance values (l = 700 nm) were monitored during 150 minutes upon 
addition of trimers (top), hexamers (middle panel) or fuzzy balls (bottom). B, percentage of 
aggregated bacteria determined at three time points (t = 75, t = 120 min and, t = 150 min), as stated 
in methods, after addition of four different concentration of SP-D trimers (top), hexamers (middle) 
or fuzzy balls (bottom). Two-Way ANOVA with Tukey’s post-test: **, p£0.01; ***, p£0.001. 
 
The ability of rhSP-D trimers, hexamers and fuzzy balls to aggregate bacteria 
was tested at different protein concentrations (0.1 µg/mL – 2 µg/mL), by monitoring 
light transmission through a suspension of E. coli after the addition of protein over 
150 minutes. Trimers did not display bacterial aggregation even at the highest 
concentration tested, 2 µg/mL (Figure 2.9A, top graph). Hexamers started to show 
activity at protein concentration of 1 µg/mL (Figure 2.9A, middle graph), while 
fuzzy balls were the most active oligomeric form, starting to trigger bacterial 
aggregation in less than 60 min at 2 µg/mL (Figure 2.9A, bottom graph). Even at low 
protein concentrations, such as 0.1 and 0.25 µg/mL, aggregation started after 2 
hours (see blue and green lines, bottom graph in Figure 2.9A). The percentage of 
aggregated bacteria was calculated for the different species at three time points 
(Figure 2.9B): 75 min, 120 min, and at the final time point (150 min). At early times, 
75 minutes, only fuzzy balls showed significant aggregation of bacteria compared 
to trimers and hexamers (Figure 2.9B, top). After two hours (120 min), significant 
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differences were also observed at low concentrations (0.25 µg/mL) between fuzzy 
balls and hexamers (Figure 2.9B, middle graph). Interestingly, at 2 µg/mL of protein 
concentration, the percentage of aggregated bacteria was significantly higher in 
hexamers compared to trimers, phenomenon that was also observed at 1 µg/mL of 
SP-D at the final time point (150 min) (Figure 2.9B, bottom graph). On the contrary, 
at final time point (150 min), the differences in activity between hexamers and fuzzy 
balls, at higher protein concentrations (1-2 µg/mL), became less significant than at 
earlier time points.  
 
 
Figure 2.10: Percentage (%) of aggregated bacteria by selected fractions eluted from the SEC 
column. The % of aggregated bacteria was calculated at two different time points (A, left: t = 90 
min; B, right: t = 180 min) at different protein concentrations (indicated by colors). The peaks 
assigned to fuzzy balls, hexamers and trimers are indicated by dashed boxes and schematic 
drawings.  
 
Figure 2.10A shows how the % of aggregated bacteria varies as promoted by 
the different column fractions, including those with isolated fuzzy balls (V60.5), 
hexamers (V77.3) and trimers (V89.2), at three protein concentration ranges, 90 
minutes after protein incorporation. It is remarkable that only fuzzy balls are active 
at the lowest concentration tested (green bars) at this time point. Moreover, at the 
other two concentration ranges (blue and red bars), the percentage of aggregated 
bacteria was maximum in the fraction that corresponded to fuzzy balls and also 
peaked in the fraction that matched with hexamers. Interestingly, fraction V66 
(Figure 2.5), which corresponds to the shoulder observed in the column elution 
profile (Figure 2.6) and it was the region where we expected to find dodecamers, 
showed lower activity than fuzzy balls, but higher than hexamers. This was also 
observed at the final time point (Figure 2.9B, time 180), where a progressive 
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decrease in protein activity was observed from fuzzy balls to trimers. Despite these 
findings, our AFM and electrophoresis results did not allow us to confirm 
accumulation of isolated dodecamers in that fraction (V66), as observed in the 
quantification of the distribution of oligomeric forms illustrated in Figure 2.5B.  
In summary, we have shown that fuzzy balls are the most potent oligomeric 
forms of rhSP-D with respect to their ability to trigger E. coli aggregation; hexamers 
were also active and the activity of trimers was negligible.  
 
Discussion 
The activity of the different oligomeric forms of SP-D has been a matter of 
discussion since it was found that the protein is assembled in different structures. 
Herein we have been able to separate trimers, hexamers and fuzzy balls of a 
recombinant human rhSP-D. It has been found that fuzzy balls are the most potent 
oligomer in the functional assays performed, binding and aggregation of E. coli. 
Trimers have shown a lower affinity of binding to bacteria and were not able to 
aggregate them. It is remarkable that the hexamers described in chapter 1 could be 
isolated and have shown to be functional oligomers, displaying an intermediate 
grade of activity between trimers and fuzzy balls, facts that demonstrate that they 
are SP-D entities and not artifacts of the production or purification processes.   
The degree of separation obtained in previous studies allowed authors to 
differentiate between high and low molecular weight oligomeric forms using a 
Superose 6 column (molecular weight (MW) separation range for globular proteins 
and dextrans in the 5 – 5000 kDa range)  (Leth-Larsen et al., 2005), and between 
fuzzy balls and dodecamers with a column with a matrix constituted by 4% 
crosslinked agarose (Hartshorn et al., 1996a). They compared binding and IAV 
aggregation, finding that fuzzy balls were the most active oligomeric form in all the 
experiments performed. 
In our study, using a Sepharose CL-6B column, where the resin matrix is formed 
by 6% of crosslinked agarose with a MW separation range for globular proteins and 
dextrans of 10 – 4000 kDa, we have achieved a higher degree of separation. We 
have been able to obtain most of the different oligomeric forms of SP-D: trimers, 
hexamers and fuzzy balls. Different fractions were highly enriched in each of the 
oligomeric forms, as shown by the quantitative study (Figure 2.6A). Despite 
numerous attempts, it was not possible to isolate pure dodecamers. Several facts 
could contribute to this failure. First, the rhSP-D produced probably had a higher 
proportion of fuzzy balls than the one observed in chapter 1. This idea was also 
discussed for a rhSP-D produced by other authors (Hartshorn et al., 1996a), where 
they obtained similar amounts of both dodecamers and fuzzy balls, and, we have 
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also observed it in hSP-D purified from amniotic fluid (seen in Chapter 3). Although 
we did not observe a dramatically increased proportion of fuzzy balls when we 
imaged the starting material in the AFM (rhSP-D obtained from ceramic column, 
Figure 2.2B), more fuzzy balls were observed compared to the recombinant version 
studied in chapter 1. Second, dodecamers were spread over all the eluted fractions 
from the fuzzy balls peak to the hexamers peak. The flexible structure of 
dodecamers likely allow them to display different conformations, as we observed 
in chapter 1, implying variations in their hydrodynamic properties. If we imagine 
the sphere that would contain the dodecamer, the diameter of this sphere changes 
along different dodecamer conformations: opened, closed and intermediate states. 
It might be possible that opened structures (with a larger diameter) would not 
penetrate resin pores, eluting earlier than partly bended structures or completely 
closed conformations. In addition, the column flow rate could influence protein 
conformation. Their flexibility could likely promote that some dodecamers 
randomly penetrate the pores and as a result, they could change to close 
conformations to be able to go through the column pores as pushed by the liquid 
flowing into the column; others could migrate faster without entering into the pores 
in their opened conformation. Third, we observed some fractions in which 
dodecamers appeared mixed with hexamers. The similarities in conformation 
between hexamers and dodecamers, with similar molecule diameter, might be 
translated into an analogous behavior due to also similar hydrodynamic volumes. 
In this line we only obtained pure hexamers at later fractions. In principle, one 
could expect finding isolated dodecamers at the earlier fractions after the fuzzy 
balls peak, but it did not happen. Therefore, the isolation of dodecamers remains 
as a challenge. They are present in our rhSP-D because they can be found in the 
starting material. 
The total concentration of protein isolated in the form of trimers was low, in 
agreement with the quantitative data from chapter 1, but it was still enough to 
perform some functional assays. Up to now, the evaluation of the activity of trimers 
had been carried out with truncated versions of the protein that prevented 
oligomerization to larger structures, such as substitution of cysteines 15 and 20 by 
serines, that served to show that trimers were not sufficient to cause viral 
aggregation, or, with mutated versions composed only by trimeric CRDs and neck 
domains (Brown-Augsburger et al., 1996a, Brown-Augsburger et al., 1996b, Zhang 
et al., 2001a, Tecle et al., 2008). Also, binding properties of trimeric forms of hSP-
D have been analyzed, but in those studies isolated trimers were constituted mainly 
by the Thr11 variant (Leth-Larsen et al., 2005, Sorensen et al., 2009), whereas our 
rhSP-D trimers contain Met11 in their sequence. In both cases, our rhSP-D trimers 
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and the low molecular weight forms in the study by Leth-Larsen et al. (2005) 
showed lower binding to bacteria than higher order oligomers. 
SP-D has shown therapeutic effects in animal models, i.e. preventing endotoxin 
shock in newborn preterm lambs (Ikegami et al., 2006). From a physiological point 
of view, it is important to know whether all the oligomeric forms found in SP-D are 
functional, and which one is the most active, particularly, if one considers 
recombinant human rhSP-D as a possible therapeutic option. We have studied the 
activity of rhSP-D trimers, hexamers and fuzzy balls in terms of binding to one of 
its physiological ligands, E. coli, and their potential to aggregate it, as one of the in 
vivo functions of SP-D. Fuzzy balls showed higher binding affinity to E. coli than 
hexamers and trimers. Increased concentrations of the two last ones did not 
increase the rate of protein bound to bacteria, and only hexamers, at the highest 
concentration tested (2000 ng/mL), exhibited greater binding than trimers (Figure 
2.8B). These results agreed with previous findings comparing high and low 
molecular weight forms of hSP-D (Leth-Larsen et al., 2005). On the contrary, affinity 
of binding of low molecular weight forms of SP-D to isolated LPS was found to be 
higher than in the case of high molecular weight forms (Leth-Larsen et al., 2005, 
Sorensen et al., 2009). The bacterial strain tested in our experiments is gram 
negative, with LPS exposed in their external wall available to be recognized by SP-
D. In our hands, trimers of SP-D did not significantly bind to E. coli, suggesting that 
they bind poorly to the LPS on the outer membrane. A possible explanation to this 
fact would be that when LPS is anchored on a bacterial wall, trimers are not able 
to interact with LPS due to its distribution and steric disposition. This idea was also 
discussed by Hakansson and Reid (2000). A lower affinity of SP-D for binding to 
LPS “in situ” might require a synergistic cooperation of more than one trimeric CRD 
domain to sustain binding, explaining why trimers with one single trimeric CRD do 
not practically bind. Hexamers, with two trimeric CRD domains might constitute 
the minimal unit with the capacity to exhibit binding cooperativity. Fuzzy balls, 
with their higher number of trimers and CRD domains would exhibit maximal 
cooperativity, maximal affinity and maximal probability of interacting with the LPS 
even when it is arranged in a specific conformation on bacterial wall.  
In the case of bacterial aggregation, it is even more evident that rhSP-D needs 
to be assembled in structures larger than trimers to trigger aggregation (Figure 2.9), 
and that fuzzy balls are the most active oligomeric form to do this. Similar results 
had been previously obtained for viral aggregation (Hartshorn et al., 1996a). As 
mentioned before, SP-D binds bacteria and viruses through its trimeric CRDs. It is 
logical that in order to aggregate pathogens, SP-D molecules need to be constituted 
by at least two trimers in order to be able to group together two bacteria, where 
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one trimer contained in the protein molecule would bind to one bacterium and 
another trimer to another bacterium. Again, fuzzy balls, with their multiple trimeric 
CRDs, would be the perfectly suited to promote the highest aggregation extent 
when compared to other protein oligomeric forms.  
In this chapter, we have also analyzed the potential redistribution of SP-D 
oligomeric forms in vitro. Hartshorn and colleagues did not find any processing or 
storage condition that influence multimerization or dissociation (Hartshorn et al., 
1996a). On the contrary, it has been reported that storage of SP-D multimers at 4 
ºC during one week induces dissociation into trimers, which is more dramatic and 
happens earlier at room temperature, although it was prevented when SP-D was 
stored at -20 ºC (Sorensen et al., 2009). The same study also showed that protein 
dilution favors an increase in the proportion of trimers. We did not find dissociation 
of fuzzy balls after 5 days of storage at 4 ºC (Figure 2.7), neither upon the dilution 
required for AFM imaging (Figure 2.4), so our data agreed better with the first report. 
In addition, it has been found that binding to N-acetyl-D-mannosamine agarose 
when this was employed as resin to purify SP-D by affinity chromatography, 
promoted oligomerization of trimers into protein multimers (Sorensen et al., 2009). 
Thus, this finding opens the question whether ligand binding in vivo could promote 
oligomerization of the protein, which could be linked to a progressive displacement 
to the most active forms and a stimulation of function.   
 
In summary, in this chapter we have achieved the separation of recombinant 
human rhSP-D oligomeric forms. Isolation of trimers, hexamers and fuzzy balls was 
particularly efficient. Fuzzy balls presented a higher affinity of binding and a higher 
potency to aggregate bacteria, which postulate them as the most active oligomeric 
form with respect to those protein functions that depend on the lectin activity. How 
much this is also the case for other biological functions of SP-D, such as its role in 
surfactant homeostasis or the regulation of the immune responses by SP-D has to 
be investigated. It could be that the versatility in SP-D oligomeric forms could be 
related to the versatility of SP-D in protein functions.   
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The AFM experiments included in the present chapter were done at the 
laboratory of Dr. Fernando Moreno Herrero in “Centro Nacional de 
Biotecnología” (CNB-CSIC; Madrid, Spain). Glyco-profiling of hSP-D 
was performed by Glycotope GmbH (Berlin, DE). Amniotic fluid was 
obtained from the Gynecology and Obstetrics Service of “Hospital 12 
de Octubre” (Madrid, Spain) in a collaboration with Drs. Emma Batllori 
Badia and Alberto Galiento Izquierdo. 
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Introduction 
In chapter 1, rhSP-D isolated from culture medium of CHO cells has been used 
for characterizing the structure of this protein and determining the quantitative 
distribution of rhSP-D oligomeric forms. Besides, in chapter 2, a functional study to 
compare the activity of isolated different rhSP-D oligomeric forms has been 
performed. However, up to now, the quantitative distribution of SP-D oligomeric 
forms of the human protein obtained from natural sources (hSP-D) is unknown. It 
also remains to be stablished whether structures, such as hexamers, are secreted 
and are present or not as intermediates assemblies in vivo. These findings would be 
relevant to validate CHO cells as an appropriate system to produce rhSP-D similar 
in structure and activity to the native protein. 
Human SP-D (hSP-D) has been routinely obtained from bronchoalveolar 
lavages of patients that suffer from pulmonary alveolar proteinosis (PAP), a disease 
characterized by altered surfactant production and metabolism. The most common 
type of PAP courses with an alteration of the granulocyte macrophage-colony 
stimulating factor (GM-CSF). This protein is important for lung surfactant recycling 
and catabolism by alveolar macrophages. Hence, its alteration causes 
accumulation of surfactant proteins and lipids that also show protein aggregates 
and altered phospholipid composition, including increased concentrations of 
cholesterol (Suzuki and Trapnell, 2016) (Ballester, et al., 2018). It has been 
described in the literature that SP-D produced by PAP patients is found in higher 
amounts, and is composed largely of higher order oligomeric forms, as a 
consequence of the disease (Crouch et al., 1993a). Thus, it is an open question how 
much this protein, which comes from a pathological condition, reflects the actual 
structure and functional behavior of the native protein in healthy human mucosae. 
Alternatively, previous works have obtained non-pathological hSP-D from amniotic 
fluid (AF) from cesareans at term pregnancy (Strong et al., 1998, Nadesalingam et 
al., 2003, Leth-Larsen et al., 2005). Human SP-D has been detected in amniotic 
fluid as early as 26 weeks’ gestation, and its concentration levels progressively 
increase until labor (Miyamura et al., 1994, Stahlman et al., 2002). Therefore, hSP-
D from AF could be a good control for structural studies. Three polymorphisms 
have been reported in hSP-D, with differences in the amino acid sequence at 
residues 11 (Met11Thr), 160 (Ala160Thr) and 270 (Ser270Thr). It is known that the 
amino acid present in position 11 is relevant for protein oligomerization: when it is 
a methionine, hSP-D is found in both low and high molecular weight forms. 
However, when a threonine is occupying this position, the protein lacks high 
molecular weight oligomers (Leth-Larsen et al., 2005). Moreover, it is also known 
that the amino acid Asn70 of human SP-D is glycosylated in its amide, as it is in 
RESULTS. Chapter 3 
 126 
rhSP-D, with biantennary structures and fucose attached to the glycan core (Leth-
Larsen et al., 1999, Ito et al., 2015). 
In chapter 2, fuzzy balls showed an increased activity in the functional assays 
performed, when compared to hexamers and trimers. In this line, the activity of 
hSP-D from PAP and AF has been previously characterized, especially in terms of 
binding and agglutination of influenza A virus (IAV), but never in a comparative 
way (Hartshorn et al., 1996a, Leth-Larsen et al., 2005). A different behavior could 
be expected in terms of activity, particularly, considering the expected differences 
in the distribution of the oligomeric forms between these two proteins, in line with 
the results obtained in chapter 2. 
In the present chapter, we have characterized the structure of hSP-D obtained 
from PAP and AF and quantified the distribution of oligomeric forms of AF-hSP-D 
to compared them with the recombinant protein produced by CHO cultures. 
Moreover, the characterization of the glycan attached to the asparagine in position 
70 has been addressed, with highly sensitive technologies available nowadays. 
Last, the activity of hSP-D from AF and PAP to bind and aggregate bacteria, as well 
as their carbohydrate binding preference have been assessed and compared. We 
found that hSP-D from AF is also formed by trimers, hexamers, dodecamers and 
fuzzy balls, being the proportion of fuzzy balls slightly higher than that of 
dodecamers. The combination of dodecamers and fuzzy balls represented ~70% of 
the total protein mass obtained from AF. It was found that the N-glycan structure 
was biantennary, core-fucosylated with partial galactosylation and sialylation, as 
well as bisecting GlcNAc. To our knowledge sialylation of SP-D has not been 
reported before. hSP-D from AF and PAP were both active in the functional assays 
performed, being PAP-hSP-D more effective, probably as a consequence of its 
abnormal increased proportion of large oligomers.  
 
Results 
Isolation of human SP-D from amniotic fluid by affinity chromatography  
Human SP-D was obtained from two different sources to carry out the studies 
in the present chapter. First, hSP-D purified from bronchoalveolar lavage of patients 
suffering from pulmonary alveolar proteinosis (PAP) was provided by Dr. Paul 
Kingma (Cincinnati Children’s Hospital; Cincinnati, Ohio). As this protein comes 
from a pathological situation in the lungs, hSP-D was also purified from amniotic 
fluid (AF) obtained in cesareans at term pregnancy.  
Superdex-75Ò resine was applied to purify hSP-D from AF. In the presence of 
calcium, SP-D binds through its CRD domains to the dextrans covalently bound to 
a matrix composed of crosslinked agarose. Superdex has better flow rates than 
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maltose-agarose, and covalently bound dextrans allow high efficiency of protein 
binding when compared to plain crosslinked agaroses. SP-D purification was 
carried out as described in the methods section. Fractions eluted from the column 
were examined by electrophoresis under reducing conditions and developed by 
silver staining to find those that contained the protein (Figure 3.1A).  
 
Figure 3.1: Purification of human SP-D from amniotic fluid (AF). A, PAGE-SDS of fractions eluted 
from SuperdexÒ-75 column under reducing conditions, including a control (C) of rhSP-D; the gel 
was developed by silver staining. B, western blot of one column fraction (lanes 1-3) developed with 
anti-SP-D (1A10A9). In lane 1 hSP-D was crosslinked with GA, lane 2 non-reducing conditions, 
lane 3 reducing conditions. 
 
hSP-D monomer from AF showed an electrophoretic mobility corresponding to 
an approximate molecular weight of ~ 43,000 Da (Figure 3.1A, B), as previously 
reported by other authors (Miyamura et al., 1994, Strong et al., 1998, Leth-Larsen 
et al., 2005). Western blot of a selected fraction from the affinity column was carried 
out to confirm that the protein was in fact SP-D, and to observe its different 
oligomeric forms. SP-D was found as a monomer under reducing conditions (Figure 
3.1B, lane 3) and mainly as trimer (MW of 150 kDa) under non-reducing conditions 
(Figure 3.1B, lane 2). When the protein was crosslinked with GA, the dodecamer 
band was observed (Figure 3.1B, lane 1), but due to the size of the pores in the 
acrylamide gels, it was not possible to detect the presence of larger oligomers. The 
endotoxin content was determined with LAL assay, being its concentration < 1 
EU/mL. 
Two purifications were performed in this study starting from different volumes 
of pooled AF from cesareans. SP-D harvested from each of them is compiled in 
table 3.1. Although high amounts of amniotic fluid are needed to obtain a 
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reasonable protein yield, SP-D was efficiently purified from amniotic fluid with 
Superdex resin.  
 
Table 3.1: Efficiency of hSP-D purification 
 
 
Structural characterization and quantification of the different oligomeric forms in 
hSP-D 
To confirm that the oligomeric forms observed in rhSP-D produced by CHO 
cells, characterized in chapters 1 and 2, are present in the human protein and that 
the distribution of those oligomers is similar, a structural analysis was performed 
with the human protein obtained from AF and PAP. 
 
Figure 3.2: AFM images of hSP-D from amniotic fluid and proteinosis BALs. AFM images of hSP-D 
from AF (top) and proteinosis (bottom) contained trimers (T), hexamers (H), dodecamers (D) and 
fuzzy balls (FB); the scale bar represents 200 nm in images on the left and middle columns and, 50 
nm in the images on the right column.  
 
Purification Volume AF (mL) Donors hSP-D purified (µg)
1 450 2 90
2 2000 7 400
D
FB
T
H
Amniotic fluid (AF)
T
D
FB
H
Proteinosis (PAP)
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AFM was the technique chosen to observe and quantify hSP-D structures. The 
protein was found as a mixture of trimers, hexamers, dodecamers and large 
oligomers (fuzzy balls) in both cases (Figure 3.2). It is remarkable the presence of 
hexamers in the native human protein as it was observed in rhSP-D in chapter 1, 
something that has been ignored or considered an artifact up to now. In the case of 
hSP-D from PAP, the most abundant species found were the heterogeneous higher 
order oligomers (fuzzy balls) (Figure 3.2, bottom row). The exact quantitative 
distribution of oligomeric forms was not assessed in the SP-D from PAP because 
these preparations were much less clean, and it was often difficult to unequivocally 
assign each molecule to a defined oligomerization group. Besides, it has been 
already described in the literature that SP-D from PAP patients has higher amount 
of large oligomeric forms, as a consequence of this disease (Crouch et al., 1993a).  
 
Figure 3.3: Quantification of the distribution of oligomeric forms in hSP-D from AF. A-B, 
quantitative distribution of the different oligomeric forms in hSP-D (from AF) as determined from 
individual molecules observed under AFM. Percentage of weight and % of molecules were defined 
as described in results. A, the number of molecules assigned and counted were 367 for the first 
purification and 273 for the second one. B, distribution by % of weight of pooled molecules from 
both purifications (n = 650).  
 
Hence, quantification was performed with hSP-D from AF. Several samples of 
purification batches 1 and 2 were prepared and imaged to count a significant 
number of molecules as in chapter 1. Interestingly, there were differences in the 
distribution of species between the material obtained from the two purifications 
(Figure 3.3A). These discrepancies could be attributed to the diverse protein 
polymorphisms described in humans, especially regarding that of amino acid in 
position 11 (Leth-Larsen et al., 2005). Further characterization is needed to 
determine other factors that could also contribute to variations in the oligomeric 
state of SP-D, which possibly reflects the rich dynamic nature of this protein and its 
potential connection with particular physio-pathological contexts. When 
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quantitative data from both purifications were pooled, dodecamers and fuzzy balls 
were the most abundant oligomers by percentage in weight with respect to total 
protein mass (% weight) (Figure 3.3B). Trimers were the most abundant structure 
referred to individual molecule distribution (% molecules). 
Altogether, these data show that hSP-D is composed by a mixture of trimers, 
hexamers, dodecamers and larger oligomers, confirming that the oligomeric forms 
observed in the rhSP-Ds produced by CHO cells are also present in human protein, 
obtained from natural sources. Moreover, fuzzy balls were the most abundant 
structures in hSP-D (40% by % weight), closely followed by dodecamers (33% by 
% weight). These results validate CHO cells as a good system to produce 
recombinant human rhSP-D similar to hSP-D and, provide for the first time, a 
reference for the oligomeric forms distribution in human protein.  
 
N-glycosylation of asparagine 70 in hSP-D obtained from amniotic fluid  
To deeply characterize hSP-D, it was investigated whether the asparagine in 
the amino acid 70 of hSP-D sequence was N-glycosylated, as it was shown in the 
recombinant rhSP-D in chapter 1 and published before by other authors (Leth-
Larsen et al., 1999). This glycosylation was observed as a bright protrusion in the 
rhSP-D AFM images (chapter 1, Figure 1.6). Although this point near the N-terminal 
domain did not look very prominent in hSP-D AFM images (Figure 3.2, top row), 
the height profiles of single molecules confirmed its existence. Height profiles for a 
total of 50 molecules were measured, revealing that the height of the region 
corresponding to the N-glycosylation site was 0.6 ± 0.2 nm (average ± SD) taller 
than the mere collagen triple helix (Figure 3.4).  
 
 
Figure 3.4: Height profile of hSP-D trimer measured by AFM. A representative height profile of the 
trimers observed in hSP-D from amniotic fluid is shown. The peak that corresponds to the N-
glycosylation site is indicated. 
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Moreover, de-glycosylation experiments were carried out with PNGase F, 
which removes the carbohydrate core attached to asparagine, to further confirm 
protein N-glycosylation. Results in Figure 3.5 showed a shift in the electrophoretic 
mobility of the protein monomer after treatment with the enzyme (gel on the right). 
It should be noted that hSP-D monomer was already found resolved in two bands 
after electrophoresis, with the upper band being more conspicuous before de-
glycosylation (black arrow) and the lower band after de-glycosylation (blue arrow). 
These data agreed with the observation of other authors (Leth-Larsen et al., 2005), 
showing that hSP-D was constituted by a mixture of its N-glycosylated and de-
glycosylated forms, being the glycosylated the most abundant. The protein was 
further de-glycosylated with neuraminidase, which removes sialic acids, and a 
larger shift was observed in the band (Figure 3.5, left gel, green arrow). This protein 
sample showed a band pattern that contained more bands at lower molecular 
weights, probably due to denaturation of the neuraminidase by the reducing buffer 
of electrophoresis. When de-glycosylation was performed under non-reducing 
conditions, it was not possible to observe differences between the electrophoretic 
mobility of the bands (Figure 3.5, left gel, bands that correspond to trimers). We 
suspect that these enzymes might not have full access to the region when the 
protein is assembled in higher order oligomers.  
 
 
Figure 3.5: De-glycosylation experiments of hSP-D. hSP-D from AF was treated with PNGase and/or 
neuraminidase in the presence or absence of denaturing buffer. Conditions for each lane are 
indicated above the gels. Left, polyacrylamide gradient (4-15%) gel. Rigth, 8%-acrylamide gel. Black 
arrows indicate the band of the glycosylated form of SP-D, the blue arrow that of the de-glycosylated 
form after PNGaseF, and the green arrow that of the de-glycosylated form after PNGaseF and 
neuraminidase. Both gels were developed by silver staining.  
 
Once N-glycosylation of Asn-70 was confirmed, we wondered about the sugars 
that constitute the actual structure. Some studies have addressed this issue in the 
past. However, new developed tools available nowadays, enabled us to obtain a 
deeper insight. Therefore, N-glycan profiling was carried out using a hydrophilic 
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interaction ultra-performance chromatography with fluorescence detection (HILIC-
UPLC-FLD) coupled to electrospray ionization quadrupole time-of-flight tandem 
mass spectrometry (ESI-Q-TOF MS/MS). Results (Figure 3.6) showed that core-
fucosylation was high (~ 80%) (Figure 3.6, “F” component in Table). Besides, high 
degrees of galactosylation were determined (>90%) (“G0-G4”in Table of Figure 
3.6), in combination with a medium-high degree of sialylation (~ 65%) which was 
mainly monosialylation (“S1”). Thus, 80% of N-glycans comprising one or more 
antennae were terminated with galactose (“tG1-4” component in the Table of 
Figure 3.6). The degree of high mannose was low (6%) and no hybrid type glycans 
were found. There was a 15% N-glycans bearing bisecting terminal GlcNAc (“B” 
in the Table of Figure 3.6).  
 
 
 
Figure 3.6: Carbohydrate-profiling of the glycan attached to the asparagine 70 of hSP-D. Glycan 
at the N-glycosylation site of hSP-D from AF was removed with PNGase F and further analyzed as 
described in the methods section to identify the sugars that it contained. The Table at the top 
indicates the amount of the different carbohydrates enclosed within the glycan structure. Glycan-
Profile (bottom), The identified peaks are numbered in the chromatogram and the carbohydrates 
assigned to those peaks are represented following the Symbol Nomenclature for Glycans (SNFG) 
(Varki et al., 2015) . Table legend: F: core-fucose; oF: outer arm fucose; B: bisecting GlcNAc; S0-S4: 
non- to tetrasialylated complex type; G0-G4: non- to tetragalactosylated complex type; GalNAc0-
GalNAc2: zero to two N-acetylgalactosamine residues; A1-A4: mono- to tetraantennary complex 
type N-glycans; LeA/LeX: Lewis-A or Lewis-X glyco-epitopes; HB: hybrid type; M: highmannose 
type; tG0-tG1: zero or one terminal galactose residues; tGalNAc0-tGalNAc 2: zero to two terminal 
N-acetylgalactosamine residues; LacNAc1:LacNAc repeat (GlcNAc-Gal attached to terminal Gal). 
 
In summary, these findings confirmed N-glycosylation of Asn-70 in hSP-D and 
characterized the carbohydrate structure with unprecedent detail. It was shown that 
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N-glycan was biantennary, core-fucosylated with partial galactosylation and 
sialylation as well as bisecting GlcNAc. 
 
hSP-D from amniotic fluid (AF) and proteinosis (PAP) binds and aggregates 
bacteria with different potency 
An important question that should be addressed is whether the differences 
observed in the proportion of fuzzy balls in hSP-D obtained from AF or PAP, would 
correlate with differences in protein function, in terms of activity. In chapter 2, we 
already saw that isolated fuzzy balls were more active than hexamers and trimers, 
in the case of rhSP-D. 
 
Figure 3.7: Binding assay of hSP-D from AF or PAP to E. coli. Plates were coated with bacteria and 
incubated with 2-fold dilutions starting at 1000 ng/mL of hSP-D from each of the two sources. Bound 
SP-D was detected with antibodies in an ELISA-like assay; (n = 2), Two-way ANOVA with 
Bonferroni’s multiple comparison post-test was performed: *, p<0.05. A, monoclonal anti-SP-D 
against an epitope in the CRD, B, against an epitope in the N-terminal domain of hSP-D. 
 
First, binding of hSP-D to E. coli was assessed in a solid-phase assay. E. coli is 
one of the typical bacterial ligands of hSP-D in vivo. Microtiter plates were coated 
with E. coli DH5a and incubated with different hSP-D concentrations, starting at 
1000 ng/mL and making progressive two-fold dilutions of the two hSP-D 
preparations in the presence of calcium 5 mM. The experiment was performed 
twice with two different monoclonal anti-SP-D antibodies, to demonstrate that the 
antibodies used did not interfere in the results. It is known that SP-D binds to 
bacteria through its CRD domains, where the epitope for many anti-SP-D antibodies 
is also located (Hartshorn et al., 2010). Once SP-D is bound to bacteria, the epitope 
in the CRD recognized by the antibody could be not accessible, which would be 
translated into an underestimation of the concentration of bound protein. Therefore, 
as in chapter 2, one antibody towards an epitope enclosed in the CRD (Figure 3.7A) 
and another with its epitope in the N-terminal domain (Figure 3.7B) of the protein 
were tested. Similar results were obtained for both of them. Both preparations, PAP-
hSP-D and AF-hSP-D, bound in a concentration-dependent manner to E. coli. In all 
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concentrations tested, PAP-hSP-D showed a significant (t-test, p = 0.0005) higher 
degree of binding to bacteria than AF-hSP-D. 
Second, SP-D promoted E. coli aggregation assays were performed to determine 
the activity of the protein to aggregate, as a previous step to clearance, potentially 
pathogenic entities such as bacteria. Bacterial suspensions were incubated with 
different concentrations of AF-hSP-D or PAP-hSP-D and light transmission 
(turbidity) through each sample was monitored during 2 hours. hSP-D from PAP 
aggregated bacteria more efficiently than protein from AF (Figure 3.8A). It was 
necessary to dilute PAP-hSP-D concentrations to 0.1 µg/mL to observe a decay in 
activity, while AF-hSP-D already showed less activity at 1 µg/mL. Moreover, higher 
concentrations of AF-hSP-D were required to reach the maximum aggregation 
activity than in the case of PAP-hSP-D. The percentage of aggregated bacteria 
referred to the control (in the absence of protein) was calculated for both proteins 
at 3 different concentrations and at two time points (Figure 3.8B). Striking 
differences were observed especially at t = 60 min, where PAP-hSP-D aggregated 
almost 50% of the bacteria at all concentrations tested, whereas AF-SP-D needed 
2.5 µg/mL to start showing some activity (Figure 3.8B, top). At final time point (t = 
120 min), AF-SP-D activity was improved, but still less than PAP-SP-D at low 
protein concentrations (Figure 3.8B, bottom).  
 
Figure 3.8: Bacterial aggregation assay induced by hSP-D from AF and PAP. Bacterial suspensions 
of E. coli DH5a were incubated with or without (control) different concentrations of hSP-D from AF 
(top) or PAP (bottom). A, absorbance values (l = 700 nm) were monitored during 2 hours. B, % of 
aggregated bacteria was determined at two time points (t = 60 and t = 120 min), as stated in methods, 
at three different concentration of SP-D; a dotted line has been traced at 50% aggregation. Two-
Way ANOVA with Bonferroni’s post-test: *, p<0.05; **, p£0.01; ***, p£0.001. 
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These data illustrate that both hSP-Ds were functional and active in the assays 
performed, but PAP-hSP-D showed apparently higher activity than AF-hSP-D, 
presumably due to its higher proportion of large fuzzy balls oligomers, as it has 
been documented for viral particles (Hartshorn et al., 1996a, Leth-Larsen et al., 
2005) and as we demonstrated for rhSP-D in chapter 2.   
 
Carbohydrate binding preference of hSP-D 
To further characterize differences between hSP-D obtained from AF or PAP, 
binding properties of hSP-D to different carbohydrates were assessed. We allowed 
hSP-D from the two sources to bind to mannan-coated beads in the presence of 
maltose, glucose, galactose or N-acetyl-glucosamine (GlcNAc) at different 
concentrations, to see how efficiently those different sugars compete to prevent 
binding of SP-D to mannose on a reference ligand.  
 
Figure 3.9: Binding competition of hSP-D to carbohydrates.  The effect of different concentrations 
(0.01, 10, 25, 50, 100, 200 mM) of maltose, glucose, galactose and N-acetyl-glucosamine (GlcNAc) 
on the binding of hSP-D from AF (A) or PAP (B) to mannan was determined. The percentage of SP-
D bound to mannan-coated beads in the presence of different concentrations of the competitors is 
represented in both A and B. A, data represented were fitted to a sigmoidal dose-response model. 
B, lines in the graph represented the linear regression of the points for the different competitors, a 
dotted line indicates where the 50% of inhibition is reached.   
 
With both proteins, AF-SP-D and PAP-SP-D, maltose and glucose inhibited SP-
D binding to mannan at lower concentrations than galactose and N-acetyl-
glucosamine (Figure 3.9). In addition, PAP-hSP-D needed lower concentrations of 
competitors to suppress 50% hSP-D binding to mannan-beads than AF-hSP-D. 
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Carbohydrate binding preference assays of hSP-D obtained from amniotic fluid 
have been previously conducted, and the results obtained in this work were 
coincident (Holmskov, 2000, Palaniyar et al., 2004). 
These results also agreed with our previous functional assays, indicating that 
PAP-hSP-D is more active than the protein isolated from amniotic fluid.  
 
Discussion 
In previous chapters, protein conformation and the distribution of oligomeric 
forms were evaluated in a recombinant human rhSP-D preparation under different 
conditions. However, a quantitative study performed with the human natural 
protein was not available, which could be used as a reference of what should be 
considered as standard values of the different oligomeric forms.  
We first showed that hSP-D from PAP was mainly composed by large oligomers 
(Figure 3.2B), as it has been already observed by other authors (Crouch et al., 
1993a, Hartshorn et al., 1996a), which is probably associated with the disease 
condition. Therefore, it is questionable whether this protein preparation could be 
used as a reference protein for quantitative studies of proteins produced by 
alternative approaches. As an alternative to this pathological source, hSP-D from 
AF was obtained to perform the analysis. It has been reported that SP-D in AF at 
term pregnancy comes from type II pneumocytes from the fetus (Stahlman et al., 
2002) and from the internal layer of the placenta, part of the human amniotic 
membrane  (Lemke et al., 2017). After quantification of the different oligomeric 
forms, discrepancies were observed between the two purifications performed, from 
two pools of different donors. The proportion of trimers and hexamers was markedly 
higher in purification 1, while that of dodecamers was lower compared to 
purification 2 (Figure 3.3A). These differences might be attributed to possible 
genetic variations that contribute to different polymorphisms of hSP-D among 
population. It was described for a Caucasian population that the distribution 
frequency of the amino acid at position 11, in hSP-D from serum, was 59% Met 
and 41% Thr. In addition, it was observed that a predominance of low molecular 
weight oligomers existed for hSP-D in the individuals with Thr11 (Leth-Larsen et al., 
2005). Purification 1 was performed from a pool of amniotic fluid from only two 
individuals, while purification 2 was from a pool obtained from 7 donors (Table 
3.1). One could expect a higher influence of polymorphisms when amniotic fluid 
is obtained from a low number of donors, while this effect should be diluted out 
when the AF pool is constituted by a higher number of individuals. Different 
polymorphisms have been also observed between ethnic groups (Liu et al., 2003), 
but in our case all donors were Caucasians. Many other factors could contribute to 
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differences in protein oligomerization and in the proportion of the different forms, 
a source of variability that should be explored in detail, as a possible way for this 
protein to respond to environmental conditions during lung and mucosa 
homeostasis. On the other hand, the proportions obtained from rhSP-D in chapter 
1 included 50% of dodecamers and 30% of fuzzy balls, numbers that are similar to 
the results obtained for AF-hSP-D from purification 2 (Figure 3.3A). Moreover, rhSP-
D was assembled into dodecamers and fuzzy balls that summed a total of 80% of 
the protein, similar to the 70% observed in AF-hSP-D total data (Figure 3.3B). 
It has been published that the degree of fucosylation of the glycan core, 
attached to the N-glycosylation site (Asn70) of hSP-D purified from serum, differs 
between COPD and healthy individuals (Ito et al., 2015). The glycan profiling of 
lung hSP-D from AF performed in the present study, with more sensitive methods 
than the ones available a few years ago, allowed us to identify and describe in more 
detail the sugars attached to the protein. We confirmed a biantennary structure, 
with galactose and GlcNAc (Leth-Larsen et al., 2005) and we found also a 
significant amount of sialic acids and high core-fucosylation. The new data could 
be useful to identify markers of different diseases as it was shown with the degree 
of fucosylation in serum SP-D. 
Last, in chapter 2, differences in activity of isolated rhSP-D oligomeric forms 
were found. SP-D activity was greater for the protein forms with higher degree of 
multimerization. Hence, after observing differences in the oligomeric distribution 
between AF-SP-D and PAP-hSP-D, we evaluated whether the differences in 
structure could be also translated into differences in protein activity. We showed 
that the increased number of large oligomers in PAP-hSP-D is associated with a 
greater binding affinity of SP-D to E. coli and to different carbohydrates, when it 
was compared with hSP-D from amniotic fluid, where the proportion of fuzzy balls 
was lower and similar to that of dodecamers. Moreover, PAP-hSP-D was also more 
efficient to aggregate bacteria. This confirms that the degree of oligomerization of 
hSP-D and the quantitative distribution of the different oligomeric forms influence 
protein activity, at least, in those functions that depends on the CRD domain. These 
results are consistent with those from a study where the activity of isolated fuzzy 
balls was compared with that of a rhSP-D with qualitatively more dodecamers. The 
protein with higher content in fuzzy ball-like aggregates was more active, in terms 
of binding and agglutination of influenza A virus, than the one with more 
dodecamers (Hartshorn et al., 1996a). However, this should be interpreted 
carefully. It cannot be concluded that the protein, in the pathological context of 
proteinosis in vivo, is more active just because it contains a higher proportion of 
large oligomers. There are many other potential factors possibly derived from the 
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pathological context, which that could affect its function in vitro and in vivo. In 
other words, an individual suffering from proteinosis, with a reactive situation in 
lungs, where SP-D has a high proportion of fuzzy balls, is not necessarily more 
protected against infections than a healthy newborn baby with lower amounts of 
fuzzy balls.  
 
In summary, we have characterized the quantitative distribution of human SP-
D from a non-pathological source, amniotic fluid, and analyzed the differences 
with respect to a protein from a disease condition, like PAP. Moreover, we have 
seen the effect of the proportion of oligomers of human native SP-D in protein 
function, which confirmed the results obtained in chapter 2. hSP-D from AF and 
PAP were both active, but it could be concluded that the greater amount of fuzzy 
balls, the greater potency in protein activity, at least in those functions that rely on 
the CRD domain.  
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SP-D modulates LPS-induced 
NETosis and protects lung 
surfactant from NETs 
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Part of the experiments included in the present chapter were performed 
during a short-term stay in the laboratory of Dr. Nades Palaniyar in 
SickKids Hospital (Toronto, ON, Canada). This short-stay was funded by 
a fellowship from the Spanish Ministry of Education Culture and Sport 
(EST16/00922). Mouse work was performed in the facilities of the 
Toronto Centre for Phenogenomics (TCP) (Toronto, ON, Canada). 
Confocal images were obtained and imaged in the Imaging Facility at 
SickKids Hospital.  
The results have been sent for publication to Nature Communications.  
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Introduction 
During respiratory infections by different pathogens, capillary alveolar 
neutrophils infiltrate to airway alveolar spaces after sensing microbial insults 
(Cheng and Palaniyar, 2013). LPS is a key bacterial component responsible for 
inducing the formation of neutrophil extracellular traps (NETs), a process known as 
NETosis. NETs are a mesh of decondensed chromatin fibers decorated with 
antimicrobial granular proteins, that help to capture and ensnare bacteria 
(Brinkmann et al., 2004). The complete regulatory mechanism of NETosis is still 
elusive. So far, NADPH oxidase 2 (NOX)-dependent and –independent types of 
NETosis have been described. NOX-dependent NETosis, triggered by bacterial 
components (e.g. LPS) or phorbol myristate acetate (PMA), courses with ROS 
production (Khan et al., 2017, Khan and Palaniyar, 2017), while NOX-independent 
NETosis needs an increase in intracellular calcium concentration (e.g. caused by 
ionophores or ionomycin secreted by Streptomyces conglobatus) to drive NETosis. 
Influx of the intracellular calcium forms a complex with peptidylarginine deiminase 
4 (PAD4) that translocates to the nuclei and citrullinates histone 3 leading to the 
formation of NETs (Li et al., 2010, Khan and Palaniyar, 2017, Papayannopoulos et 
al., 2010). Citrullination is the posttranslational enzymatic conversion of arginine 
residues to peptidylcitrulline, which is catalized by PAD4 (Konig and Andrade, 
2016). The modification of arginine residues results in a loss of positive charge, 
increasing its hydrophobicity, which in the case of histones promotes chromatin 
decondensation, leading to the formation of NETs (Wang et al., 2009). 
Although NETs are beneficial for controlling infection, an excess in NET 
formation is deleterious to surrounding tissues and associated with lung injury and 
inflammatory lung diseases, such as cystic fibrosis (CF), where it affects lung 
function and exacerbates disease conditions (Cheng and Palaniyar, 2013). The 
biophysical function of lung surfactant (LS), which allows compression and 
expansion of alveoli during normal breathing without collapse, could be 
compromised by the presence of increased NETs in the airways, which could be a 
potential contribution to respiratory failure in lung pathologies, as it happens when 
there is an overproduction of other inflammatory components (Echaide et al., 
2017). On the contrary, the innate immune function of lung surfactant, where SP-
A and SP-D play key roles (Kishore et al., 2006), could help to counteract 
exacerbated NETosis and its deleterious effects, especially with the action of SP-D. 
As it was described in the introduction, SP-D opsonizes particles to be further 
cleared by immune cells (Crouch, 2000). It has been stablished that SP-D binds to 
lipopolysaccharides (LPS) of some bacterial strains through the CRD domain in a 
calcium-dependent manner (Lim et al., 1994). Moreover, it has been also found 
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that SP-D can interact with DNA (Palaniyar et al., 2004) and NETs (Douda et al., 
2011), through ionic interactions. Though calcium is not essential, these 
interactions are stronger when it is present (Palaniyar et al., 2004). It was also 
described that SP-D enhances the clearance of DNA from the airways by 
macrophages (Palaniyar et al., 2005). Interestingly, in some lung diseases where an 
excess of NETs causes disease exacerbation, such as cystic fibrosis or ARDS, a 
relationship between low SP-D levels and exacerbated NETs in bronchoalveolar 
lavages (BAL) has been found (Sorensen, 2018, Sorensen et al., 2007, Nishikiori et 
al., 2014, Cheng and Palaniyar, 2013, Saffarzadeh et al., 2012).  
However, whether SP-D has a role in modulating NET formation during LPS-
induced NETosis or whether SP-D could protect LS function from potential NET-
mediated inhibition is unknown.  
With these antecedents, this chapter has addressed:  
¨ Whether SP-D could modulate LPS-induced NETosis  
¨ The probable mechanism for SP-D to modulate NETosis  
¨ The potential inhibition of LS function by NETs 
¨ The consequences of NETs release on respiratory mechanics 
 
These findings should help to understand the role of SP-D in regulating the 
development of NETosis and in protecting lung compliance when neutrophils are 
released to the airways.  
 
Results 
SP-D binds LPS and suppresses LPS-mediated NETosis in neutrophils 
The LPS (0128:B12) strain used in this chapter is different from other strains 
previously tested elsewhere (Khan et al., 2017), which differs in the O-antigenic 
polysaccharide chain (the sugar constituents, their sequence and their mode of 
linkage) that determines the serological O-specificity. Hence, in a first step, we have 
determined the potential of the LPS (0128:B12) strain to trigger NETosis by using a 
SytoxGreen dye based assay in human neutrophils. The results showed that this LPS 
strain induces NETs release in a dosage dependent manner (Figure 4.1A). Based on 
these results, 5 µg/mL of LPS was chosen as the optimal working concentration for 
most of the experiments. 
Then, the ability of SP-D to interact with LPS (0182:B12) was determined. For 
this purpose, we used a dot blot analysis. Different concentrations of LPS (2.5 to 80 
µg/mL; 2µL) were placed as dots on a membrane, and incubated with 5 µg/mL or 
15 µg/mL of SP-D, in the presence of 5 mM calcium or 20 mM EDTA. A negative 
control experiment was carried out in the same conditions without SP-D. The 
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amount of SP-D bound to LPS was determined by developing the blot after detecting 
the SP-D with anti-SP-D antibodies. Blot images showed that SP-D binds to this LPS 
in a dose dependent manner (Figure 1A). Moreover, calcium was required for this 
interaction, suggesting that SP-D binds LPS through its CRD domains, as it has been 
previously shown with other LPS strains as well (Ohya et al., 2006, Yamazoe et al., 
2008). 
 
 
Figure 4.1: SP-D binds LPS (0128:B12) and suppresses LPS-induced NETosis. A, C-D, NETosis 
kinetics assessed by Sytox Green plate reader assays, where the %DNA released in the presence of 
0.5% (v/v) Triton was considered as 100%. A, LPS dose dependently induces NETosis. LPS at 
concentrations ³5 µg/mL produced substantial degree of NETosis. B, Dot blot showing that SP-D 
binds to LPS. LPS (0128:B12) at different concentrations was dotted onto a membrane, which was 
later incubated with SP-D at different concentrations in the presence of 5 mM calcium or 20 mM 
EDTA. C, SP-D dose-dependently suppresses LPS (5 µg/mL)-induced NETosis (n=3; Two-way 
ANOVA with Bonferroni’s multiple comparison post-test: *, p<0.05). The regression graph in the 
inset represents the values at time 240-min, showing a linear decrease of NETosis with increase in 
the concentration of SP-D. D, the percent differences of DNA released at 240-min time points shown 
in panel C (n=3, One Way ANOVA with Tukey’s multiple comparison post-test: * p<0.05; **, 
p£0.01). Error bars represent standard deviation. 
 
After determining that SP-D binds to LPS (0128:B12), we investigated whether 
the presence of SP-D could modulate LPS-induced NETosis. For that, a Sytox Green 
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assay was conducted upon exposure of neutrophils to 5 µg/mL LPS concentration 
in the presence or absence of different SP-D concentrations. Before adding LPS to 
the cells, the agonist was first incubated with SP-D at a final calcium concentration 
of 0.5 mM. The percentage of DNA release data showed that SP-D reduces DNA 
release in a dosage dependent manner (Figure 4.1C). The decrease in DNA release 
was significantly higher at higher protein concentrations, leading to a significant 
reduction of 35% in the presence of 40 µg/mL of SP-D (Figure 4.1D).  
 
Figure 4.2: Kinetics of NETosis induced by LPS and other agonists, where SP-D did not show any 
effect. A-D, NETosis kinetics assessed by Sytox Green assay, where the %DNA released in presence 
of 0.5% (v/v) Triton was considered as 100%. A, SP-D was first added to the cells and incubated for 
30 minutes. After incubation, LPS agonist was added at 5 µg/mL and NETosis kinetics was 
monitored, as previously described; (n=2), error bars represent SD. B, controls to discard any effect 
of SP-D on neutrophils in the absence of LPS or any effects of SP-D buffer components to reduce 
LPS-induced NETosis. LPS concentration was 5 µg/mL; (n=3), error bars represent SD. C and D, no 
effect of SP-D (at 10, 20 or 40 µg/mL) modulating NETosis was observed when NETosis was induced 
by 25 mM of PMA (B) or 2.5 µM of Ionomycin (C). 
 
On the other hand, when different concentrations of SP-D were pre-incubated 
with the cells before adding LPS, no effect was observed in the release of DNA 
(Figure 4.2A). Therefore, direct binding of LPS by SP-D is defining the mechanism 
of action. The batch of SP-D used in these experiments was different; for that reason, 
a control with the pre-incubation procedure, explained in methods section, was 
also included (PM-LPS + SP-D10 µg/mL), which showed that this batch of SP-D 
worked well at 10 µg/mL. This effect of SP-D was shown to be specific for LPS, as 
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it is shown in Figure 4.2 (B-D). NETosis induced by other agonists like PMA (NOX-
dependent NETosis) or Ionomycin (NOX-independent NETosis) was not modulated 
by SP-D: neutrophils underwent NETosis and the percentage of DNA release was 
not altered by the presence of SP-D. 
Altogether, these findings showed that SP-D binds to LPS (0128:B12) in a dose 
dependent manner and as a consequence, LPS-induced NETosis is suppressed by 
SP-D. Moreover, calcium is required for this protein function. PMA- or ionomycin-
mediated NETosis are not altered by the presence of SP-D. These findings suggest 
that SP-D binds to LPS and suppresses LPS-induced NETosis.  
 
Confocal microscopy confirms that SP-D suppresses LPS-mediated NETosis 
To directly examine the effect of SP-D on LPS-mediated NET formation, we 
stained the specimen for DNA and immunostained them for myeloperoxidase 
(MPO), containing neutrophils treated with LPS, in the presence or absence of SP-
D.
 
Figure 4.3: Confocal microscopy images confirm that SP-D suppresses LPS-mediated NETosis. A-
B, neutrophils were activated for 2 hours by LPS (A) or Ionomycin (B) with or without SP-D at two 
calcium concentrations, and imaged after immunostaining for myeloperoxidase (MPO)-green and 
staining with DAPI for DNA-blue. MPO co-localized to NET-DNA upon stimulating neutrophils with 
LPS or Ionomycin. A, preincubation of indicated concentrations of SP-D with LPS showed that SP-
D suppresses NETosis. B, SP-D did not suppress NETosis induced by ionomycin. (n=2, scale bar 20 
µm).  
 
Confocal microscopy images of neutrophils stained for DNA (DAPI; blue) and 
MPO (green) confirmed the effect of SP-D on LPS-mediated NETosis (Figure 4.3). 
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strings colocalized with MPO in the cytoplasm, confirming the release of NETs. 
Also, some NETs were observed protruding out from the cell.  By contrast, the 
control condition (unstimulated neutrophils) showed intact nuclei with MPO 
granules in the cytoplasm. In the presence of SP-D, NETs were almost absent and 
neutrophils morphology was similar to control cells. No differences were observed 
in the suppressive effect at the two calcium concentrations tested (Figure 4.3A). 
Neutrophils treated with Ionomycin did not show any response to SP-D, where 
similar amounts of NETs were observed in the presence and absence of SP-D (Figure 
4.3B).  
Collectively, confocal images confirmed the release of NETs by LPS and the 
suppressive effect of SP-D only in LPS-mediated NETosis, but not in the induced by 
other ligands such as PMA and ionomycin. 
 
SP-D suppresses histone 3 citrullination induced by LPS in human neutrophils 
Certain agonist can induce PAD4-mediated citrullination of histone 3 to 
facilitate NETosis (Li et al., 2010, Papayannopoulos et al., 2010, Douda et al., 2015, 
Khan and Palaniyar, 2017).  
 
Figure 4.4: LPS (0128:B12) induces citrullination of histone 3 (citH3) during NETosis and SP-D 
prevents LPS-induced citH3 formation. Neutrophils were activated for 2 hours with buffer control, 
LPS or ionomycin with (bottom row) or without (top row) 40 µg/mL of SP-D. The specimens were 
immunostained and imaged for citrullinated histone 3 – red. LPS and ionomycin, but not buffer 
control, induced citH3 formation. SP-D suppressed LPS-mediated, but not ionomycin-mediated 
citH3 formation (n=2, scale bar 40 µm). 
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To determine whether LPS (0128:B12) provokes citrullination of the histone H3 
(citH3) in neutrophils, and assess the regulatory effect of SP-D, the specimens were 
immunostained for citH3 (red) and imaged by confocal microscopy. Ionomycin was 
used as positive control to induce citH3 formation. 
Neutrophils treated with LPS showed the immunostaining of citH3, while this 
staining was almost absent in the control condition (Figure 4.4). When 5 µg/mL of 
LPS were preincubated with SP-D at a concentration of 40 µg/mL, it showed 
reduced citH3 immunostaining (least staining), indicating the suppressive effect of 
SP-D. Interestingly, the citH3 suppressive effect of SP-D was not observed in 
ionomycin treated cells (Figure 4.4, bottom row).  
Results determined the presence of citH3 in LPS and ionomycin treated cells 
while again, the presence of SP-D only suppressed citrullination during LPS-, but 
not the calcium ionophore (ionomycin)-induced NETosis. 
 
LPS instillation induces exacerbated NETosis in the airways of SP-D-/- (KO) mice 
With the aim to address whether SP-D has any modulatory role during NETs 
release in the lungs under inflammatory conditions, we performed an in vivo 
experiment, where we instilled LPS in both SP-D Knock-out (KO) and wild type 
(WT) mice. 
Total protein concentration in bronchoalveolar fluid (BAL) was determined by 
BCA assay, as a landmark for airway inflammation. Data showed that the protein 
concentration was higher in LPS given mice than in the PBS-instilled mice, and a 
slightly increased amount was found in KO LPS mice compared to WT LPS mice 
(Figure 4.5A). Additionally, the BAL samples from these instilled mice were 
examined for the presence of DNA and citH3 to assess the presence of NETs. 
PicoGreen DNA binding fluorescence dye was employed to quantify the NETs 
DNA in BAL-supernatants. LPS-instilled mice showed higher amounts of DNA in 
BAL-supernatants compared to PBS-instilled mice (Figure 4.5B). Moreover, the 
DNA concentration values were significantly higher in BAL from KO LPS mice than 
in that from WT LPS, especially for a subgroup of animals within the KO LPS 
condition, suggesting an important protecting role for SP-D against NETosis in mice 
airways. CitH3 was found in LPS-instilled mice samples (Figure 4.5C, left panel), 
being greater the degree of citrullination in KO mice with respect to WT mice 
(Figure 4.5C, right panel).  
These in vivo data reveal that LPS induces NETosis in neutrophils in mice 
airways and also support ex vivo data, showing again an important role for SP-D to 
prevent LPS-induced NETosis in mouse lungs.  
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Figure 4.5: SP-D-/- (KO) mice suffered exacerbated NETosis after LPS instillation compared to WT 
mice. A, total protein concentrations in BAL for the different mouse groups. Symbols represent 
averaged values (n=2). One-way ANOVA with Tukey’s multiple comparison post-test, p=0.0776 (no 
significant). B-C, cell free DNA concentration and citH3 in BAL were determined as markers of the 
presence of NETs. Higher amounts of NETs were found in KO-LPS mice compared with WT-LPS. B, 
DNA concentrations in BAL assessed by PicoGreen assay. Symbols represent averaged values (n=2). 
One-way ANOVA with Tukey’s multiple comparison post-test: *, p<0.05; ***, p£0.001. C, left panel: 
WB anti-citH3 for all mouse groups; right panel: densitometry of the bands in LPS-instilled mice.  
 
 
Lack of SP-D worsen surfactant biophysical function and efficiency of breathing 
in LPS-instilled mice  
The biophysical activity of lung surfactant (LS) pelleted from BAL-supernatants 
was evaluated in the captive bubble surfactometer (CBS) for individual mouse 
samples. This setup somehow mimics, in vitro, the in vivo situation of a single 
alveolus during breathing. LS is applied directly onto the air-liquid interface of an 
air-bubble inside a chamber filled with buffer, which upon adsorption of surfactant, 
can be compressed and expanded like the alveolus is in the lung. Repetitive 
compressions-expansions are called dynamic cycles and in this work were 
performed at 30 cycles/min, trying to mimic mouse breathing rate, although it is 
known that mouse breathing is even faster (Irvin and Bates, 2003, Zehendner et al., 
2013).  
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In terms of surfactant initial adsorption to the interface, adsorption of the 
surfactants obtained from all the experimental groups was excellent; no differences 
were observed between surfactants obtained from the different mouse groups 
(Figure 4.6, left). In all cases, surfactant rapidly produced equilibrium surface 
tensions around 22 mN/m. Nevertheless, when testing post expansion adsorption, 
which analyses the ability of the surface film to re-spread and replenish the interface 
upon expansion, some mouse samples from KO LPS group were not able to re-
stablish the equilibrium surface tension, even though the differences were not 
significant. 
 
 
Figure 4.6: Adsorption properties of LS from mice evaluated in the CBS. 150 nL of LS at a PL 
concentration of 10 mg/mL were applied with a capillary inside the chamber near the surface of the 
air bubble. Adsorption of the material to the air-water interface was evaluated initially at Initial 
Adsorption (IA) and Post-Expansion (PEA). The shape of the bubble was monitored and recorded 
during 5 minutes to assess changes in the surface tension (g). Data in the graph correspond to values 
of surface tension at the end of the IA and PEA period for individual mouse samples. One-way 
ANOVA with Tukey’s multiple comparison post-test: p=0.7599 (IA), p=0.1385 (PEA) (no significant). 
 
Regarding the behavior of surfactant during dynamic cycles, WT mice instilled 
either with PBS or LPS and KO mice instilled with PBS had a competent surfactant 
to reach very low minimum surface tensions <2 mN/m, while maintaining 
maximum surface tensions around 30 mN/m (Figure 4.7, top row), which are 
common values for a LS that works well (Schurch et al 2010). Interestingly, KO 
mice instilled with LPS had LS whose function was severely affected. During 
compression, it was unable to reach the low surface tensions that are required for 
efficient breathing. Surfactant impairment was already evident at the first cycle, but 
became worse after 20 compression-expansion cycles (Figure 4.7, top row). 
Maximum surface tensions exhibited by these surfactant films were too high when 
compared to other mouse groups, indicating that LS was not efficiently 
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reincorporated to the interface during the periods of expansion of the bubble, which 
mimic inspiration in vivo (Figure 4.7, bottom row). Again, these differences were 
more significant once the material went through repetitive compression-expansion 
cycles (see data from cycle 20 compared to cycle 1), likely as a consequence of the 
cumulative losses of LS towards the interface. 
 
Figure 4.7: Dynamic behavior of surfactant films from different mice groups. Minimum (gmin) and 
maximum (gmax) surface tension produced by LS (10 mg/mL) from the different mouse groups during 
compression-expansion cycling. Symbols represent data obtained from individual mouse (average 
of three replicates.) WT-PBS (n=7), KO-PBS (n=7), WT-LPS (n=9), KO-LPS (n=11); (One-way 
ANOVA with Tukey’s multiple comparison post-test: **, p£0.01; ***, p£0.001; ****, p<0.0001). 
 
Representative replicates of the CBS isotherms from all the individual mouse 
samples have been summarized in Figure 4.8. Initial adsorption to the air-liquid 
interface of LS from KO LPS mice was delayed 5-10 seconds in some cases (see for 
example Figure 4.8; first and third IA graphs of KO-LPS samples). In addition, post-
expansion adsorption was also retarded and even not able to reach minimum 
surface tension in some mice (see for example Figure 4.8; first, third and two last 
columns in PEA graphs of KO-LPS samples). Thus, although final surface tension 
values after 5 min adsorption of surfactant from KO LPS were not significantly 
different compared to other mice groups (Figure 4.6), initial adsorption was actually 
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affected, being retarded in some cases or not even able to reach the equilibrium 
surface tension (~ 20-22 mN/m) after post expansion adsorption (PEA).  
Taking into consideration these data, we conclude that there is a significant 
difference in the surfactant biophysical activity when comparing WT and KO mice 
challenged by LPS. Therefore, it seems that SP-D counteracts and regulates the 
NETosis process within the lungs. Thus, SP-D contributes to the protection of 
surfactant membranes from the inhibition caused by NETs and other inflammatory 
components released from cells, such as neutrophils, as a consequence of LPS 
stimulation. 
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Figure 4.8: Surface activity of lung surfactant from WT or KO mice instilled with PBS or LPS. 
Surface activity is represented as isotherms obtained from the CBS, thermostated at 37 ºC. One 
replicate from each individual mouse is represented for WT PBS (A), KO PBS (B), WT LPS (C) and 
KO LPS (D) mouse groups. For all mouse groups, the top row shows isotherms of IA into the air-
water interface of a bubble over a 5 min period. Middle row compares post expansion adsorption 
(PEA) over a 5 min period. Bottom row, dynamic compression-expansion cycling isotherms at 30 
cycles/min. PL concentration in LS was 10 mg/mL. 
 
SP-D-/- (KO) mice showed higher cholesterol and reduced SP-A and SP-C levels 
To determine whether there were differences in SP-A, SP-B and SP-C levels 
between LS from the different mouse groups, which could be associated with the 
differences observed in their biophysical activity, western blots of these proteins 
were carried out.  
Figure 4.9A shows the results for the complete set of samples, while 
representative WBs for each surfactant protein are shown in Figure 4.9B. Results 
showed that SP-D KO mice had significantly lower levels of SP-A and SP-C than 
WT mice while no differences were observed in SP-B levels (Figure 4.9A). Similar 
differences in surfactant protein composition have been reported previously, in 
experiments in which the mice were not subjected to instillation (Ikegami et al., 
2000). In the current work, the possibility that PBS or LPS instillation could modify 
surfactant protein levels was also explored. SP-B and SP-C levels in surfactant from 
WT mice were significantly reduced as a consequence of LPS instillation. However, 
no significant changes of the already reduced levels of SP-B and SP-C were 
observed upon instillation of LPS in KO mice, neither in the levels of SP-A from all 
mouse groups (Figure 4.9A).  
The proportion of cholesterol in LS has been associated with surfactant 
inactivation in cases of lung injury and ARDS (Markart et al., 2007). Determination 
of cholesterol revealed that LS from KO mice had higher proportions of cholesterol 
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with respect to PC than LS from WT mice (3.3-3.7% compared to 2-2.4%) (Figure 
4.9C).  
 
 
Figure 4.9: Differences in SP-A, SP-B and SP-C and cholesterol levels in LS in the surfactant of SP-
D+/+ (WT) and SP-D-/- (KO) mice. A, densitometry of the bands of surfactant proteins (SP-A, -B and 
-C) shown in Western blots for LS samples from all mice; One-way ANOVA with Tukey’s multiple 
comparison post-test: **, p£0.01; ***, p£0.001; ****, p<0.0001. B, representative Western blots for 
SP-A, SP-B and SP-C from the different mouse groups. C, [cholesterol]/[phosphatidylcholine] (w/w) 
ratio, One-way ANOVA with Tukey’s multiple comparison post-test: **, p£0.01; ***, p£0.001. These 
differences do not explain the differences in SP-D-mediated effect on surface active properties of 
surfactant (see text). 
 
These data show that in SP-D-/- KO mice, lung surfactant contains a higher 
proportion of cholesterol and a reduced amount of surfactant proteins SP-A and SP-
C. No significant differences were observed in SP-B levels between WT and KO 
groups, neither within KO mice as a consequence of LPS or PBS instillation.  
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SP-D protects lung surfactant complexes from the inhibitory effects of NETs  
The overproduction of NETs by neutrophils and its harmful effects in lungs have 
been well described as a consequence of infectious and inflammatory conditions 
(Cheng and Palaniyar, 2013), but nothing is known about the possibility that NETs 
could interfere directly with the surface active properties of surfactant complexes. 
The organic extract (OE) of porcine lung surfactant, which is depleted of collectin 
proteins and is the base of clinical surfactants (Echaide et al., 2017), was used as 
an in vitro model to study the direct effect of NETs in LS biophysical function. 
Reconstituted OE material was combined with purified NETs from human 
neutrophils and its biophysical activity was evaluated in the CBS. Surfactant 
function was completely inhibited by the presence of NETs. Surface tensions after 
initial (IA) and post expansion (PEA) adsorption were no lower than ~50 mN/m 
(Figure 4.10 and Table 4.1), when a good surfactant reaches values close to ~20 
mN/m (Schurch et al 2010). 
 
Table 4.1: Parameters defining the behavior of surfactant films when its function is inhibited by 
NETs and restored by the presence of SP-D 
 
1Minimal surface tension after 5 min of IA. 
2Minimal surface tension after 5 min of PEA. 
3Minimal surface tension after 4 quasi-static compression-expansion cycles. 
4Maximal surface tension after 4 quasi-static compression-expansion cycles. 
5Minimal surface tension after 20 dynamic compression-expansion cycles (at 20 cycles/min). 
6Maximal surface tension after 20 dynamic compression-expansion cycles (at 20 cycles/min). 
7DA: Reduction in relative area needed to reach minimal surface tension. 
All, n= 4, average of 4 replicates, being 2 of them from a different sample. One-way ANOVA with 
Tukey’s multiple comparison post-test, p-values: <0.05 (*), ≤0.01(**), ≤0.001(***). 
 
The dynamic behavior of surfactant films exposed to NETs, once subjected to 
compression-expansion dynamics, was also affected and minimum and maximum 
surface tensions reached after quasi static and dynamic cycles were high, far from 
the minimal values of £2 mN/m and ~25 mN/m, respectively, produced by a fully 
operative surfactant film. SP-D was found to counteract the inhibitory effect of 
NETs. When SP-D was added to the organic extract (OE) material prior to their 
exposure to NETs, as described in methods, surface tension values upon adsorption 
and after CBS cycling were significantly improved (Table 4.1).  
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Figure 4.10: Effect of SP-D on the susceptibility of pulmonary surfactant to inhibition by NETs. 
Surface activity is assessed by the isotherms obtained from the CBS, thermostated at 37 ºC. 
Representative isotherms from each group of samples were chosen. Surfactant films were formed 
upon injection of a suspension of porcine surfactant OE reconstituted at 20 mg/mL in the absence 
or in the presence of NETs, as described in methods, and in the absence (middle column) or presence 
(right column) of SP-D at 0.67% (w/w with respect to phospholipid). The upper set of isotherms 
show initial (IA; top row) and post-expansion (PEA; bottom row) adsorption to the air-water interface 
of a bubble over a 5 min period. The lower set of isotherms illustrate Q-static (top row) and dynamic 
(bottom row) compression-expansion cycling at 20 cycles/min. 
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These experiments revealed for the first time that NETs can directly inhibit 
surfactant biophysical function, suggesting that NETosis should be considered as an 
additional mechanism that impairs surfactant function during lung inflammation. 
Besides, a novel role for SP-D in LS biophysical function was found because it 
protects LS against NETs inhibitory effects. 
 
Discussion 
SP-D plays an important role in the immune defense of the lungs and LS 
homeostasis (Sorensen, 2018). In infectious and inflammatory lung diseases, 
NETosis has been described as one of the processes that takes place (Cheng and 
Palaniyar, 2013). Furthermore, SP-D/NETs interaction has been reported (Douda et 
al., 2011), but the consequences of this interaction in alveolar homeostasis and 
pulmonary mechanics, for example at the level of lung surfactant function, 
remained unknown. In this chapter, we studied the regulatory effect of SP-D on the 
mechanism of NETosis induced by a new strain of LPS. Moreover, we investigated 
how SP-D attenuates NETs damaging effects on LS in vivo, which affects lung 
compliance during breathing, using a SP-D-/- Knock out mice model. The results 
obtained have demonstrated that SP-D i) suppresses LPS-induced NETosis ex vivo, 
ii) modulates NETosis in vivo and, iii) protects lung surfactant performance from 
NETs-inhibition during breathing-like interfacial mechanics. 
Previous studies have reported some relationships between SP-D and NETs. 
First, it was reported that SP-D binds to different LPS strains (Yamazoe et al., 2008, 
Lim et al., 1994), which may act as a NETosis agonists. Second, bronchoalveolar 
lavage (BAL) from LPS-instilled mice, designed as an animal model for NETosis, 
was found to present increased levels of SP-D when compared to mice that did not 
undergo NETosis (Douda et al., 2011). Last, some inflammatory lung diseases, such 
as ARDS and cystic fibrosis, that course with exacerbated NETosis, were 
characterized by low SP-D levels in the BAL (Sorensen, 2018, Sorensen et al., 2007, 
Cheng and Palaniyar, 2013, Saffarzadeh et al., 2012, Nishikiori et al., 2014).  
Altogether these findings suggest that SP-D might have a role modulating NETs 
production and clearance. It has been previously shown that SP-D indeed 
participates in the clearance of DNA, the major component of NETs, by 
macrophages (Palaniyar et al., 2005). On the top of that, we have demonstrated 
that SP-D can reduce NETs production by neutrophils (Figure 4.1 and 4.3), 
stablishing a clear role for SP-D to prevent or at least ameliorate the development 
of LPS-induced NETosis. We show evidences here that this regulation takes place 
via a direct binding of the protein to LPS.  
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The negative effects of exacerbated NETs in the lungs have been studied in 
terms of lung inflammatory response and lung tissue injury (Cheng and Palaniyar, 
2013). However, whether NETs could impair lung compliance, associated with a 
distortion of surfactant biophysical function, remained as an open question. Herein, 
we have shown that NETs exert a direct inhibitory effect on LS in vitro and that SP-
D can prevent that inhibition (Figure 4.10). Moreover, surfactant inactivation was 
also found in vivo, in LS from mice suffering from exacerbated NETosis in the 
absence of SP-D, after LPS-instillation (Figure 4.7 and 4.8). Although we cannot 
ignore the possible contribution of other inflammatory components, such as 
liberation of ROS and/or other pro-inflammatory components to LS inhibition, we 
propose that NETs have a major role in the inhibition of LS biophysical function, at 
least in this model. Serum proteins leaked to the airways during lung injury have 
been reported to inactivate lung surfactant (Zuo et al., 2008), but total protein 
concentrations in BAL from our LPS-instilled mice were low compared to the 
concentrations that were previously reported to cause inhibition (Sato et al., 2010).  
In addition, it has been described that SP-D-/- (KO) mice have higher amounts, 
but with altered composition, of LS lipids together with lower relative proportions 
of SP-A and SP-C proteins (Ikegami et al., 2000). Our data agreed with those 
findings (Figure 4.9), but we also found that LS from KO mice had a higher 
concentration of cholesterol (ratio chol:PC), also documented previously for those 
BALs from mice (Botas et al., 1998). However, we do not think that in our model, 
the altered content cholesterol and SP-C (high levels of cholesterol and lower levels 
of SP-C) contribute significantly to the LS inhibition observed because: i) when SP-
D KO mice were PBS-instilled, the same phenotype (low SP-C, high cholesterol) 
was found with no detrimental effect on LS function, ii) in vitro NETs-inhibition 
experiments showed inhibition of organic extract (OE), which has normal 
concentrations of SP-C and cholesterol and only lacks collectin proteins (Blanco 
and Perez-Gil, 2007), indicating that unaltered concentrations of SP-C and 
cholesterol did not prevent LS inhibition by NETs; and iii) it has been reported that 
cholesterol concentrations of at least 20 % (w/w) with respect to PL are needed to 
abolish surfactant function (Gunasekara et al., 2005), whereas in KO mice 
cholesterol concentrations only raised to 4% as a maximum that is not enough to 
inhibit LS. It should be noted that SP-B has been described as the most critical 
protein for LS biophysical function (Schurch et al., 2010, Olmeda et al., 2013). We 
did not observe differences in SP-B levels between the different mouse groups 
studied (Figure 4.9). Last, it has been reported that SP-D protects surfactant lipids 
from oxidation in vitro (Bridges et al., 2000), and that oxidation of PL and 
hydrophobic proteins contribute both to impairment of LS biophysical function 
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(Rodriguez-Capote et al., 2006). Therefore, ROS generated in LPS-induced NETosis 
could also contribute to LS inhibition. 
The implications of the reduced levels of SP-A observed in SP-D KO mice are 
unknown (Ikegami et al., 2000). However, SP-A/DNA interaction (Palaniyar et al., 
2004) and the participation of SP-A in DNA clearance by macrophages (Palaniyar 
et al., 2005) have been shown to be low when compared to the activities of SP-D. 
So, in principle, we would not expect important effects of SP-A on modulating LPS-
induced NETosis, neither in the protection of LS from NETs. Further experiments 
with SP-A-/- mice should confirm or discard this possibility.  
Considering all the data, we propose that in the absence of SP-D, lung injury 
and inflammation could lead to a sustained over-accumulation of NETs in the lungs, 
where ionic interactions between negatively charged DNA in NETs and LS 
positively charged components, such as hydrophobic surfactant proteins, could 
lead to disruption of the multilayered surfactant structures and impairment of their 
function (figure 4.11). In the presence of SP-D, NETs would be opsonized by the 
protein and cleared by macrophages, preventing the interference with LS 
membranes. Besides, SP-D could avoid exacerbation of NETosis by its binding to 
LPS. 
 
 
Figure 4.11: A model summarizing the effect of SP-D on LPS-mediated NETosis and NET-mediated 
inhibition of surfactant. In the presence of SP-D (+SP-D), SP-D sequesters LPS and suppresses LPS-
mediated induction of NETosis; any NETs formed by the neutrophils will be coated with SP-D. These 
two effects of SP-D would suppress NET formation and NET-mediated inactivation of lung surfactant. 
In the absence of SP-D (-SP-D), LPS would directly interact with neutrophils and induce NETosis. 
NETs released from these neutrophils will inhibit the surface-active properties of the surfactant. Our 
data sets indicate that SP-D significantly contributes to the protective effects seen in our in vitro, ex 
vivo and in vivo experiments. The keys are listed at the bottom of the diagram. 
 
(+) SP-D (-) SP-D
Figure.
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In summary, in the present chapter it has been determined that SP-D regulates 
LPS-induced NETosis at different levels. First, reducing NETs release by neutrophils 
because SP-D binds to LPS and reduces its agonist effect. Second, once NETosis is 
developed in the lungs, SP-D prevents overproduction or overaccumulation of 
NETs in the airways and thus it protects lung surfactant biophysical function during 
breathing. These findings could have relevance in the context of the 
pathophysiological mechanism of severe lung diseases, which course with strong 
inflammation, accumulation of NETs and reduced levels of SP-D, such as cystic 
fibrosis (Cheng and Palaniyar, 2013), the current results suggest that treatment of 
these patients with exogenous SP-D (Sorensen, 2018) could improve some aspects 
of these diseases. 
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Since surfactant protein SP-D was discovered in rat bronchoalveolar lavage in 
the late eighties, first named as CP4 (Persson et al., 1988) and then as SP-D (Persson 
et al., 1989), structural and functional studies have been performed to understand 
its functions in different organs and tissues, but mainly in lungs, where the role of 
SP-D in the innate immune defense has been well documented.  
The observation of purified SP-D from different species has revealed that the 
protein is assembled in trimers, dodecamers and large oligomers, so called fuzzy 
balls or asterisk-like structures (Crouch et al., 1994b, Crouch, 2000). Results 
presented in this Thesis have included hexamers, constituted by the association of 
two trimers, as an additional oligomeric form and as an intermediate state between 
trimers and dodecamers or fuzzy balls (Chapter 1). Studies with SP-D obtained from 
different animals and with human proteins from two different sources, amniotic 
fluid (AF) and bronchoalveolar lavage of patients suffering from proteinosis (PAP), 
have shown some level of variability in the distribution of SP-D oligomeric forms 
among them. Although previous studies did not perform quantitative measurements 
like those included in this Thesis, it was already proposed that rat SP-D assembles 
mainly as dodecamers (Crouch et al., 1994b), while fuzzy balls seem the most 
abundant form in the case of porcine SP-D (van Eijk et al., 2002). In humans, SP-D 
from PAP was principally found as fuzzy balls (Chapter 3 and (Crouch et al., 1993a), 
whereas in AF both dodecamers and fuzzy balls were the most abundant structures 
in a proportion close to 1:1, as observed in Chapter 3. Several aspects can be 
discussed to interpret the variability observed in the distribution of SP-D oligomeric 
forms.  
First, the kind of interactions defining protein oligomerization. It has been 
reported that neck domains are essential for protein trimerization (Zhang et al., 
2001b) to align three monomers in which their collagen domains fold following a 
zipper-like mechanism (Hakansson and Reid, 2000). Trimers are further stabilized 
by disulfide bonds between cysteines within the N-terminal domains (Brown-
Augsburger et al., 1996b). Disulfide bonds are not essential for protein secretion as 
trimers (Brown-Augsburger et al., 1996a), but they are necessary for secretion of 
higher order oligomers, even though these are not bound by disulfide bridges as 
observed in Chapter 1. However, formation of disulfide bonds could promote the 
exposition of certain residues that would favor the assembly of hexamers through 
non-covalent interactions at the N-terminal domains, and afterwards, of higher 
order oligomers. As we observed in Chapter 1, beyond trimers, the whole 
oligomerization process is governed by non-covalent interactions, which would be 
more sensitive to amino acid sequence variations and external conditions, being 
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translated into different distributions of the oligomeric forms of the protein among 
different species.  
 
 
Figure 22: Alignment of SP-D sequences from different species. The N-terminal domains and part 
of the collagen domains of human, mouse, rat and pig SP-D have been aligned. Black bold: amino 
acid in position 11, corresponding to the numeration of hSP-D. In red bold, cysteines at the N-
terminal domain. In green bold, asparagine, which is N-glycosylated in the collagen domain. 
Prolines which are non-conserved among species have been highlighted in yellow, lysines in pink. 
Other basic amino acids non-conserved are highlighted in green and acids in blue.  
 
Second, variations between species in non-conserved amino acids residues 
within the N-terminal and collagen domains near the N-terminal end, which are 
the regions implicated in the assembly of hexamers, dodecamers and fuzzy balls, 
could cause a distinct specie-specific degree of protein oligomerization. The 
alignment of amino acid sequences from rat, mouse, pig and human SP-D in Figure 
22 showed some divergences in their non-conserved amino acids (Figure 22). It has 
been described that the first exon codifying for the collagen domain, which contains 
the “charged patch” as defined in Chapter 1, is more hydrophilic than the rest 
(Crouch, 2000). Modifications in amino acids within this region could introduce 
variations in the local charge and influence oligomerization. Also, hydroxylation of 
prolines and lysines and subsequent glycosylation of lysines at the collagen 
domain, could be altered and have implications in the development of larger 
oligomers. Last, the N-glycosylation site could affect protein oligomerization, as we 
have observed dodecamers interacting also through these points in some AFM 
images. Altogether, the particular amino acid sequence and consequently, the local 
charge in the N-terminal and the first region of the collagen domains, seem critical 
for the establishment of non-covalent interactions that drive protein 
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oligomerization. Interestingly, conglutinin - a bovine collectin-  possesses a similar 
structure to the one of SP-D, with a 78% of identity in the amino acid sequence 
and an assembly also into cruciform-like oligomers (Strang et al., 1986, Lu et al., 
1993, Holmskov, 2000). In PAGE-SDS under non-reducing conditions, conglutinin 
has been found as a main band of 260-300 kDa, which coincides with the 
molecular weight expected for hexamers (Lu et al., 1993). The amino acid sequence 
of the protein has a cysteine in position 38 in the collagen domain, which forms 
disulfide bonds and may stabilize hexamers. However, structures larger than 
dodecamers have not been observed in conglutinin (Strang et al., 1986). It should 
be noted that the position of Cys38 in conglutinin collagen domain coincides with 
the area we proposed in SP-D as important for dodecamer formation, although SP-
D lacks a cysteine residue in the collagen domain. Other interactions and 
mechanisms, like the ones we have proposed should be implicated in dodecamer 
formation by human SP-D, but the parallelism between SP-D and conglutinin 
oligomerization is remarkable. 
Third, influence of the surrounding conditions in the distribution of oligomeric 
forms of SP-D. As a result of the non-covalent character of interactions that keep 
dodecamers and fuzzy balls associated, a variation in their proportion as a 
consequence of the external conditions, could be expected. This was the case of 
the changes in pH described in Chapter 1 or, in a disease condition such as 
proteinosis as seen in Chapter 3. Thus, the malleable character of SP-D 
oligomerization could be an advantage to respond to challenging situations in 
lungs. In vivo, the alveolar sub-phase could be subjected to changes, for example, 
in response to inflammation, affecting the oligomers distribution of SP-D. This has 
been also observed in Chapter 3, comparing human SP-D from a particular healthy 
situation, amniotic fluid, with that from a disease one, pulmonary alveolar 
proteinosis, where the protein is immersed in a more reactive pathological 
environment that could promote oligomerization to fuzzy balls. Interestingly, the 
total amount of dodecamers and fuzzy balls in recombinant human rhSP-D (81%) 
(Chapter 1) was similar to that in hSP-D from AF (73%) (Chapter 3), although the 
most abundant structures were dodecamers in rhSP-D and fuzzy balls in hSP-D. 
The rhSP-D used in Chapter 2 probably presented a higher proportion of fuzzy balls 
than rhSP-D in Chapter 1. Therefore, an additional level of variation could exist, 
affecting the distribution of oligomeric forms as a function of production and 
purification processes. Still in all batches of rhSP-D obtained, the protein was very 
similar to hSP-D, validating CHO cells as a good system to produce recombinant 
SP-D.  
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Collectin proteins possess carbohydrate recognition domains with lectin 
activity, which is calcium-dependent (Hakansson and Reid, 2000, Holmskov, 
2000). The lectin activity of SP-D is involved in most of its functions, where trimeric 
CRDs are essential (Crouch, 2000, Sorensen, 2018). However, several protein 
activities have been described where collagen and N-terminal domains are 
important (Palaniyar et al., 2002, Kingma et al., 2006). In some cases, binding to 
ligands takes place through the collagen domain, such as in DNA binding 
(Palaniyar et al., 2004). In other cases, such as in the effect of SP-D on surfactant 
ultrastructure, homeostasis and recycling, the collagen domain is required, 
although whether it only provides an appropriate spacing between trimeric CRDs 
or it is implicated itself in these functions is unknown (Kingma and Whitsett, 2006, 
Korfhagen et al., 1998). N-terminal domains are critical for the transformation of 
surfactant large aggregates into small aggregates (Palaniyar et al., 2002, Ikegami et 
al., 2005), likely because higher order oligomers rather than trimers are needed to 
this function, and the N-terminal domain is essential as a junction hub of 
dodecamers and fuzzy balls (Zhang et al., 2001a). Moreover, modified recombinant 
proteins carrying on the substitution or deletion of any single domain of the protein 
have failed to correct foamy enlarged macrophages typical in SP-D-/- mice, where 
only full-length SP-D has been able to correct this issue (Ikegami et al., 2009). 
Apart from the role of each SP-D domain in protein functions, the implication 
of the different oligomeric forms (trimers, dodecamers and fuzzy balls) in protein 
activity and function has been also discussed. In this Thesis, functions related to 
bacteria binding and aggregation were assessed with isolated trimers, hexamers and 
fuzzy balls. We were able to distinguish between activity of trimers and hexamers 
for the first time. The results revealed that hexamers are the minimal unit necessary 
to produce bacteria aggregation and that fuzzy balls are the most potent and active 
structure (Chapter 2). These findings agreed with results obtained in previously 
published viral aggregation assays, where fuzzy balls were the most active oligomer 
(Hartshorn et al., 1996a). However, affinity of binding to bacteria was similar in the 
case of trimers and hexamers and significantly higher for fuzzy balls. Previous 
studies have shown similar outcomes, but with less differentiation between protein 
oligomeric forms (Leth-Larsen et al., 2005). Moreover, protein activity trends were 
consistent with the behavior of two human SP-Ds with a different oligomeric form 
distribution. Proteinosis hSP-D, with fuzzy balls as the most abundant structure, 
showed higher activity in the functional assays performed than amniotic fluid SP-
D, with a similar content of dodecamers and fuzzy balls (Chapter 3). Perhaps, from 
the comparison of these two cases, it might be interpreted that fuzzy balls exhibit 
higher activity than dodecamers, at least in terms of bacteria aggregation and 
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binding, functions that depend on the lectin activity contained in the carbohydrate 
recognition domains. Thus, AF-hSP-D that contains a proportion close to 1:1 
between fuzzy balls and dodecamers showed less activity than PAP-hSP-D, where 
fuzzy balls are significantly increased in detriment of dodecamers. It should be kept 
in mind that these assays were done in vitro with isolated protein. Therefore, it 
should not be interpreted that proteinosis patients could be somehow more 
protected against infections than babies inside the uterus. In vivo, the distribution 
of SP-D oligomeric forms could be more dynamic attending to changes in the 
surrounding environment, for example, promoting association into fuzzy balls in 
response to bacterial infection. Last, we have only evaluated the activity of isolated 
trimers, hexamers and fuzzy balls for SP-D functions mediated by lectin activity. 
Further experiments would be required to analyze and compare their behavior in 
SP-D surfactant homeostasis related functions. It has been reported that trimers are 
not sufficient to restore phospholipid metabolism in SP-D-/-, but SP-D trimers used 
in those studies were obtained by mutation of cysteines 15 and 20 to serine. The 
situation could be different for true native wild-type trimers. Hexamers are the 
minimal unit that provide a proper spacing between two trimeric CRDs, being less 
complex than dodecamers and fuzzy balls, and it would be interesting to see their 
potential influence in surfactant ultrastructure and homeostasis.  
In proteinosis disease, a similar altered context has been found with respect to 
lipid accumulation than in SP-D-/- phenotype (Ikegami et al., 2000). Considering 
that SP-D participates in surfactant recycling, and that in PAP there is an 
accumulation of SP-D – mainly assembled as fuzzy balls- in the alveolar sub-phase 
(Chapter 3), SP-D should not contribute to accumulation of lipids in PAP lungs. 
However, it has been demonstrated that the alteration in PL homeostasis in SP-D-/- 
differs from the one found in PAP, where the problem resides in the GM-CSF gene 
and the lack of surfactant catabolism by macrophages (Ikegami et al., 2001). SP-D 
is implicated in surfactant recycling by ATII cells, while GM-CSF mediates PL 
catabolism by macrophages.  
Up to date, the interest in SP-D functions has been mainly focused on immune 
functions of the protein. Although SP-D is a surfactant protein, not many studies 
have been conducted on its possible role to sustain surfactant biophysical functions. 
It seems that SP-D only interacts with phosphatidylinositol (PI) among surfactant 
phospholipids (Ogasawara et al., 1992). Despite influencing surfactant 
ultrastructure (Poulain et al., 1999) and homeostasis (Korfhagen et al., 1998), 
mediating PL uptake by ATII cells (Ikegami et al., 2005), it is believed that SP-D 
does not in principle interfere in surfactant biophysical function, directly or 
indirectly. However, some evidences in the literature showed that it could have an 
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indirect role, protecting LS membranes from disturbing agents that could cause 
impairment of their function. In several lung diseases, such a cystic fibrosis, low SP-
D levels in bronchoalveolar lavage has been found, along with an exacerbated 
inflammatory response in lungs with high cytokines, neutrophil extracellular traps 
(NETs), ROS, etc., which provokes tissue damage (Sorensen, 2018, Cheng and 
Palaniyar, 2013, Sorensen et al., 2007). The release of those inflammatory 
mediators may interfere with surfactant phospholipids and hydrophobic proteins, 
inhibiting lung surfactant biophysical function, impairing its ability to sustain low 
surface tensions at the end of expiration (Echaide et al., 2017, Zuo et al., 2008). We 
have investigated the role of SP-D to protect lung surfactant biophysical function, 
using an in vivo mice model of airway inflammation. Wild type (SP-D+/+) and SP-D 
knock out (SP-D-/-) mice were instilled with LPS causing NETosis, which was 
exacerbated in the case of KO mice (Chapter 4). The biophysical activity of LS from 
mice subjected to different conditions was evaluated and showed that surfactant 
from LPS-instilled KO mice was inactivated, being unable to reach low surface 
tensions during breathing dynamics. We attributed this inhibition mainly to NETs 
released to the airway spaces, as we also found direct inhibition of LS by NETs in 
vitro. The presence of SP-D turned out to protect lung surfactant from NETs 
inhibition, which may occur at two levels. First, SP-D suppresses LPS-induced 
NETosis by sequestering LPS, mediated by the lectin activity of CRDs (Chapter 4), 
which also brought to light a modulatory role of SP-D in NETosis development. 
Second, it has been reported that SP-D binds NETs through the collagen domain of 
the protein (Douda et al., 2011). In this way, SP-D would opsonize NETs, 
preventing their interference with surfactant components and also its inhibition. 
This would be supported by findings in Chapter 4, where the presence of SP-D 
prevented surfactant inactivation by NETs in vitro and in vivo. A protective effect of 
SP-D in lung surfactant biophysical function in the presence of plasma proteins has 
been also reported previously (Sato et al., 2010). Thus, SP-D may influence 
surfactant biophysical function indirectly, without necessarily interacting with 
surfactant phospholipids, but keeping surfactant membranes free of disrupting 
components, especially under inflammatory conditions. Last, the SP-D used for in 
vitro experiments was obtained from proteinosis BAL, hence, it was mainly 
assembled as fuzzy balls. Performance of SP-D was good binding LPS, which agrees 
well with the functional assays performed in Chapters 2 and 3. Moreover, it was 
functional interacting with NETs, in principle mediated by the collagen tails.  
 
In summary, we have characterized SP-D oligomeric forms, investigated the 
oligomerization pathway from monomers to fuzzy balls and studied the kind of 
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interactions involved in protein assembly, which are principally governed by non-
covalent interactions in higher order oligomers. Moreover, isolated trimers, 
hexamers and fuzzy balls have been functionally evaluated and compared, being 
fuzzy balls the most active oligomer in functions mediated by lectin activity. These 
studies have been performed with recombinant human rhSP-D and further 
validated with human hSP-D from amiotic fluid and proteinosis BAL, where the 
different oligomeric forms of rhSP-D were also present with a functional activity 
consistent with the functional behavior described for specific oligomeric forms 
distribution. Last, we have gone further to assess the function of SP-D in vivo 
modulating NETosis, a in vivo process implicated in the immune response and with 
important consequences in lung surfactant biophysical behavior. The results 
allowed us to determine the protective role of SP-D against LS inhibition mediated 
by NETs and its modulatory effect on NETosis triggered by neutrophils. 
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The research presented in this Doctoral Thesis provides new insights into the 
structure and oligomerization pathway of surfactant protein SP-D. It also reveals 
further details about the structural-function relationships of the different oligomeric 
forms of the protein. In addition, the implication of SP-D in lung homeostasis has 
been demonstrated at the level of the immune defense of the lungs and the 
biophysical function of lung surfactant. Taking all the results into consideration we 
may conclude that: 
¨ Surfactant protein SP-D is assembled into trimers, hexamers, dodecamers 
and larger order oligomers (Known as fuzzy balls). Beyond trimers, which 
are stabilized by disulfide bonds, the oligomerization pathway is governed 
by non-covalent interactions that take place between the N-terminal 
domains and the nearest collagen regions.  
¨ The quantification of the distribution of oligomeric forms of SP-D revealed 
that dodecamers and fuzzy balls are the most abundant species, being the 
proportion sensitive to the surrounding conditions, such as pH, which also 
affect protein conformation and thermal stability. 
¨ The study of human SP-D obtained from amniotic fluid has served as a 
reference to validate CHO cells as a good system to produce recombinant 
human rhSP-D. The types of oligomers observed were the same in both cases 
and hSP-D presented a proportion close to 1:1 of dodecamers and fuzzy 
balls. 
¨ The glycosylation site is observed in human and recombinant SP-D as 
protrusion in the collagen domain near the N-terminal domain. The glycan 
structure in hSP-D is biantennary, core fucosylated and it contains sialic 
acids and galactose.  
¨ Fuzzy balls are the most active oligomeric forms in protein functions that 
rely on the lectin activity of SP-D, at least with respect to binding and 
aggregation of bacteria. Hexamers are functional structures, although their 
activity is lower compared to fuzzy balls. Trimeric structures are not 
sufficient to aggregate bacteria. 
¨ Human SP-D from proteinosis BAL is mainly assembled as fuzzy balls, while 
hSP-D from amniotic fluid presents a predominance of fuzzy balls, but 
closely followed by dodecamers. Purified human SP-D from proteinosis is 
more active than hSP-D from amniotic fluid, probably due to its higher 
content in fuzzy balls. 
¨ SP-D suppresses LPS-induced NETosis. SP-D binds in a calcium-dependent 
manner to LPS through its trimeric CRD domains, therefore it reduces free 
LPS to trigger NETosis by neutrophils. Absence of SP-D in vivo implies 
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exacerbated NETosis, and the excess of NETs contributes to functional 
impairment of lung surfactant. In vitro, NETs directedly inhibits lung 
surfactant biophysical function, which can be prevented in the presence of 
SP-D. Thus, SP-D protects lung surfactant from NETs inhibition. 
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